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THESIS SUMMARY 
Peptide immunotherapy for Type 1 diabetes aims to restore tolerance to self, 
whilst leaving the rest of the immune system intact. Once the right peptide is 
delivered to the right cell, it is important to closely monitor the effect of such a 
therapy, both in the regards to the immune and metabolic response. 
Clinical trials are designed to test the effect of a drug at the end of the trial 
period, which can be years later. Ex-vivo human models are not subject to 
extensive regulatory requirements, and can rapidly provide proof of principle 
on the efficacy of a treatment, which can be then translated to the clinic.!
I have shown that the skin organ bath culture is a useful system for studying 
treatment effects of variety of ex-vivo delivered agents. When used to 
optimise peptides delivery, it indicated a potential role of dry coated 
microneedles in targeting epidermal DCs, important because of their 
endogenous tolerogenic potential, which can be further modified by topical 
treatments and locally injected agents. Whether true tolerogenic potential can 
be achieved in such a way, is subject to further studies designed to optimise 
the type, dose and the duration of the treatment by the conditioning agent.  
My data also suggested that lymph node fine needle aspiration biopsy is a 
feasible non-invasive method suitable for monitoring the cellular immune 
responses after antigen skin delivery. Subject to confirmatory study, it has a 
potential to find immediate application as an efficient and reliable tool for 
monitoring immune response after antigen-specific immunotherapy in clinical 
trials. Once recognised as ‘immune responders’ in such a way, participants in 
clinical trials can be subjected to the monitoring of the metabolic response to 
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the immune intervention, by measuring !-cell function via stimulated UCPCR 
as a non-invasive and more compliant-prone alternative to the standard 
MMTT.!
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ABBREVIATIONS 
 
Abbreviation Explanation 
5-TAMRA 5 - Carboxytetramethylrhodamine 
AIRE autoimmune regulator gene 
ANOVA Analysis of variance 
AP-1 activator protein - 1 
APC Antigen presenting cell 
APC dye Allophycocyanin 
ASI Antigen-specific immunotherapy 
AUC Area under the curve 
BCG Bacillus Calmette–Guérin 
BCIP/NBT  5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium 
BMI Body mass index 
BSA Bovine serum albumin 
C1R-A2 cells HLA-A2 expressing, human plasma leukemia cell line 
CCR Chemokine receptor 
CD Cluster of differentiation 
CI Confidence interval 
CLA Cutaneous leukocyte antigen 
CMV Cytomegalo virus 
cpm counts per minute 
CTLA-4 Cytotoxic T-lymphocyte antigen 
Cy Cyanine dye 
DC Dendritic cell 
DC SIGN Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing 
Non-integrin (CD209) 
DCCT Diabetes Control and Complication Trial 
DDC Dermal dendritic cell 
Dex-DC Dexamethasone modulated dendritic cell 
DI water Deionized water 
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Abbreviation Explanation 
DIPP Type 1 diabetes prediction and prevention project 
DMEM Dulbecco’s modified Eagle medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DNA-se Deoxyribonuclease 
DPT-1 Diabetes Prevention Trial 1 
DTH Delayed type hypersensitivity 
EBV Epstein Barr virus 
EBVP1 Lytic protein BMLF-1 (280-288) Epstein-Barr virus peptide 
GLCTLVAML 
EC Epidermal cell 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ELISPOT Enzyme linked immunosorbent spot 
EpCAM Epithelial cell adhesion molecule 
FCB Flow-cytometry buffer 
FCF Flow-cytometry fixative 
FCS Foetal calf serum 
FITC Fluorescein isothiocyanate 
FNA Fine needle aspiration 
Foxp3 Forkhead/winged-helix transcription factor box P3 
FP1 HLA DR1 restricted cloned T cells, specific for hemagglutinin (306-
318) Influenza A virus peptide PKYVKQNTLKLAT 
FPIR first phase insulin response 
FSC Forward scatter 
G-CSF Granulocyte colony stimulating factor 
GAD Glutamate-decarboxylase 
GC Glucocorticoid 
GITR Glucocorticoid-induced tumour necrosis factor receptor family-related 
gene 
GLIS Gli-similar 
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Abbreviation Explanation 
HAEP HLA Epitope Analysis Programme 
HEV High entothelial venules 
HLA Human leukocyte antigen 
HRP Horseradish Peroxidase 
HSP Heath shock protein 
i.d. Intradermal 
i.n. Intranasal 
i.v. Intravenous 
IA-2 Islet antigen-2, islet tyrosine phosphatase 
IAA insulin 
IAPP Islet amyloid polypeptide 
ICA insulin cell cytoplasmic antibodies  
ICOS inducible co-stimulator 
IDO Indolamine-2,3 diooxygenase 
IFIH1 genes Interferon induced with helicase C domain 1 gene 
IFN-# Interferon # 
Ig Immunoglobulin 
IGRP Islet-specific glucose-6-phosphatase catalytic subunit related protein 
IL Interleukin 
IL-10p Interleukin-10 pure 
ILT immunoglobulin like transcripts 
INS gene Insulin gene 
LAG-3 Lymphocyte activation gene-3 
LC Langerhans cell 
LD marker Life/dead marker 
LN Lymph node 
LNCs Lymph node cells 
MECLR Mixed epidermal cell lymphocyte reaction 
MFI Mean fluorescent intensity 
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Abbreviation Explanation 
MHC Major Histocompatibility Complex 
MIP-1! Macrophage Inflammatory Protein 1 ! 
MLR Mixed lymphocyte reaction 
MM-UCPCR Mixed meal stimulated UCPCR 
MMP Matrix metalloproteases 
MMTT Mixed meal tolerance test 
MN Microneedle 
MNc Microneedle coated with the coating solution only 
MNpep Microneedle coated with the peptide 
mRNA Messanger ribonucleic acid 
NFAT-1 nuclear factor of activated cells -1 
NF$B nuclear factor kappa-light-chain-enhancer of activated B cells 
NOD mouse Non-obese diabetic mouse 
NP Nanoparticle 
NP IL-10 IL-10 attached to nanoparticle 
NPPEs naturally processed and presented peptide epitopes 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDL programmed death ligand 
PE Phycoerythrin 
PerCP Peridinin chlorophyll 
PHA Phytoheamagglutinin 
PI Proliferation index 
PIT Peptide immunotherapy 
PTH Parathyroid hormone 
PTPN 22 T-cell protein phosphatase gene on chromosome 1 
PVDF membrane Polyvinylidene difluoride membrane 
RD Reagent diluent 
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Abbreviation Explanation 
REC Research ethics committee 
ROR#T RAR-related orphan receptor gamma 
s.c. Subcutaneous 
s.l. Sublinqual 
sCP Serum C-peptide 
SD Standard deviation 
SLC Secondary lymphoid tissue chemokine 
SSC Side scatter 
SST Serum separator tubes 
SST tubes Serum separator tubes 
STAT 1 signal-transducing activator of transcription 1 
T1D Type 1 diabetes 
T2A2 cells HLA-A2 expressing, antigen processing (TAP)-deficient human T-B 
lymphoblastoid hybrid cell line 
TAE buffer Tris-acetate-EDTA buffer 
TCR T cell receptor 
TCR T-cell receptor 
TEDDY  Environmental Determinants of Diabetes in the Young 
TEDDY Study Trial of Environmental Determinants of Diabetes in the Young 
TEMRA Effector memory RA positive T cells 
TGF-! Transforming growth factor ! 
TGF-! Transfroming growth factor- ! 
Th1 T helper 1 cells 
Th17 T helper 17 cells 
Th2 T helper 2 cells 
Th3 T regulatory cells type 3 
TMB Tetramethylbenzidine 
TNF% Tumour necrosis factor-% 
Tr1 T regulatory cells type 1 
Tregs T regulatory cells 
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Abbreviation Explanation 
TU Tuberculin units 
Tuberculin PPD Tuberculin protein purified derivative 
uCP Urinary C-peptide 
UCPCR Urinary C-peptide to creatinine 
VEGF Vascular entothelial growth factor 
VIP Vasoactive intestinal peptide 
VitD3 Vitamin D3 
VM Viral mix 
VNTR variable numbers tandem repeat 
ZnT8A zinc transporter-8 
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Despite nearly 100 years of experience and improvement in insulin 
replacement therapy, Type 1 diabetes (T1D) remains a challenge to control 
and manage from the perspectives of the patients, their families and their 
physicians. The implications of poor diabetes control involve acute life-
threatening conditions, such as diabetic ketoacidosis and hypoglycaemia, and 
chronic complications, including heart disease, retinopathy, neuropathy and 
kidney disease. Understanding the aetiology and pathogenesis of T1D is 
crucial to base strategies to prevent and treat this life-changing and potentially 
fatal disease. 
1.1 Pathogenesis of Type 1 diabetes 
T1D is the result of selective immune-mediated attack on the insulin 
producing !-cells of the pancreas. This chronic destructive inflammation, 
influenced by various factors, exhibits variable severity in different individuals, 
from rampant insult in childhood, to the slowly developing disease 
encountered in some adults. In genetically predisposed individuals, 
immunological assault begins with one self-antigen and spreads to relevant 
others, leading to metabolic abnormalities, starting from attenuated first phase 
insulin response (FPIR) to intravenous glucose challenge, loss of glucose 
tolerance and, finally, clinical diabetes S!Figure 1-1.[1, 2] It has been estimated 
that takes approximately 1.5 to 5 years from attenuated FPIR to diagnosis of 
Type 1 diabetes[3], at which point 50-80% of !-cell function has been lost.[4] 
It seems that the loss of !-cell function after diagnosis follows biphasic pattern, 
with faster decline in the first year after diagnosis, implying different intensity 
and/or type of metabolic and immunological factors in the early stage.[5]!
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Figure 1-1. Development of Type 1 diabetes. Adapted from: 
Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune 
disease. N Engl J Med. 1986;314(21):1360-8. 
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Indeed, autoantibodies against pancreatic self-antigens, such as glutamate-
decarboxylase (GADA), islet tyrosine phosphatase (islet antigen-2, IA-2A), 
insulin (IAA), and zinc transporter-8 (ZnT8A) are detectable in blood, years 
before clinical presentation of the disease. They can appear any time during 
life, but peak at one to three years of age in children who go on to develop 
early diabetes, and again in puberty, with the second wave of high incidence 
of T1D.[6-8] The rate of the autoimmune process varies significantly between 
individuals and can be influenced by factors such as HLA type, age, gender, 
the presence of insulin resistance and autoreactive antibodies.[2] The 
humoral response to pancreatic self-antigens, including changes in antibody 
number, type and concentration, gives us a valuable glance into the dynamic 
of this intriguing process. First to appear are usually IAA, followed by GADA, 
then IA-2A and ZnT8A. The latter usually represent more aggressive 
autoimmunity and are a critical turning point in the pathogenesis, announcing 
impending clinical diabetes. In addition to this intermolecular antigen 
spreading that is more likely to be sequential [9], it seems that the process 
shifts intra-molecularly as well, with antibodies to juxta-membrane parts of the 
IA-2A appearing first, followed by intracytoplasmatic tyrosine phosphatase 
epitopes later in the course of disease development. A study that analysed 
the antibody profile in children early after diagnosis observed an increase in 
the proportion of children with multiple antibodies, and antibodies suggestive 
of more aggressive autoimmunity, such as ZnT8 and IA-2!, over a period of 
20 years.[10] These authors speculated that an increase in body mass index 
(BMI) of children might be a contributing factor, leading to the role of insulin 
resistance and consequent apoptosis of !-cells leading to more widespread 
! #!
antigen exposure. However, findings in the BABYDIAB study did not support 
the role of increasing BMI in the development of the autoimmunity.[11] 
Although seroconversion peaks early in life, it seem that the first antibody can 
appear any time between the ages of one and 60 years, according to some 
early observations.[9] A number of studies, mainly involving children and 
young adults, tried to understand and predict the rate of progression to clinical 
diabetes from this early seroconversion. In a study involving the siblings of 
patients with T1D aged 16 to 39 years, it was calculated that the 5-year risk of 
developing the disease increased from 13% in individuals with one or more 
detectable antibodies, to 34% in people with three or more. In another study, 
the majority of children with multiple antibodies progressed to diabetes within 
15 years, and even faster if they seroconverted at very young age, three 
years and younger.[12] But, the presence of certain antibodies increased the 
risk even further, such as that individuals with positive IA-2A had a risk of 
developing diabetes in 5 years as high as 59%.[13] This was in agreement 
with the finding of the prospective TEDDY study where, alongside a first 
degree relative with T1D, the combination of IA-2A, GADA and IAA, was 
found to be a risk factor for early development of T1D, as well as the 
combination of GADA and IAA.[14] However, it seems that after 
seroconversion, children with certain genotypes (carriers for risk alleles in 
CD25, IL2, INS, IFIH1 genes, see below) progress quicker than others.[15]  
In an attempt to link the dynamic of the humoral autoimmunity to the 
metabolic status in pre-diabetic phase of T1D, the Type 1 diabetes prediction 
and prevention project (DIPP), conducted in genetically predisposed children 
aged one to five years, found that decreased FPIR during intravenous glucose 
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challenge is an early metabolic predictor of the imminent diabetes, which was 
correlated with the presence of insulin cell cytoplasmic antibodies (ICA), 
multiple antibodies and their titers. However, approximately half of the 
children did not present with the clinical diabetes during the four years long 
follow up, suggesting the role of immune and/or metabolic compensation 
mechanisms operating in some individuals, that certainly contribute to the 
variety in the duration of the pre-diabetic stages.[16] 
When combined with antibody status, diminished FPIR increased the risk of 
progression to clinical diabetes in the large ICARUS cohort of the first degree 
relatives with positive ICA (85% within 5 years) [17] and in a Finnish study 
where a combination of low FPIR and positive antibodies increased the risk of 
developing T1D to 92%, in comparison to only 66% when FPIR was not 
considered.[18] 
Although the role of B-cells is emerging as a significant contributor in the 
pathogenesis of T1D, the cellular autoimmunity is still seen as the main culprit 
in this process that takes place in the islets of the Langerhans. 
In the non-obese diabetic (NOD) mouse model, it has been shown that the 
disease progression correlates with the degree of insulitis, the inflammatory 
process in the islet of Langerhans.[19] It is difficult to establish the same 
temporal character of the histological changes in humans, but post-mortem 
material from patients early in the disease showed various degrees of insulitis 
with cell infiltrate consisting predominantly of CD8 T cells, with CD4 T cells, B 
cells and macrophages also present.[20] Another study using panceratic 
biopsies from recently diagnosed patients showed that affected pancreatic 
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cells hyper-expressed Major Histocompatibility Complex (MHC) class I, which, 
together with the degree of insulitis, correlated with deteriorating glycaemic 
control.[20, 21]. This hyper-expression of class I was recently confirmed in 
nPod samples, together with single and multiple CD8 T cell autoreactivities 
using tetramer technology.[22] Frozen sections of pancreata from patients 
with Type 1 diabetes stained positive for glucose transporters, suggesting 
capacity of remaining !-cells to sense glucose years after diagnosis[23], 
which is in line with some preservation of C-peptide in selected number of 
patients with T1D, all pointing towards chronicity of the process. However, it is 
likely that the autoimmunity changes its nature with time and moves from the 
insult mediated by single-specificity islet-autoreactive T-cells towards one 
involving multiple islet reactive species, which is possibly a consequence of 
the apoptotic process that could contribute to disease progression.[22] This is 
in line with the well-documented presence of single and multiple 
seroconversion discussed earlier. 
To explain the process underlying this chronic inflammation, almost 30 years 
ago Botazzo1 postulated that environmental attack results in the release of !-
cell antigens that are then taken up by macrophages, presented to T cells, 
leading to the activation of T helper cells, which in turn activate B cells to 
produce antibodies, as well as activation of cytotoxic T cells. A constant influx 
of new information over time has broadened this concept to reveal very a 
complex, but only partially understood, interplay between the immune system, 
the environment and the !-cell. Before going into further details of T1D 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!&!'()*++(!,-.!/*012342!524)612.!72*)8!(9!:2)*!4255;!8(<=4=>2!(1!?6=4=>2@!7=*:2)!A2>!&BC$D!E;&&BF&EG.!
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pathogenesis, it is helpful to review our current understanding of several key 
events occurring during a normal immune responseHI"J.  
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Mature recirculating T cells that have not yet encountered their specific 
antigen are known as naïve T cells, which fall into two main categories: CD4 
and CD8 cells, depending which co-receptor molecule they express. When 
the naïve T cell meets its respective antigen, presented to it as MHC-peptide 
complex on the surface of the antigen presenting cell (APC), it becomes an 
activated effector T cell, ready to perform various functions contributing to 
the removal of an antigen. At the same time as providing effector T cells, this 
primary immune response generates memory T cells that afford protection 
when the same antigen is encountered at a later stage.  
Activation of the naïve T cells is step-by-step process that can be separated in 
3 parts (Figure 1-2):  
• Signal 1 is provided during the interaction of T cell receptor (TCR) and 
the MHC-peptide complex on the APC; this process is facilitated by co-
receptor molecules on the T cells: CD4 or CD8. CD4 cells recognise 
their antigen in the context of MHC class II (expressed by professional 
APCs), whilst the CD8 cell requires antigen to be presented in the 
context of MHC class I (expressed on all cells). 
• Interaction of co-stimulatory molecules on the APC (B7.1 or CD80, 
B7.2 or CD86, CD40) and their ligands on the T cell (CD28 for B7.1 
and B7.2 and CD40L for CD40) delivers signal 2; this step is important 
for clonal expansion of T cells, mainly through an increase in the 
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production and the responsiveness to IL-2. Another T cell co-
stimulatory molecule, known as inducible co-stimulator (ICOS), binds to 
its ligand (LICOS) on activated dendritic cells and monocytes, and 
stimulates proliferation of an activated clone through production of 
cytokines other than IL-2. Interestingly, T cells express CTLA-4, an 
additional receptor for B7 molecules, which contrary to CD28, delivers 
an inhibitory signal to the activated T cell.  
Another molecule, known as programmed death ligand- 1 (PD-1), also 
mediates inhibitory T cell proliferation signals. It binds to specific 
ligands: PD-L1, constitutively expressed on variety of cells, and PD-L2, 
exclusively expressed on activated APCs during inflammation. The 
interplay between stimulatory and inhibitory signals regulates T cell 
responses. 
Also, immunoglobulin like transcripts (ILTs 2, 3 and 4) are members of 
the immunoglobulin gene super-family. They are expressed on 
dendritic cells. When they bind to their ligands on the T cells, the 
cascade of the intracellular signaling starts that causes T cell anergy 
and/or induction of allospecific T regulatory cells. [25] 
• Finally, cytokines that govern differentiation into various types of 
effector cells induce signal 3, rendering the activation process 
complete.  
The crucial moment in this process is the increase in the production and 
responsiveness to IL-2. The initial encounter with the appropriate antigen in 
the presence of co-stimulatory signals induces the synthesis of IL-2, as well 
! &G!
as the "-chain of the IL-2 receptor, known as CD25. Naïve T cells express a 
low sensitivity variant of the IL-2 receptor that consists only of !- and #-chains. 
Binding of "-part to the rest of the receptor complex, upon cell activation, 
increases sensitivity to IL-2 and propels the cells into the proliferation. On the 
other hand, an increase in the production of IL-2 is achieved by induction of 
transcription factors such as NFAT-1 (nuclear factor of activated cells -1), AP-
1 (activator protein - 1) and NF$B (nuclear factor kappa-light-chain-enhancer 
of activated B cells), which bind to the promoter region of IL-2 gene. In 
addition, stabilisation of the otherwise unstable IL-2 mRNA in the naïve T cells, 
contributes to the increased production of IL-2.  
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Figure 1-2. Activation of naïve T cells. Adapted from Murphy, K., et al., Janeway's immunobiology. 7th ed. 2008, New York: Garland Science. xxi, 887 p. 
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CD8 naïve cells differentiate into cytotoxic T cells, capable of killing their 
target cells during defense against intracellular pathogens, such as viruses. 
Because their effector functions are so destructive, they require more co-
stimulatory activity to become activated. This can be achieved by mature 
dendritic cells that have intrinsic co-stimulatory activity capable of stimulating 
CD8 cells to produce IL-2 that drives their own proliferation and differentiation. 
Another way to provide this additional co-stimulatory activity is through the 
CD4 cell, that binds the antigen on the same APC (presenting both MHC 
class I and II) as CD8.  
Unlike the CD8 cell, CD4 naive cells can differentiate into a number of 
different effector cells:   
• T helper type 1 cells (Th1) are responsible for activating macrophages 
and facilitating the process of phagocytosis of intracellular bacteria, 
during which they produce IFN-! and TNF-". The signal 3 for their 
differentiation comes from APCs producing IL-12 and IFN-!, which 
activates signal-transducing activator of transcription 1 (STAT 1) that, 
in turn, activates transcription factor tbet (t-box expressed in T cells), 
which is responsible for promoting the transcription of the IFN! gene in 
the T cell, as well as the IL12 receptor, hence determining the fate of 
the cell towards Th1 pathway.  
• T helper type 2 cells (Th2) are mainly involved in facilitating B cell 
function, after differentiation governed by IL-4 through activation of the 
STAT6 and GATA-3 transcription factors. They produce IL-4, IL-5, IL-
10 and IL-13. 
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• T helper 17 cells (Th17) receive differentiation signal 3 through a 
different transcription factor, ROR!T, which is activated in an 
environment rich in TGF-#, IL-6 and IL-21[26]. This results in the 
expression of the receptor for IL23, committing the cell to the Th17 
pathway, which requires IL-23. These cells are induced early in the 
adaptive immune response to extracellular bacteria during which they 
stimulate a neutrophil response through production of IL-17. 
• Regulatory T cells (Tregs) have the main function of suppressing 
immune responses. They differentiate after exposure to cytokines such 
as TGF-# and IL-10. Tregs are described in detail later in this chapter.  
Focusing defense solely on foreign antigens and, at the same time, 
maintaining tolerance to “self” is extremely important process that 
continuously takes place during the development of normal immune response. 
It is viewed as multi-step process. It starts with the central tolerance in the 
thymus, which involves deletion of the T-cells that strongly react with self-
antigens expressed on thymic epithelial cells. Many autoreactive T-cells, 
whose TCR weakly reacts with endogenous antigens, escape this control 
checkpoint. Other mechanisms, known as peripheral tolerance, are in place to 
eliminate these cells from the periphery. They include:  
1) peripheral deletion of self-reactive T-cells by apoptotic cell death;  
2) anergy, a mechanism during which effector T-cells are made functionally 
unresponsive due to failure to fully activate upon encounter with their 
respective antigen. [27] 
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3) Tregs, part of the CD4 lymphocyte family, that have the ability to suppress 
potentially deleterious activities of effector T-cells.  
Many studies have suggested that Tregs, or their dysfunction, maybe 
responsible for uncontrolled autoreactive T cells in the periphery. For this 
reason they are seen as promising therapeutic target and have been the 
focus of research into autoimmune diseases over the past decade. The 
concept is based on the hypothesis that an increase in the number and/or 
function of Tregs can achieve targeted immunomodulation without 
generalised suppression.  
The large population of Tregs, formerly known as natural Tregs, is mainly 
generated in the thymus following encounters with organ-specific ligands that 
are ectopically expressed on the thymic epithelial cells – thymus derived 
Tregs (tTregs).[28, 29] They represent approximately 10-15% of the CD4 
positive population in the human blood. These are CD4 positive cells that 
express CD25 ("-chain of the IL-2 receptor) and the transcription factor 
FoxP3, which affects the interaction between AP-1 and NFAT at the level of 
the IL-2 promoter, preventing transcriptional activation of IL-2 gene. [24] 
Thymic selection is not the only way that Tregs cells can be created. There is 
evidence that naïve T cell can be converted into “induced” Tregs in the 
periphery as a part of the adaptive immune response. According to the new 
nomenclature, these are peripherally derived Tregs (pTregs)[29] that include 
several subtypes: 
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•  CD4+CD25+Foxp3+ pTregs can be generated following 
administration of low dose agonist peptide and/or a lack of co-
stimulation, i.e. “subimmunogenic” conditions. [30, 31]  
• Tr1 cells are a distinct type of pTreg in regards to their phenotype 
(CD4+CD25-IL-10+), cytokine dependent mode of action (rich in IL-10 
and low in IL-4) and migratory behavior, in comparison to the 
CD4+CD25+Foxp3+ cells. Data in mice suggest that they mediate 
their actions through production of IL-10, and can be induced by 
repeated in vivo intranasal administration of antigenic peptide or 
repetitive administration of IL-10 and rapamycin.[32] 
• Th3 cells produce IL-4, IL-10 and TGF-#, and populate the mucosal 
immune system where they can be activated through antigen 
presentation, particularly in the gut, as evidenced by a study in mice in 
which oral insulin favoured the generation of TGF-# producing Th3 
cells. [33] 
It is important to mention that the new nomenclature[29] also distinguishes in 
vitro-induced Tregs (iTregs), recognising the limitations of translating the in 
vitro models to the in vivo conditions.  
 
 
 
 
 
! "'!
There have been numerous attempts to characterise Tregs phenotypically. 
The most widely used markers are presented in the Table 1-1. 
Marker Description Expression in Tregs Reference 
CD25 "-chain of the high affinity IL-2 
receptor, which enables Tregs to 
respond to the much lower 
concentrations of IL-2 in comparison to 
the effector T cells and NK cells. 
 
 
 [34], [35] 
CTLA-4 Cytotoxic T lymphocyte-associated 
antigen-4 binds B7 molecules, 
delivering tolerogenic signal to APC. 
 
 
 [36], [37], 
GITR Glucocorticoid-induced tumour 
necrosis factor receptor-related gene 
has suppressive effect on T cell 
proliferation. 
 
 
 [38] 
LAG-3 Lymphocyte activation gene-3 is a 
homolog of CD4 that binds MHC class 
II and exhibits suppressive effects on T 
cell. 
 
 
 [39] 
 
CD127 
 
IL-7 receptor 
 
 
 
 
 [40] 
 
Foxp3 Forkhead/winged-helix transcription 
factor box P3 affects the interaction 
between AP-1 and NFAT at the level of 
IL-2 promoter, preventing 
transcriptional activation of IL-2 gene. 
 
 [41], [42], 
[43] 
Table 1-1. Phenotyping of the T regulatory cells. 
 
All of these markers that are presently used to define Tregs, are also general 
T-cell activation markers, suggesting that activation is required for a T cell 
mediated suppression, but not offering definitive phenotyping of these cells. 
[44] As a consequence, attempts to show reduced number of Tregs in Type 1 
diabetes lead to inconsistent data due to variability in the strategies defining 
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Treg populations, influence of age and duration of diabetes.[33] This makes 
them even less reliable marker for monitoring disease progression, with or 
without immune intervention. 
Identifying and studying antigen-specific Tregs is even more challenging, 
given their low frequency of 1 in 104 or 1in 105 PBMCs.[45] A sensitive 
cytokine ELISPOT assay, that detects peptide-specific IL-10 secreting cells at 
frequencies as low as 1 in 105 [46], gives the potential to monitor at least 
some of the actions of these cells through their functionality, rather then 
phenotype. Tetramer technology is another approach to address this issue, 
promising superior sensitivity in detecting HLA class I CD8+ T cell epitopes 
(preproinuslin and GAD), compared to ELISPOT, in patients recently 
diagnosed with Type 1 diabetes.[47] On the other hand, more unstable class 
II tetramers, although successful in detecting proinsulin and GAD epitopes, 
were discordant with ELISPOT method, suggesting that these assays detect 
different populations of CD4+ cells.[48] 
That brings us to the importance of understanding the mechanism through 
which Tregs achieve suppression. It seems that antigen bearing APCs 
simultaneously engage with the naïve or effector T cells and the Tregs, which 
then work at several levels to halt self-reactivity or control overstimulation by 
the foreign. Tregs can influence priming and the effector stage of the immune 
process by acting on APCs and T cells alike. Activation of Tregs, and the 
suppression they mediate, is antigen-specific [49], although they may be able 
to suppress effectors with different antigen specificity.[50] It seems that they 
have several modes at their disposal, depending on environment: 
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• Cytokine production, such as IL-10 [51] and TFG-#- [52], through which 
they modulate activation of the T cells, acting both on APC and T cell 
level. 
• Direct cell contact involving the release of granzyme inducing 
apoptosis in the target cells, such as CD4+ and CD8+ T cells, CD14+ 
monocytes and immature and mature dendritic cells [53]. The concept 
of granzyme induced apoptosis was also documented in human clones 
originating from patients with Type 1 diabetes, where antigen-restricted 
interaction between APC, effector T cells and Tregs was halted through 
granzyme induced killing of the antigen-bearing APC by Treg, but not 
“bystander” presenters.[54] 
• Treg activation of indolamine-2,3 diooxygenase (IDO) metabolism 
when their CTLA-4 binds to CD80 or CD86 on antigen presenting cells 
(APC). This results in a reduced amount of tryptophan that prevents 
activation of effector T-cells.[55] 
The generation of different subtypes of the Tregs with their different modes of 
action is not a mutually exclusive process during the encounter with the 
antigen. The predominance of a certain pTreg probably depends on the type 
of antigen, the conditions around its presentation and the type of the tissue 
where the process takes place. As an illustration, Tregs express L-selectin 
receptor CD62L, which together with CCR7 enables them to home in on their 
respective antigen draining lymph nodes. However, they are also capable of 
travelling into the inflamed tissue by expressing markers such as "E#7 integrin 
in mice, which enables them to execute control of the effector response 
triggered by the inflammation.[56] It is possible that the suppression early in 
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the process requires a more gentle approach, such as cytokine modulation of 
APCs and T cells, whilst primed and activated effectors need more radical 
approach consisting of killing the culprit T cells or APCs that triggered them.  
Antigen presenting cells also play important role in this process, and there is 
ample data to suggest a capacity of DCs to induce T cell tolerance. This is 
particularly important for the efficacy of the antigen-specific immunotherapy 
delivered in the skin, given the abundance of tolerogenic APCs and Tregs in 
this organ, and this will be explored in detail in Chapters 4 and 5. 
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The autoimmunity process starts in the thymus, where peptides of peripheral 
antigens (including insulin) [57] are presented in the context of MHC 
molecules by medullary thymic epithelial cells to T cells, leading to the 
deletion of the majority, but not all, autoreactive T cells. The autoimmune 
regulator gene (AIRE) encodes a protein that plays an important role in the 
tissue-restricted antigen expression by thymic epithelial cells, an important 
pillar of self-tolerance. Indeed, patients with defective AIRE develop 
autoimmunity, which affects the parathyroid and adrenal glands, and many 
other organs, including pancreatic #-cell leading to T1D. It has been 
postulated that AIRE may function as a regulator of the expression of the 
insulin gene in thymus via an INS-VNTR (variable numbers tandem repeat) 
element. Polymorphisms in the VNTR region affect the propensity to Type 1 
diabetes, with haplotypes associated with a lower expression of insulin in the 
thymus causing higher propensity to the disease.[58] 
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Tregs are produced alongside other effector cells and their balance is crucial 
for maintaining tolerance to ‘self’ in the periphery. The insulin producing #-cell 
produces target antigens, but also process them creating peptides that are 
taken up by APCs, either as a whole (dead #-cells) or as granules of #-cells, 
for further processing and presentation to the effector T cells. In the next step, 
the autoreactive T cell, with its T cell receptor (TCR) recognises the 
endogenous peptide in the context of the MHC class. There is no doubt that 
CD4 cells orchestrate this process with, according to some evidence, a 
predominantly Th1 response, but also involving multiple arms such as 
cytotoxic T cells, cytokine production, B cell activation etc.[59]. It is most likely 
that the final insult is executed by the autoreactive cytotoxic CD8 cell that kills 
#-cell wrongly perceived as foreign.  
It is intriguing to understand why is #-cell such an “easy victim” of the 
imbalanced immune system, when many other neighbouring cells in the 
pancreas that produce similar array of antigens, remain intact in autoimmune 
diabetes. A vulnerability of the #-cell to the stress-induced changes during 
local infections, it’s increased sensitivity to cytokine-mediated killing and 
hyperexpression of class I molecules once immunity has been initiated, are 
some of the potential explanations.[59] A number of studies have focused on 
#-cell biology to identify the etiology of the cell-specific killing in T1D, and 
these have been recently reviewed. [59] 
The focus of this text is the approach of immune interventions, based on the 
concept that the disastrous reactivity to ‘self’ in T1D is the result of immune 
dysregulation, rather than the #-cell itself. It involves the presence of a 
sufficient number of autoreactive T cells that have escaped central or 
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peripheral control points, and/or lack a matching number of Tregs to 
counterbalance them, which will cause the destruction of the critical number of 
#-cells leading to T1D. The process is influenced by genetic predisposition, 
environmental factors and targeted antigens. 
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It is clear that T1D diabetes develops in genetically predisposed individuals 
and the major risk factor is a first-degree family history of Type 1 diabetes.[60] 
In the Diabetes Prevention Trial -1 (DPT-1), islet autoimmunity developed 
particularly in the siblings of affected individuals.[61] Interestingly, almost all of 
susceptibility genes associated with Type 1 diabetes are connected to the 
immune system. Amongst them, HLA class II region on chromosome 6 has 
been studied the most.[60] These genes encode the MHC complex 
responsible for antigen presentation. It is very well known that certain MHC 
class II alleles are strongly associated with the disease, whilst others provides 
protection (Table 1-2).  
Susceptibility alleles Protective alleles 
 
HLA-DRB1*03:01 
 
HLA-DRB1*15:01 
 
HLA-DRB1*04:01 HLA-DRB1*14:01 
HLA-DRB1*04:02 HLA-DRB1*07:01 
HLA-DRB1*04:05 HLA-DQB1*06:02 
HLA-DQA1*03:02 HLA-DQB1*05:03 
HLA-DQB1*03:02 HLA-DQB1*03:03 
Table 1-2! Protective and susceptibility MHC class II alleles in Type 1 diabetes [62] 
! ##!
However, the combinations of certain alleles define a haplotype risk. Analysis 
of over 600 Caucasian families determined a number of susceptible, neutral, 
and protective DR-DQ haplotypes. The most susceptible haplotypes were 
DRB1*0301-DQA1*0501-DQB1*0201, DRB1*0405-DQA1*0301-DQB1*0302, 
DRB1*0401-DQA1*0301-DQB*0302, and DRB1*0402-DQA1*0301-
DQB1*0302 haplotypes. The most protective haplotypes were DRB1*1501-
DQA1*0102-DQB1*0602, DRB1*1401-DQA1*0101-DQB1*0503, and 
DRB1*0701-DQA1*0201-DQB1*0303.[63] 
The HLA Epitope Analysis Programme (HAEP) studied HLA epitopes 
associated with propensity or resistance to Type 1 diabetes, and found that 
they appear in alleles previously known to be associated with the disease. In 
addition, individuals diagnosed with diabetes at young age were found to 
carry the highest number of high-risk epitopes and the lowest number of 
protective epitopes. The opposite was true for the individuals that developed 
diabetes at an older age.[64]  
Other genes have also been associated with an increased risk of Type 1 
diabetes, such as the insulin gene on chromosome 11 (INS), which shows 
polymorphism in its promoter region with shorter tandem repeat 
polymorphisms associated with risk and longer with protection; the CLTA-4 
gene on chromosome 2; the T-cell protein phosphatase gene on chromosome 
1 (PTPN 22), which downregulates immune responses by inhibiting TCR 
signaling; the CD25 gene on chromosome 10, which may affect Treg function; 
and the Interferon induced with helicase C domain 1 gene (IFIH1) on 
chromosome 2, which encodes an intracellular detector of viral RNA, the 
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reduced expression of which may protect from T1D.[65] A recent analysis 
tested over 20 additional regions, and identified further candidate genes such 
as IL-10, IL-19, IL-20, Gli-similar (GLIS) protein 3, CD69 and IL-27.[66]  
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Traditionally, it has been postulated that environmental agents, such as 
viruses, microbes, diet-related, anthropomorphic and psychosocial factors, 
trigger the onset of the disease in genetically susceptible individuals. However, 
a number of studies have failed to identify a clear culprit, amongst many 
studied, such as early exposure to cow’s milk, breast feeding, enteroviral 
infections, timing of vaccinations, birth weight and vitamin D exposure. [67] 
[68]  
One of the most studied factors has been viruses, particularly ones with 
tropism for pancreatic tissue, where they were investigated as possible 
triggers of autoimmunity, or direct perpetrators, lysing the #-cells. However, 
evidence for this is not substantial.[69] Rather than triggers, viruses could be 
facilitators of the autoimmunity. Enteroviral infections in children with positive 
autoreactive antibodies were shown to accelerate progression to clinical 
diabetes in the DAISY study.[70] On the other hand, particular gut microbiota 
may be protective. This “hygiene hypothesis” is supported by the finding that 
the incidence of Type 1 diabetes in Finnish children is six-fold higher than in 
ethnically and geographically matching Russian Karelian children, with 
documented equal frequency of the predisposing HLA DQ genotypes.[71] 
Modern hygiene standards, presumably practiced in economically developed 
Finland, more so than Karelia, reduce “protective” exposure to the 
environmental antigens. On the other hand, some studies showed increased 
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incidence of T1D in children with multiple infections during first years of life, 
but protective effect of pre-school care. They suggest that environmental 
factors can promote or attenuate disease dependent upon timing and quantity 
of exposure.[72] In this model, environmental factors are seen as modifiers 
rather than triggers of autoimmunity on a background of inherited immune 
dysregulation. [67]  
Studies looking at the link between the exposure to cows milk and Type 1 
diabetes did not provide consistent evidence, but a recent finding suggests 
that exposure in early infancy is associated with the disease, but only in 
carriers of a particular allele of the PTNPP22 gene.[73] It is possible that 
certain factors work in certain genotypes at certain times, further supporting 
the importance of the timing of the causative agents and their interplay with 
genetics.  
Another promising modifying factor is vitamin D, with a number of 
observational[74] and one prospective study[75] indicating that exposure to 
high dose vitamin D reduces the incidence of diabetes in predisposed children.  
The TEDDY Study (Environmental Determinants of Diabetes in the Young; 
http:teddy.epi.usf.edu/) is currently prospectively analyzing environmental 
factors that may be responsible for modifying disease incidence. 
The importance of the environment is further reflected in the fact that the 
concordance for Type 1 diabetes is 30-50% in monozygotic twins and 8% in 
dizygotic.[68] It is clear that genetic predisposition plays significant, but not 
self-sufficient role in the pathogenesis of T1D. It should rather be viewed as a 
framework on which environment works to either accelerate or attenuate 
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processes leading to autoimmunity. The speculation is that strong 
predisposing genetics needs only gentle influence from the environment to 
propel an individual to diabetes, whilst mild susceptibility or even protective 
genotype, requires much stronger insult or number of them to facilitate 
progression to the disease – Figure 1-3.  
 
Figure 1-3. Interplay between genetic and environmental factors in the pathogenesis of 
Type 1 diabetes. Factors offering protection from T1D are indicated with the green arrows; 
predisposing factors are indicated with the red arrows. !
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Alongside hereditary susceptibility and environmental modifiers, important 
players in the autoimmunity process are targeted antigens in the #-cell. 
Autoantibodies in T1D are generally regarded as a marker of autoimmunity, 
and whilst their role in pathogenesis is not clear, their target antigens have 
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been the focus of studies trying to identify epitopes of autoreactive T cells. In 
mouse and man, insulin and proinsulin are common targets of T cells of 
patients with Type 1 diabetes. [76] Whilst proinsulin is a major source of target 
epitopes for autoreactive CD8 cells in humans, CD4 cells tend to target 
epitopes residing mainly in GAD65, IA2, proinsulin. Antigens such as heath 
shock protein (HSP) 60 and 70, islet-specific glucose-6-phosphatase catalytic 
subunit related protein (IGRP) and islet amyloid polypeptide (IAPP) are the 
less common source of target epitopes in human – Figure 1-4.[77]  
"
Figure 1-4. Antigenic distribution of (a) CD4 and (b) CD8 T cell epitopes in autoimmune 
diabetes in humans and mice. Adapted from Di Lorenzo, T.P., M. Peakman, and B.O. Roep, 
Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in 
autoimmune diabetes. Clin Exp Immunol, 2007. 148(1): p. 1-16. 
 
Amongst this wide array of candidate epitopes, it is difficult to precisely 
establish which are the relevant or “real” targets responsible for the 
pathogenesis. In mouse models, it is possible to imply strict criteria and 
consider an epitope essential only if it could be shown that genetic ablation of 
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its expression led to the protection from disease[77], which has been 
achieved with murine pre pro insulin 1.[78] However, it is impossible to apply 
this criterion in human studies, and some of the work in identifying relevant 
epitopes came from studies using elution of epitopes peptides from HLA 
complexes of patients with T1D. This methodology used recombinant versions 
of known target antigens, such as IA-2 and PI, which were then delivered to 
the APCs of certain HLA type known to be prevalent in patients with T1D. 
After processing by APCs, peptides were acid eluted and separated by 
reverse phase HPLC. The presence of T cell reactivity to naturally processed 
and presented peptide epitopes (NPPEs) obtained in such a way was further 
tested by high sensitivity ELISPOT assay in patients with T1D and compared 
with healthy controls.[46, 79] This is how proinsulin C19-A3 came into the 
light[46], which was then followed by clinical trial designed to establish its 
safety [80] and efficacy. 
In the study assessing GAD65, different epitopes were designed based on the 
GAD65 GenBank sequence. The reactivity to these epitopes was further 
tested by tetramer technology. It was surprising to find that patients and 
healthy subjects did not differ in the presence or absence of autoreactive T 
cells to GAD65 epitopes, but the magnitude of the response was much higher 
in patients, suggesting a higher percentage of activated T cells in the 
disease.[81] 
In addition, it is likely that the initial loss of tolerance is targeted against a 
particular epitope of the given antigen (insulin or GAD in humans), but is later 
spread over time in the inflamed tissue to other epitopes within the given 
antigen (intramolecular or epitope spreading).[82-84],[59]  
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1.2 Immune interventions in Type 1 diabetes 
Starting from the concept that autoimmunity is a dominance of unwanted 
autoreactive effector T cells over Tregs, many immune intervention studies 
have aimed to restore the balance. They target various arms and molecules 
involved in the immune process, as shown in Figure 1-5.[85] Non-antigen 
specific immune interventions fit into the picture by performing global 
immunosuppression that will abolish autoreactive cells, together with many 
other innocent by-standers. More subtle in their approach, antigen-specific 
interventions (ASI) aim to restore tolerance to self by inducing antigen-specific 
Tregs, whilst leaving the function of the rest of the immune system intact. One 
very optimistic view is that to achieve suppression, we may not need to know 
or administer the initiating autoantigen, or multiple antigens. Induction of 
Tregs, whatever their specificity, may induce bystander immunomodulation 
through production of protective cytokines, or promoting tolerogenic antigen 
presentation.[76, 86]  
 
Timing of immune intervention trials spans from primary prevention in 
genetically high-risk individuals, with no detectable autoimmunity, to 
secondary prevention in people who have detected islet cell autoantibodies 
and, finally, tertiary prevention, aimed to preserve residual #-cell function after 
diagnosis of diabetes, which may have impact on control and complications of 
T1D later in life. Primary prevention trials involving oral insulin in subjects with 
high titer of islet cell antibodies showed promising preliminary results [87]. In 
addition, administration of nasal insulin showed good safety and tolerability 
records.[88] This was not confirmed in the DIPP trial in which nasal insulin 
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was administered in the large cohort of high-risk infants or their siblings.[89] 
The concept of primary and secondary prevention is challenging in regards to 
the need for the large-scale population screening, the balance of safety and 
efficacy, as well as the impact of the alternative approach of not treating. In 
addition, recent review of the various studies points towards the lack of 
consistent in achieving delay or prevention of diabetes.[90, 91] These are 
some of the reasons why the prevention concept shifted its focus towards 
tertiary prevention. 
 
Figure 1-5. Targets of therapeutic agents used in immune intervention studies in Type 
1 diabetes. Adapted from Ryden, A.K., et al., Non-antigenic and antigenic interventions in 
type 1 diabetes. Hum Vaccin Immunother, 2013. 10(4). !
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Studies on immune intervention in T1D started with cyclosporine, a peptide of 
fungal origin with a potent immunosuppressive capacity through inhibition of T 
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cell activation. Although this agent was rendered unacceptable for this 
purpose due to serious side effects, and the need for repetitive dosing, it 
proved the concept that T-cell directed immunosuppression is capable of 
preserving # cell function and insulin production. [92, 93] 
However, studies using different immunosuppressants, mycophenolate mofetil 
and daclizumab, a monoclonal antibody targeting CD25, which is widely used 
in transplantation, did not preserve #-cell function in T1D. This approach may 
be a double-sided sword, in which by targeting CD4+CD25+ Tregs, 
daclizumab destroys T-cells important for maintaining self-tolerance.[94]  
All together, these observations suggested the need for more targeted 
immunotherapies and led to anti-CD3 monoclonal antibodies against CD3 
molecules expressed on the surface of T cells as a part of the TCR complex. 
These antibodies have been successful in preventing transplant rejections, 
but had the significant side effect of causing cytokine-storm.[95] Their 
modification to reduce Fc receptor binding affinity led to the reduction in side-
effects, but retained immunosuppression.[96] Two of these antibodies have 
been developed for use in the immune interventions: teplizumab and 
otelixizumab.  
Teplizumab, was promising in arresting the loss of #-cell function, in both 
children and adults, when administered within 6 weeks of diagnosis, an effect 
that extended up to two years of follow-up.[97, 98] The effect was individual, 
with a number of patients showing decline in #-cell function after two years. 
This was particularly the case in a study that included a younger cohort, 
known to have more aggressive disease and some thymus function that can 
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regenerate autoimmunity. However, an effect of immune regulation was 
detected in some patients, including significant increases in the amount of IL-
10 and IL-5 in the serum, as well as an increase in the number of 
FOXP3+CD8+ Tregs. [99]  
In the Protégé study on the efficacy of teplizumab, which involved patients 
diagnosed 4-12 months before enrolment in the study, the treatment group 
showed reduced decline in C-peptide after two years, with most of the effect 
observed in patients with recent T1D onset.[100] The same effect was 
replicated in a larger study, although the trial did not meet its endpoints, which 
were focused on diabetes control (HbA1c level and insulin requirement) that is, 
unlike C-peptide level, dependent on manipulation by physicians and 
patients.[101] However, younger patients with good metabolic control and 
higher C-peptide levels had better therapeutic benefit.[102] 
Otelxizumab failed to show benefit in #-cell preservation in a larger study 
[103], despite promising results of a higher dose otelxizumab in a smaller 
cohort, extending up to 18 months of follow up after a single treatment.[104] 
Interestingly, a subgroup of patients showing the most benefits, extending up 
to 48 months, were the younger ones and those with the highest #-cell 
function at diagnosis. [105] 
Another approach is based on the observation that stimulation of T-cells 
through the TCR complex without co-stimulation (interaction of CD28 on T 
cells and B7 molecules on APC) leads to T cell inactivation. Modulating co-
stimulation would, in theory, affect only T cells that have their antigen-specific 
receptors engaged. This is the basis of trials studying the CD28 homologue, 
! $#!
cytotoxic T-lymphocyte antigen 4 immunoglobulin (CTLA4-Ig), also known as 
abatacept. It selectively binds the B7 molecules on the APC, interfering with 
APC – T-cell interaction and inhibiting T-cell. 
Indeed, when abatacept was tried in patients with recent onset Type 1 
diabetes, it showed limited #-cell preservation properties early in the disease, 
but not after prolonged treatment.[106] A possible explanation for the failure in 
this later stage is that main wave of T cell activation happens earlier in the 
disease. For this reason, the drug is now been investigated in a secondary 
prevention trial.[85]  
The success of rituximab, a monoclonal anti-CD20 antibody directed against 
B cells, in rheumatoid arthritis, indicated the possibility for its use in diabetes. 
The rationale for this approach is to affect a large population of cells with 
antigen presenting properties, such as B cells. A phase II trial showed initial 
improvement in stimulated C-peptide, and HbA1c and insulin requirement, 
particularly in younger patients, but the effect that did not sustain over the 12 
months follow-up.[107] An interesting analysis of the rituximab responders 
indicated that they showed enhanced responses to diabetes-associated target 
antigens. The authors speculated that rituximab enabled recovery of #-cell 
function through interruption of pathogenic T cell recruitment via surface 
immunoglobulin-captured autoantigens. This effect was transient and post-
treatment recovery of B cells enabled targeting of new antigens leading to the 
recovery of autoimmunity and decline in C peptide levels.[108] Although 
difference was seen in the frequency of the different T cell populations in this 
study, including Tregs, in another trial involving patients with vasculitis, 
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rituximab was associated with higher level of follicular T cells and Tregs in 
comparison to conventional treatments.[109] 
The rationale for targeting cytokine IL-1# or its receptor is based on the fact 
that these receptors are highly expressed on #-cells, and that hyperglycaemia 
promotes the binding of IL-1# to its receptor, which can lead to #-cell 
apoptosis.[110] Despite a solid background, efficacy of anakinra, a human IL-
1 receptor antibody, and canakinumab, a human IL-1 receptor antagonist, has 
not been observed in the clinic.[111]! 
Combination therapy of low dose IL-2 and rapamycin in humans, contrary to 
the success in mice, worsened #-cell function, despite an increase in Treg 
number.[112] This suggests the need for fine-tuning of the immune system in 
order to promote tolerance and reduce inflammation at the same time.  
The choice of these therapies has to be influenced by their 
immunosuppressive effect. For example, it has been suggested that 
abatacept decreases the magnitude of antibody responses to recall 
vaccination.[113] There were also some concerns of progressive multifocal 
leukoencephalopathy with rituximab[114], although full clinical presentation 
was not observed after four treatment doses in Type 1 diabetes, not excluding 
the theoretical possibility for the disease the case for the long term 
treatment.[115]   
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Antigen-specific immunotherapy (ASI) is a manipulation designed to deliver #-
cell autoantigens via a route and regime that will restore immunological 
tolerance to the #-cell and thus halt further immune-mediated #-cell damage. 
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As previously discussed, one of the major autoantigens considered for use in 
ASI is proinsulin[46], the precursor molecule of the hormone insulin and 
therefore many ASI strategies are insulin/proinsulin based. Amongst ASI 
approaches, peptide immunotherapy (PIT) is a strategy in which specific 
peptide sequences of #-cell autoantigens that are targeted by autoreactive T 
lymphocytes are administered in an attempt to restore immunological 
tolerance.[116] 
One of the first trials in the field of ASI interventions was a GAD–alum trial. 
GAD65 is one of the major autoantigens in Type 1 diabetes, hence the large 
interest in the therapeutic application of this agent. For the purpose of the 
human trial, it was combined with an aluminum hydroxide adjuvant called 
alum, known to preferentially induce Th2 responses[117] and promote Treg 
expansion[85], which can potentially be beneficial in Type 1 diabetes reversal. 
Administration of GAD-alum in children within 18 months of diagnosis, 
showed less decline in fasting and stimulated C-peptide only in patients 
treated within 6 months of diagnosis.[118] This was not confirmed in another 
trial using GAD-alum in children and adults within 100 days of diagnosis, 
which showed no effect on stimulated C-peptide [119], and also in the latest 
Phase III trial.[120] Looking back, this is not surprising, as GAD prevented 
diabetes in animal models, but never reversed diabetes in the later stage of 
developed disease. It was therefore probably too optimistic to expect that 
GAD will reverse diabetes in humans. In addition, GAD alum used in clinical 
trials was never preclinically tested in animal models. It has only recently been 
shown to have no efficacy in NOD and B6 diabetes models.[121] The dose of 
GAD in the human trial was probably not the reason for the failure, as people 
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mounted detectable antibody response, but alum may not be the right 
adjuvant. It showed T helper type 2 – dominated cytokine response that did 
not result in protective cell populations.[122] 
A more successful trial (DiaPep277), involving s.c. administration of HSP60 
derived peptide (p277, amino acids 437-460) in adults within 6 months of 
diagnosis, slowed glucagon stimulated C-peptide decline in adults [123], but 
not in children [124]. These pilot results in adults were confirmed in the Phase 
III trial that showed not only slower decline in #-cell function, but also 
improvement in HbA1c independent of insulin dose. Interestingly, the 
beneficial effect on C-peptide was evident only when glucagon was used as a 
stimulus, but not standard mixed meal.[125] This provides the ground for 
skepticism, given the difference in sensitivity to glucose during stimulation by 
these two agents.[126] 
An interesting trial, involving administration of plasmid-encode proinusulin in 
subjects with Type 1 diabetes, showed better preservation of C-peptide in the 
selected treated group, but the effect disappeared after withdrawal of the 
treatment. Alongside the metabolic effect, reduction of proinsulin-specific CD8 
cells was also detected. Plasmid based therapies open a new potential in 
combining antigen encoding gene with the genes encoding suppressive 
cytokines such as IL-4 and Il-10 inhibiting Th1 response.[127]  
1.3 Optimising immune interventions in Type 1 diabetes 
Experience over the past years taught us that achieving and proving the 
efficacy of immune intervention depends on number of factors that have to fit 
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together like a jigsaw puzzle for the treatment to be successful and to be 
recognized as such.  
Design and monitoring of the “ideal” immune intervention trial in Type 1 
diabetes requires addressing number of issues. 
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With a more advanced autoimmune process, immune intervention may be 
less effective. Antigen-specific tolerance would be easier to induce in the 
earliest stages of the disease, with a broader approach needed later in the 
pathogenesis, when the polyclonal repertoire develops. This is certainly the 
case at the time of diagnosis, and possibly even earlier, when multiple 
antibodies are detected in pre-diabetic individuals, indicating intermolecular 
spreading. As previously discussed, GAD prevented diabetes in animal 
models, but never reversed diabetes in the stage of developed disease. It was 
not surprising that the effect was not consistent in humans with developed 
disease.  
It is possible that, at this late stage, multiple antigen therapy is needed. 
Alternatively, a dual approach therapy of systemic immunosuppression with, 
for example, monoclonal anti-CD3 antibody followed by antigen specific 
immunotherapy, maybe the optimal combination. This approach was effective 
in the NOD mouse model, when anti-CD3 treatment was combined with the 
intranasal proinsulin peptide.[128] 
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Finding the optimal balance between side effect and an adequate dose 
sufficient to elicit substantial effect on immunity is of paramount importance. 
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Taken wrongly, it can compromise the whole trial and the future of an 
otherwise promising drug, as was the case with otelxizumab in a Phase III trial. 
Antigen specific immunotherapies for the induction of immune tolerance were 
successful in animal models, but less so in the clinic. Difficulties encountered 
in translating the dose may be explanation for these less promising results. 
Dose titration in humans requires a reliable monitoring tool of the immune 
response, and cannot simply be based on the presence or the absence of 
metabolic outcome.  
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Apart from skin delivery, other possible routes for administration of antigen-
specific immunotherapy are the intranasal, the sublingual, the subcutaneous 
and the intravenous. Skin is most preferred route due to its accessibility and 
the abundance of cells, such as potent APCs and Tregs that can take up 
delivered peptide and send an antigen-related tolerogenic message to the rest 
of the immune system. The optimal mode of skin administration, taking into 
account depth and potential pro-inflammatory impact of delivery, will be 
discussed in Chapter 3.  
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Immune interventions work better in people with higher insulin production, 
which was certainly the case with the monoclonal anti-CD3 antibody trials. 
Some people with T1D have an aggressive and strong autoimmune process 
capable of fast #-cell destruction. Others have mild disease that progressively 
destroys #-cells over number of years, and some exhibit remitting/relapsing 
disease.[129] Identifying the mode and severity of the autoimmune process in 
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each patient is an important basis for choosing the right type, intensity and the 
right timing of immunotherapy. Supportive of this are the findings that the 
DiaPep277 trials worked in people with an HLA type associated with less 
aggressive disease and only in adults, but not in children with rapidly 
progressing autoimmunity.[130] 
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Effective immune interventions in T1D would an elicit immune response that 
can potentially be evident promptly after administration of the agent, and more 
long-term metabolic outcomes, such as an effect on #-cell function, and 
glycaemic control.  
The majority of trials have focused on #-cell function as a gold standard 
measure of efficacy. #-cell function is expressed as stimulated serum C-
peptide, with standardised mixed meal used as a stimulus in most trials. 
Interestingly, the DiaPep277 study showed an effect only when serum C-
peptide production was stimulated with glucagon, but not a standardised 
mixed meal, indicating the influence of a difference of sensitivity to glucose 
during these two types of stimulation.[126] No other studies have routinely 
used both stimulations, so it remains to be clarified which one is a more 
sensitive method for the assessment of #-cell function in clinical trials.  
In addition, there is some recent evidence suggesting that #-cell function can 
be assessed by measuring urinary C-peptide production after standardised 
mixed and random meals.[131] The simple and non-invasive nature of this 
method makes it a good candidate for the estimation of #-cell function in trials. 
This will be discussed in detail in Chapter 6.  
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Although a positive effect on glycaemic control is the most desirable one to be 
recorded in any trial on T1D, it is not the most reliable one as it can be 
influenced by other factors not necessarily related to the intervention. Indeed, 
HbA1c and insulin dose are affected by starting residual #-cell function, the 
patient’s compliance with the medication, quality of care etc. Changing the 
outcome from the effect on #-cell function, that gave promising results in 
earlier stages of the teplizumab trial, to the effect on glycaemic control in 
Phase III, resulted in failure to reach study outcomes, probably due to the 
reasons discussed above.[101]  
Separately from metabolic outcomes, effects on immune system are important 
to record, as some patients may experience one without another. In addition, 
immune outcomes would, by definition, happen earlier than metabolic 
outcomes, which would help to identify responders and/or guide dose 
adjustments. However, detection of the effect on immune processes in the 
blood following antigen specific immunotherapy has been a challenge for 
many trials, and to this day no ideal marker for monitoring immune and 
therapeutic efficiency has been established.[132] Detection of cellular immune 
responses to self-antigen in the blood is very difficult, as the frequency of cells 
responding to any given antigen is very low (less than 1 in 10,000 cells).[45] 
Irrespective, the accessibility of blood makes it the most commonly used 
source of immune cells in human studies. On the contrary, in murine models, 
lymphoid organs, such as spleen and lymph nodes, are usually used to 
harvest cells and monitor immune interventions. 
It is becoming more and more clear that simple administration of candidate 
antigen with various frequencies, followed by monitoring of the metabolic 
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outcome, is ineffective to achieve and record efficacy in halting autoimmune 
response in Type 1 diabetes.  
Firstly, the site and mode of the delivery, including the choice of optimal 
delivery device and co-administration of agents that will facilitate the 
generation of the tolerogenic response, has to be carefully considered and 
planned. 
Secondly, choosing the right monitoring tool of the immune and metabolic 
response is equally important because, without evident effect, any potential 
benefit of the ASI may be missed. The immune response needs to be 
detected with the minimally invasive, but sufficiently sensitive tool, but also in 
the site where immune process takes place, which is not the blood but the 
lymph node (or local tissues), as known from murine studies. On the other 
hand, assessment of ! cell function requires a test acceptable and sensitive 
enough to identify rapid changes in C-peptide production. Such a test would 
help in identifying patients with rapid decline of insulin production as excellent 
candidates for intensive therapeutic interventions, as well as responders to 
the treatment.  
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1.4 Summary of aims 
This project is focussed on, firstly, establishing the optimal means and 
conditions for antigen skin delivery in order to achieve tolerance and, 
secondly, establishing the optimal tool to monitor immune and metabolic 
responses to a given treatment.  
1.4.1 -195/&(*5,/.(0/9)1C,0/*09(&(7,7/CC3,(*,./.&(0/,3D(*,0/C(:/9+,E,9(5=&,.C17/F,9(5=&,
&''C,GH=1.&/9,;I. !
1. To study the targeting of epidermal DCs by peptide delivered by 
hollow microneedles. 
2. To study the targeting of epidermal DCs by peptide delivered by 
dry coated microneedles. 
!"A"# J*=1*7/)/*&,'8,&=/,&'C/9'5/*(7,/*:(9'*)/*&,(*,.9/.191&('*,8'9,&=/,./.&(0/,
())%*'&=/91.+,GH=1.&/9,AI,!
1. To study the effect of topical steroid pretreatment on tolerogenic 
potential of skin DCs 
2. To study the effect of pretreatment of intradermally injected IL-
10, alone or attached to gold nanoparticles, on tolerogenic potential of 
skin DCs. 
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1. To assess feasibility and to optimise methods for monitoring 
immune response in the draining lymph nodes after intradermal antigen 
skin delivery in comparison to PBMCs isolated from the blood of the 
same subject at the same time. 
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1. To confirm in our center that standard mixed-meal stimulated 
UCPCR  correlates well with gold standard MMTT. 
2. To determine whether stimulated UCPCR can be used to 
monitor changing #- cell function over time. 
3. To determine which form of stimulation is optimal for this 
purpose. 
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2.1 Ex-vivo methods for the optimal targeting and conditioning   
of skin dendritic cells 
#"!"! P3'C1&('*,'8,./9(.=/91C,2C''0,)'*'*%7C/19,7/CC3,GMUKH3I,,
PBMCs were isolated by Ficoll-Paque Plus gradient centrifugation from 
healthy donors with full ethical approval (REC number 05/MRE06/57) and 
after informed consent. [133] 
Samples were collected in heparinized tubes (0.5ml of 1000 units/ml Na-
heparin per 20 ml of blood) and mixed with 25ml of warm RPMI 1640 per 20 
ml of blood. The mixture was layered on Ficoll-Paque Plus (15 ml of the 
mixture on 10 ml of Ficoll-Paque Plus) and centrifuged on 400xg for 40 min on 
ambient temperature. Supernatants, containing serum and PBMCs, were 
aspirated, washed twice in RPMI 1640 and finally re-suspended in 10% (v/v) 
human serum in RPMI 1640 supplemented with 0.5mM l-glutamine, 50IU/ml 
penicillin, 0.05mg/ml streptomycin and 0.1mg/ml neomycin.  
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An organ skin bath culture system was developed and optimised for the ex-
vivo study of various treatment effects (antigen delivery and pre-treatment 
with immunomodulatory agents) on the human skin dendritic cells assessed 
by means of flow cytometry and functional assays. 
Skin samples were obtained from female patients aged 19-82 years, following 
mastectomy or breast reduction with full ethical approval (SE Wales Local 
Research Ethics Committee, reference number 08/WSE03/55) and informed 
consent. Skin without obvious pathological findings, and that was surplus to 
diagnostic histopathology requirements, was excised and transported to the 
laboratory on ice in organ culture medium comprising Dulbecco’s modified 
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Eagle medium (DMEM) supplemented with 50 IU mL-1 penicillin and 50µg mL-
1 streptomycin. 
Subcutaneous adipose tissue was removed by blunt dissection to yield full-
thickness skin, which was exposed to treatment depending on the experiment. 
Circular biopsy punches of the treated skin were obtained by using a 
disposable 8mm biopsy punch. Punches were then cultured at the air-liquid 
interface in cell culture inserts with perforated bottoms in a 24-well plate 
(Figure 2-1) in DMEM supplemented with 50 IU mL-1 penicillin and 50µg mL-1 
streptomycin at 37°C in an atmosphere of 5% (v/v) CO2/95% (v/v) air for 
24h.[134] 
 
Figure 2-1. Organ skin bath culture: a) 24-well plates with well inserts creating air-liquid 
interface; b) top aspect of the insert with the skin punch; c) bottom aspect of the insert with 
the skin punch.  
 
After the incubation (duration varied depending on the experiment), the skin 
was taken out of the culture and the bulk of the lower dermis was removed by 
blunt dissection. The remaining tissue containing epidermis and upper dermis 
was immersed in enzyme solution containing Dispase II (2 units/ml), 
Collagenase I (197units/ml) and Deoxyribonuclease I (DNA-se I) from bovine 
pancreas (20 units/ml) in RPMI 1640 for 1 h on 37°C. Epidermal sheets were 
mechanically separated from the rest of the dermis and transferred in the 
#$" %$" &$"
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0.25% (w/v) trypsin solution in phosphate buffered saline (PBS) for 30 min at 
37°C.[135] 
After incubation, the remnants of the epidermal sheets were pipetted up and 
down to increase cell yield, centrifuged at 400xg for 10 min and re-suspended 
in DNAse I (0.85units/ml) in 10% (v/v) fetal calf serum (FCS) in PBS for 1h at 
37C.  
Single cell suspensions were subsequently centrifuged at 400xg for 10 min 
and re-suspended in the appropriate solution depending on the experimental 
procedure. 
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"-irradiated (2000 rad) PBMCs (200.000 live cells/well) from one donor were 
incubated with allogeneic PBMCs (200,000 live cells/well) in 10% (v/v) human 
serum in RPMI 1640 supplemented with 0.5mM L-glutamine, 50IU ml-1 
penicillin, 0.05mg ml-1 streptomycin and 0.1mg ml-1 neomycin (complete RPMI 
1640) in a 96-well plate at 37°C and 5% (v/v) CO2/95% (v/v) air. Each well 
contained 200µl of medium. 
The number of cells was counted in a haemocytometer after staining with 
trypan blue (1:3 dilution in PBS). 
After 96h of culture, 100µl of medium was collected from the surface and 
stored at -20°C for cytokine detection at the later date. 1µCi [3H] thymidine 
was added to each well, and the incorporation of radioactivity was measured 
after 16h using a !-microplate scintillation counter. [136] 
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To assess the functional capacity of the skin dendritic cells, epidermal cells 
(50,000 live cells/well, containing dendritic cells) were incubated with 
allogeneic PBMCs (200,000 live cells/well) in complete RPMI 1640 in a 96-
well plate, at 37°C and 5% (v/v) CO2/95% (v/v) air. Each well contained 200µl 
of medium. 
The number of cells was counted in the haemocytometer after staining with 
trypan blue (1:3 dilution in PBS). 
After 96h of culture, 100µl of medium was collected from the surface and 
stored at -20°C for cytokine detection at the later date. 1µCi [3H] thymidine 
was added to each well and the incorporation of radioactivity was measured 
after 16h using !-microplate scintillation counter. [137] 
#"!"B WC'>67+&')/&9(7,1*1C+3(3,
Before staining, cells were filtered through a 70µm cell strainer. For viability, a 
near-IR fixable Live/Dead Cell Stain was used (APC Cy7 channel). The stain 
reacts with amines, which are available both on the cell surface and in the 
interior of the dead cells with compromised membranes, giving bright 
fluorescence. Amines on the live cells with the intact membranes are available 
only at the surface, giving less bright colour intensity and easy distinction from 
the dead cells. Epidermal cells were re-suspended in 1µl/1000 cells of 0.1% 
(v/v) Live/Dead stain in PBS and incubated for 30 min in the dark at 4°C.  
The cells were centrifuged at 400xg for 5 min, re-suspended in the solution of 
flowcytometry antibodies in flow-cytometry buffer (FCB) (Section 2.1.5), and 
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incubated for 20 min in the dark at 4°C. Staining was performed in a 100µl 
volume with up to 1x105 cells/test.  
Simultaneously, in some experiments and for the compensation purposes, the 
appropriate species matching compensation beads were incubated with each 
dye separately under the same conditions.  
After incubation, centrifuging at 400xg and re-suspending in FCB twice, 
additional step of 20 min long incubation with biotinylated fluorochrome was 
included in some experiments (Section 2.1.5). Otherwise, in some 
experiments, flow-cytometry fixative (FCF) was added to cell solutions 
(FCB:FCF=1:2), but not to the compensation beads. Cells were analysed on a 
FACS Canto II flow cytometer (BD biosciences) and data was processed 
using FlowJo software version 8.8.6 (Leland, Stanford). 
I used this protocol for the following purposes:  
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The following test tubes were used: 
• Test tube containing cells stained with Live/Dead stain only 
• Test tube containing cells stained with antibodies listed in the Panel A 
(Table 2-1, Table 2-2) 
• Test tube containing cells stained with antibodies listed in the Panel B 
(Table 2-1, Table 2-2) 
• Test tubes containing compensation beads stained with each dye 
separately and unstained beads 
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Panel A Panel B 
Marker Dilution Manufacturer Marker Dilution Manufacturer 
Pacific Blue 
anti-human CD1a 1:20 
E-bioscience, 
Hatfield, UK 
Pacific Blue 
anti-human CD1a 1:20 
E-bioscience, 
Hatfield, UK 
AF488* 
anti-human CD207 1:50 
Dendritics, 
Lyon, France 
FITC 
anti-human CD40 1:50 
E-bioscience, 
Hatfield,UK 
PE 
anti-human Epcam- 1:50 
E-bioscience, 
Hatfield, UK 
PE 
anti-human CD83 1:50 
E-bioscience, 
Hatfield, UK 
APC 
anti-human CD86 1:50 
BD Pharmigen, 
Oxford, UK    
biotin anti-human 
CD80 (+anti-biotin 
PerCPCy5.5) 
1:50 
(1:50) 
BD Pharmigen, 
Oxford, UK  
(E-bioscience, 
Hatfield, UK) 
PerCPCy5.5 
anti-human HLA-DR- 1:100 
BD Pharmigen, 
Oxford, UK 
Near-IR fixable  
Live/Dead stain see text 
Invitrogen, 
Paisley, UK 
Near IR fixable  
Live/Dead stain see text 
Invitrogen, 
Paisley, UK 
PeCy7 
Anti-human CD11c 1:100 
E-bioscience 
Hatfield, UK 
PeCy7 
Anti-human CD11c 1:100 
E-bioscience 
Hatfield, UK 
Table 2-1! Monoclonal antibodies for flow-cytometry – panels for the epidermal cells  
*Later in the project PE anti-human CD207 (dilution 1:30) used for some studies, Biolegend, 
London, UK !
Marker Role 
CD1a Membrane glycoprotein, role in non-peptide glycolipid antigen presentation to T cells 
CD207 
Member of C-type lectin family, role in processing pathway through 
capture and internalization of its ligands (mannose, N-acteylglcosamine 
etc.) 
Epcam Epithelial cell surface antigen involved in the cells adhesion 
CD86 Ligand for CD28 and CD152 (CTLA-4), involved in T cell co-stimulation  
CD80 Ligand for CD28 and CD152 (CTLA-4), involved in T cell co-stimulation 
CD11c Glycoprotein expressed by dendritic cells, important for cell-cell contact by binding to its ligands such as fibrinogen 
CD40 Co-stimulatory protein, required for activation of APCs upon binding to its ligand CD154 on lymphocytes 
CD83 Trans-membrane protein, marker of maturity of dendritic cells, involved in regulation of T cell development 
HLA-DR MHC class II, trans-membrane protein, essential for T antigen presentation 
Table 2-2! Role of the surface markers used for the flow-cytometric analysis of DCs. !!!!!
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The following test tubes were used: 
• Test tube containing cells stained with Live/Dead stain only 
• Test tube containing cells stained with antibodies listed in the Panel A 
(Table 2-3) 
• Test tubes containing compensation beads stained with each dye 
separately and unstained beads 
!!!!!!
Table 2-3! Monoclonal antibodies for flow-cytometry – panels for the T cells cultivated in 
the culture driven by steroid exposed and untreated  ECs. !
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The following test tubes were used: 
• Test tube containing cells stained with Live/Dead stain only 
• Test tube containing cells stained with Live/Dead stain and FITC anti-
human HLA-A2 antibody ( Table 2-4) 
Marker Dilution Manufacturer 
FITC 
anti-human HLA-A2 1:50 
Biolegend,  
London, UK 
Near-IR fixable  
Live/Dead stain see text 
Invitrogen, 
Paisley, UK 
 
 Table 2-4. Monoclonal antibodies for flow-cytometry – panel for HLA-A2 typing 
Panel A 
Marker Dilution Manufacturer 
V450 anti-human 
CD3 1:30 
Invitrogen, 
Paisley, UK 
eFluor®506 
viability dye 
1:500 E-bioscience, 
Hatfield, UK 
FITC 
anti-human CLA 1:30 
Biolegend,  
London, UK 
PE 
anti-human CD127 1:10 
Miltenyi Biotec, 
Surrey, UK 
APC 
anti-human CD25 1:10 
Miltenyi Biotec, 
Surrey, UK 
Per CP Cy 5.5 
Anti-human CD8 1:30 
Biolegend,  
London, UK 
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Production of pro-inflammatory cytokine Interferon " (IFN") and pro-
tolerogenic Interleukin 10 (IL-10) was measured in the supernatants of MLR 
or MECLR reactions by using ELISA (Human IFN! ELISA Ready-Set-Go! and 
Human IL-10 ELISA Ready-Set-Go!; E-bioscience, Hatfield, UK). 
The kit consists of the following reagents: 
• Capture antibody: Purified anti-human IFN! (250x); Purified anti-human 
IL-10 (250x) 
• Standard (Recombinant human IFN! protein - 1µg ml-1, reconstituted in 
the 1xassay diluent to prepare top standard solution (500pg ml-1); 
Recombinant Human IL-10 protein – reconstituted in 1xassay diluent to 
prepare top standard solution (300pg ml-1))  
• Detection antibody; biotin-conjugated anti human IFN! (250x), biotin-
conjugated anti human IL-10 (250x) 
• Enzyme: Avidin-Horseradish Peroxidase (HRP) – 250x 
• 5xassay diluent, reconstituted in deionized water to make 1xassay 
diluent 
• Substrate solution: 1xtetramethylbenzidine (TMB) solution 
• 10xELISA coating buffer, reconstituted in deionized water to make 
1xELISA coating buffer. 
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The following incubation steps were performed:  
• The ELISA plate was coated with 100µl/well of capture antibody in 
coating buffer (1:250) and left overnight at 4°C.  
• Blocking with 1xassay diluent and incubation at ambient temperature 
for 1h.  
• Two-fold serial dilutions of the top standard (500pg ml-1 for IFN! and 
300pg ml-1 for IL-10) were made down to lowest standard 
concentration of (7.8pg ml-1 for IFN! and 4.7pg ml-1 for IL-10), by using 
1xassay diluent. Fifty µl/well of standard dilutions and samples 
(including sample dilutions 1:1, 1:10 and 1:20 in 1xassay diluent) were 
added to the plate and incubated for 2h at ambient temperature.  
• 100 µl/well of detection antibody diluted in 1xassay diluent (1:250) was 
added to the plate and incubated at ambient temperature for 1h.  
• 100 µl/well of avidin-HRP diluted in 1xassay diluent (1:250) was added 
to the plate and incubated at ambient temperature for 30 min. 
• Finally 100µl of substrate solution was added to each well and 
incubated up to 15 min. 100µl of 2M H2S04 was added to each well to 
stop the reaction. The plate was read at 450nm on a microplate 
spectrophotometer.  
Each incubation step, with the exception of the last one, was completed by 
the thorough wash of the wells with 200µl/well of wash buffer (5x). 
Optical density values were transformed to the cytokine concentration on the 
basis of the respective standard curves (Figure 2-2). 
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Figure 2-2. Representative examples of ELISA standard curves: a) IFN!: standard curve 
range 4 – 500 pg/ml; a) IL-10: standard curve range 2 – 300 pg/ml. !
#"!"I"# MNOP$2&?.@,&2&'($)'$*/5*@6(@,&.$/<$&+)-&,2?6$*&66.$?'-$FGH$=L!$,&.(,)*(&-$
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IFN! in the supernatants of co-cultures of epidermal cells and HLA DR1 
restricted FP1 specific cloned T-cells was measured by the use of the exactly 
same IFN! ELISA kit and protocol as described in the part 2.1.6.1 of this 
section. 
#"!"I"3 KM85!4$2&?.@,&2&'($)'$*/5*@6(@,&.$/<$&+)-&,2?6$*&66.$?'-$FGH5H#$
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Production of Macrophage Inflammatory Protein 1 # (MIP-1#) in the 
supernatants of co-cultures of epidermal cells and HLA-A2 restricted EBVP1 
specific cloned T-cells, was measured by ELISA (human CCLR/MIP-1#, 
DuoSet® Development System, R&D Systems, Abingdon, UK). 
The kit consists of the following reagents: 
• Capture antibody, reconstituted in PBS to 180µg/ml stock 
concentration 
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• Detection antibody, reconstituted in Reagent Diluent - RD (see below) 
to 9µg/ml stock concentration 
• Human MIP-1# standard, reconstituted in RD to the top concentration 
of 1000ng/ml, which was used to make 2-fold serial dilutions (7 in total) 
• Streptavidin-HRP 
 
Additional required solutions were: 
• Wash Buffer - 0.05% Tween®20 in PBS 
• Reagent Diluent (RD) – 1%BSA 
• Substrate Solution: 1:1 mixture of Colour A reagent (H2O2) and Colour 
reagent B (tetramethylbenzidine) 
• Stop solution: 2M H2S04.  
 
The following incubation steps were performed:  
• The ELISA plate was coated with 100µl/well of capture antibody in PBS  
(1µg/ml) and left overnight at ambient temperature.  
• Blocking with 300µl/well of RD and incubation at ambient temperature 
for 1h.  
• Two-fold serial dilutions of the top standard (1000pg ml-1) were made 
down to lowest standard concentration of (15.6 pg ml-1), by using RD. 
Fifty µl/well of standard dilutions and samples (including sample 
dilutions 1:1 and 1:2 in RD) were added to the plate and incubated for 
2h at ambient temperature.  
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• 100 µl/well of detection antibody diluted in RD  (50ng/ml) was added to 
the plate and incubated at ambient temperature for 2h.  
• 100 µl/well of Streptavidin-HRP diluted in RD (1:200) was added to the 
plate and incubated at ambient temperature for 20 min. 
• Finally 100µl of substrate solution was added to each well and 
incubated up to 20 min. 100µl of 2M H2S04 was added to each well to 
stop the reaction. The plate was read at 450nm on a microplate 
spectrophotometer.  
Each incubation step, with the exception of the last one, was completed by 
the thorough wash of the wells with 200µl/well of wash buffer (5x). 
Optical density values were transformed to the cytokine concentration on the 
basis of the respective standard curves (Figure 2-3). 
 
 
 
 
Figure 2-3. Representative example of MIP-1! ELISA standard curve. Standard curve 
range 16 – 1000 pg/ml. 
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I used Miltenyi Naïve CD4+ Isolation Kit II, which included the following steps:  
• PBMCs were resuspended in 40µl of MACS buffer per total of 107 cells 
and incubated for 10min. (2-8°C) with 10µl of Naïve CD4+ T cell Biotin-
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Antibody Cocktail II (against CD8, CD14, CD15, CD16, CD19, CD25, 
CD34, CD36, CD45R0, CD56, CD123, TCR!/$, HLA-DR and CD235a) 
per 107 cells. 
• After incubation, cells were washed by adding 1ml of buffer per 107 
cells, centrifuged at 300xg for 10 min and resuspended in 80µl of buffer 
per 107 cells; then further incubated for 15 min. at 2-8°C with 20µl of 
Anti-Biotin Microbeads per 107 cells. 
• Cell were washed and centrifuged as previously described, and 
resuspended in 500µl of buffer.  
• After priming the MS column placed in the magnetic field with 500µl of 
MACS buffer, cell suspension was passed through the column followed 
by washing step (3x500µl). 
• Follow-through containing unlabeled cells was collected as naïve CD4+ 
T cells. 
During the procedure all buffers and cell suspensions were kept cold and 
sufficient time was allowed for the column reservoir to become empty before 
proceeding with the another step. 
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I used Miltenyi CD4+CD25+CD127- Isolation Kit II, which included the following 
steps:  
• PBMCs were resuspended in 40µl of MACS buffer per total of 107 cells 
and incubated for 5min. (2-8°C) with 10µl of CD4+CD25+CD127- biotin-
Antibody Cocktail II per 107 cells. 
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• After 5 min, 30µl of buffer and 20µl of Anti-Biotin Microbeads was 
added per 107 cells for further incubation for 15 min. at 2-8°C.  
• After incubation, the volume was adjusted to a minimum of 500µl of 
buffer. 
• After priming the LD column placed in the magnetic field with 2ml of 
MACS buffer, cell suspension was passed through the column followed 
by washing step (2x1ml).  
• Total effluent of cell suspension was collected as population depleted 
from non-CD4+ and CD127high cells. 
• Cells were washed and resuspended in 90µl of buffer per 107 of cells 
and incubated at 2-8°C for 15 min. with 10µl of CD25 MicroBeads II per 
107. 
• After priming, the MS column placed in the magnetic field, with 500µl of 
MACS buffer, cell suspension was passed through the column followed 
by washing step (3x500µl). 
• Column was removed from the magnetic field and flushed with 1ml of 
buffer to remove magnetically labeled cells that were desired CD4+ 
CD25+CD127- cells. 
During the procedure all buffers and cell suspensions were kept cold and 
sufficient time was allowed for the column reservoir to become empty before 
proceeding with the another step. 
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Betamethasone dipropionate cream 0.05% (w/v) (treatment) or PBS (control) 
was applied to the skin in the organ bath culture (Figure 2-4). 
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Figure 2-4. Ex-vivo topical application of the betamethasone cream 
 
After 24h of incubation at the air-liquid interface at 37°C, the epidermis was 
enzymatically separated and single cell suspension was obtained as 
described in Section 2.1.2.  
The effect of the steroid pre-treatment on DCs was studied by identifying their 
phenotype by flow cytometry (Section 2.1.5) and by assessing their ability to 
stimulate proliferation of PBMCs in the Mixed Epidermal Cells Lymphocyte 
Reaction - MECLR (Section 2.1.4).  
Production of pro-inflammatory cytokine IFN-! and pro-tolerogenic Interleukin 
IL-10 was measured in the supernatants of these reactions by using ELISA 
(Section 2.1.6). 
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Immuno-modulatory agents used in this set of experiments were:  
• Pure human recombinant IL-10, reconstituted as carrier free at the 
concentration of 50µg ml-1 in PBS – IL-10p 
• Human recombinant IL-10 attached to gold nanoparticles, stock 
containing 62.5µg ml-1 IL-10 and 227µg ml-1 gold – NP IL-10 
! &*!
• Control: pure gold nanoparticles, stock containing 325 µg ml-1 of gold– 
NP.  
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The effect of IL-10 was assessed in vitro by adding IL-10p or NP-IL10, with 
and without 10µg ml-1 of human anti-IL-10 antibody, to MLR type cultures 
(Section 2.1.3). I used a range of IL-10 concentrations, starting from 0.1ng ml-
1 and increasing 10 fold to 100ng ml-1.  
The effect on MLR was assessed by measuring proliferation and the 
production of IFN! (ELISA) as described in Sections 2.1.3 and 2.1.6. 
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A 50µl solution containing 10µg ml-1 of IL-10p, NP IL-10 or NP was injected via 
standard intradermal 26G needle (Figure 2-5), creating a bleb measuring 
approximately 5-7mm. This was followed by punch biopsy around the bleb. 
Three injections/punches were performed per condition. 
 
 
 
 
Figure 2-5. Ex-vivo injection and bleb formation of IL-10. 
After 4h of incubation at the air-liquid interface at 37°C, the epidermis was 
enzymatically separated and single cell suspensions were obtained as 
described in Section 2.1.2.  
! '+!
The effect of injected IL-10 on DCs was studied by assessing their ability to 
stimulate proliferation of PBMCs in the MECLR (Section 2.1.4). Production of 
the cytokine IFN-! and IL-10 was measured in the supernatants of these 
reactions by using ELISA (Section 2.1.6). 
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The study, approved by South West 3 Research Ethics Committee, UK, 
involved healthy volunteers aged 22-46 years with no history of any skin 
condition and no current or recent use of topical or systemic steroid, vitamin D 
preparation or any other potentially immunomodulatory therapy.  
Participants applied DiproSone® cream, 12 hourly for four days, to the medial 
aspect of one arm (with other arm left untreated) prior to receiving two 50%l 
intradermal injections of 0.9% saline, one at each site of blister formation 
performed 6-18h later.  
Skin suction blisters were performed by gradually applying negative pressure 
(up to 50kPa) from a suction pump machine VP25 through a suction blister 
cup with a 15 mm hole in the base for two to six hours until a unilocular blister 
had formed within the cup. The blister roof was removed by using a surgical 
blade and prepared for obtaining single epidermal cell suspension the same 
day, as described above. The procedure of suction blisters was performed by 
Dr Mohammad Ali Alhadjali – Figure 2-6. 
Epidermal cells obtained from blister donor (donor A) from untreated skin (EC-
c) and steroid treated skin (EC-s) were co-cultured with allogeneic donor 
(responder B) CD4+CD45RA+ naïve T cells for 2 weeks, in in 10% (v/v) 
human serum in RPMI 1640 supplemented with 0.5mM L-glutamine, 50IU ml-1 
! '"!
penicillin, 0.05mg ml-1 streptomycin and 0.1mg ml-1 neomycin (complete RPMI 
1640) in a 48-well plate at 37°C and 5% (v/v) CO2/95% (v/v) air. Each well 
contained 1000µl of medium. The final expansion phase includes addition of 
recombinant human 20 IU/ml IL-2 on day 7 – Figure 2-6. 
 
Figure 2-6."Flow chat of the culture of the T cells stimulated by epidermal DCs with and 
without previous in vivo topical steroid exposure. ECc – epidermal cells originated from 
the untreated arm; ECs – epidermal cells originated from the steroid treated arm; Tc – T cells 
originated from the culture stimulated by ECc. Ts – T cells originated from the culture 
stimulated by ECs. 
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The suppressive capacity of T cells expanded in such a way (Tc from co-
culture with ECc, and Ts from co-culture with ECs) was assessed by their 
ability to suppress proliferation in the co-culture containing irradiated PBMCs 
from donor A and responder CD4+CD45RA+ naïve T cells from responder B in 
10% (v/v) human serum in RPMI 1640 supplemented with 0.5mM L-glutamine, 
50IU ml-1 penicillin, 0.05mg ml-1 streptomycin and 0.1mg ml-1 neomycin 
(complete RPMI 1640) in a 96-well plate at 37°C and 5% (v/v) CO2/95% (v/v) 
air. Each well contained 200µl of medium – Figure 2-7. After 96h of culture, 
100µl of medium was collected from the surface and stored at -20°C for 
cytokine detection at the later date. 1µCi [3H] thymidine was added to each 
well, and the incorporation of radioactivity was measured after 16h using a !-
microplate scintillation counter.  
Efficacy of suppression was compared to the one achieved by addition of 
CD4+ CD25+ CD127- natural regulatory T cells (Treg) from donor B to the co-
culture containing irradiated PBMCs from donor A and responder 
CD4+CD45RA+ naïve T cells from responder B. 
CD4+CD45RA+ naïve T cells were isolated from PBMCs by magnetic 
depletion of non-T helper cells and memory CD4+ T cells. CD4+ CD25+ 
CD127- natural regulatory T cells (Treg) were isolated from PBMCs in the two 
step process involving: first, magnetic depletion of non- CD4+ and CD127high 
cells, and the second, a positive selection of magnetically labelled CD4+ 
CD25+ CD127- Treg. 
! '$!
 
Figure 2-7. Assessment of the suppressive capacity of the T cells previously 
stimulated by epidermal DCs with and without previous in vivo topical steroid 
exposure. The content of wells in the 96 well plate is shown.  MLR – Mixed lymphocyte 
reaction; Ir PBMCs – donor A PBMCs irradiated by 2000rad; Tc – T cells originated from the 
culture stimulated by ECc. Ts – T cells originated from the culture stimulated by ECs; Tregs – 
CD4+ CD25+CD127 – T cell from donor B. 
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Cloning medium 
 
Content of the medium 
 
Cloning medium 1 
10% (v/v) AB serum in RPMI 1640 (supplemented with 0.5mM l-
glutamine, 50IU/ml penicillin, 0.05mg/ml streptomycin and 0.1mg/ml 
neomycin), containing PHA (1µg/ml), IL 2 (20IU/ml) and IL15 
(50IU/ml) 
 
Cloning medium 2 
10% (v/v) AB serum in RPMI 1640 (supplemented with 0.5mM l-
glutamine, 50IU/ml penicillin, 0.05mg/ml streptomycin and 0.1mg/ml 
neomycin), containing IL 2 (200IU/ml) and IL15 (50IU/ml) 
Table 2-5. Content of cloning media !
HLA DR1 restricted cloned T cells, specific for hemagglutinin (306-318) 
Influenza A virus peptide PKYVKQNTLKLAT (FP1) and HLA-A*0201 (HLA-
A2) restricted cloned T cells, specific for lytic protein BMLF-1 (280-288) 
Epstein-Barr virus peptide GLCTLVAML (EBVP1) were grown in cycles 
lasting 14±3 days. The cloned T cells were the kind gift of Dr A. Godkin 
(Clinical Reader, Cardiff University, Institute of Infection and immunity) and 
Prof. A. Sewell (Professor, Cardiff University, Institute of Infection and 
immunity). 
The cycle started with the stimulation of 1x106 cloned T cells with a total of 
10x106 !-irradiated PBMCs (3000 rad) from 3 different allogeneic donors in 
20ml of cloning medium 1 (Table 2-5) for 7 days in T25 cell culture flasks tilted 
at 25°. On day 7, cells were harvested, washed in RPMI 1640 and transferred 
to 24-well plates, at a density of 2-4x106/well in 2ml of cloning medium 2 
(Table 2-5). 
From day 9 to day 14±3, 50% of the medium 2 was changed every 3 days. 
The cells were half-split if the density exceeded 3-4x106/well. During this 
! '&!
period, cloned T cells were ready to respond to peptide-loaded skin DCs - 
Figure 2-8.  
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Figure 2-8. EBVP1 specific, HLA-A2 restricted cloned T-cells in the culture (day 9)" 
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Cells were grown 10% (v/v) FCS supplemented RPMI in upright T75 flasks at 
37°C and 5% (v/v) CO2/95% (v/v) air, at density of 0.2-0.4x106/ml. 50 % of 
medium was changed every 3 days. Cells were half split if the density 
exceeded optimal. I grew 3 types of cells under the described conditions:  
• HLA DR1 expressing, EBV transformed B cells 
• HLA-A2 expressing, antigen processing (TAP)-deficient human T-B 
lymphoblastoid hybrid cell line – T2A2 cells  
• HLA-A2 expressing, human plasma leukemia cell line - C1R-A2 
cells  
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A system was developed to study peptide loading of DCs with different 
delivery methods, based on antigen specific responses of the cloned T cells. 
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Ten µg of FP1 in a 50µl volume was injected by hollow microneedle or 
standard 26G intradermal needle into ex-vivo skin explants (Figure 2-9). Blebs 
measuring approximately 5mm were created, followed by punch biopsy 
around the bleb. Three injections/punches were performed per condition 
including untreated skin. 
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Figure 2-9. Hollow microneedle. MicronJet 600 Needle, device containing 3x0.6mm length; 
NanoPass Technologies Ltd., Nes Ziona, Israel. 
 
After 4h of incubation in the organ bath culture at 37°C, single cell suspension 
was obtained as per protocol (Section 2.1.2), and co-cultured with HLA DR1 
restricted, FP1 specific cloned T cells for 12h. The measure of the response 
was the production of IFN-! in the supernatants of these reactions, harvested 
after incubation period and quantified by ELISA (Section 2.1.6).  
Cultures with cells derived from HLA DR1 positive skin donors were used as a 
treatment group, whilst cultures with cells derived from HLA DR1 negative 
skin donors were used as a negative control.  
The positive controls in this experiment was a culture of FP1 specific cloned T 
cells with in-vitro added FP1 (0.5µM) with or without EBV transformed HLA 
DR1 expressing B cells.1 
HLA DR1 typing was performed by using rapid PCR on epidermal cells 
derived from skin explants.  
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Microneedles were made by wire-electrical discharge machining from 
stainless steel plates. Preparation of microneedles for optimal delivery is the 
subject of PhD thesis of Xin Zhao. The following paragraph will describe this 
process in brief. To deburr and clean microneedle edges and to make the tips 
sharp, microneedles were electropolished in a solution containing glycerin, 
85% ortho-phosphoric acid and water in ratio of 6:3:1 by volume. 
Electropolishing was performed in a 300ml glass container at 70°C and 
stirring rate of 150rpm. A copper plate was used as a cathode, while 
microneedles acted as anode. The anode was vibrated at a frequency of 
10Hz throughout the electropolishing process using a custom built vibrating 
device to help to remove gas bubbles generated at the anodic surface during 
electropolishing. A current density of 1.8mA/mm2 was applied for 15min to 
electropolish the microneedles. Subsequently, miconeedles were cleaned by 
dipping alternatively three times in the de-ionised water and 25% nitric acid for 
30s each. This was followed by another washing step in hot running water 
and a final wash in running de-ionised water. Microneedles were dried using 
compressed air before storing in the air tight container until the later use.  
Microneedles were arranged into the array consisting of 10 needles – Figure 
2-10. Each needle in the array has pyramidal shape with following dimensions: 
500µm long, 200µm wide in the base and 100µm thick. Due to the 
electropolishing process, the length of the needles reduced to 400µm. 
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Figure 2-10. The shape and the dimensions of steel dry microneedle. !
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Microneedle arrays consisting of ten 400µm long polished needles were 
coated with 11.8µg EBVP1 peptide dissolved in 1µl of vehicle solution of 
glacial acetic acid, 2-methylbuten-2-ol and 20mg/ml, PVA 2000 (10:5:2, by 
volume) or 1µl of vehicle solution without peptide. Microneedles were 
repetitively dipped into the solution kept at the pipette tip until all the solution 
was used. After coating, needles were left to dry for 10 min. and kept at -80°C 
for the use in less than 24h. 
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I used 5-TAMRA labeled EBVP1 peptide to assess amount of peptide 
delivered to the skin during 15 min long insertion of the dry coated 
microneedle. Microneedle array was coated with 11.8µg of TAMRA-EBVP1 in 
1µl of vehicle solution as described above, left to dry and inserted into the 
skin ex-vivo for 15 min. After insertion needles were washed in 100µl of 
50%DMSO in DI water for 15 min. The amount of peptide left on the needle 
was quantified on the basis of the concentration of peptide in the washing 
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solution by using spectrophotometry. Example of the standard curve is shown 
in Figure 2-11. The comparison was made to the amount washed from non-
inserted needles. "
 
 
 
 
 
 
 
 
Figure 2-11. Representative example TAMRA-EBVP1 standard curve. !
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11.8 µg of EBVP1 was inserted into the skin explants via microneedle and 
kept in situ for 15 min – Figure 2-12. Skin explants were also treated with 
microneedle coated with vehicle solution only (the same conditions as for 
peptide coated needles) or injected with 11.8 µg of peptide dissolved in 50µl 
of PBS from 5mM stock solution (20% DMSO and 80% DI water) via standard 
26G needle. One punch was obtained per condition including untreated skin. 
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Figure 2-12. Peptide administration into the skin explant via dry coated microneedle. 
 
After overnight incubation in the organ bath culture at 37°C, single cell 
suspension was obtained as per protocol (Section 2.1.2), and co-cultured with 
HLA A2 restricted, EBVP1 specific cloned T cells for 12h. The measure of the 
response was the production of MIP-1# in the supernatants of these 
reactions, harvested after incubation period and quantified by ELISA (Section 
2.2.3).  
Cultures with cells derived from HLA-A2 positive skin donors were used as a 
treatment group, whilst cultures with cells derived from HLA-A2 negative skin 
donors were used as a negative control. The positive controls in this 
experiment were a culture containing EBVP1 specific cloned T cells with in-
vitro added EBVP1 (1µM) with or without T2A2 HLA-A2 expressing cells. 
HLA-A2 typing was performed by flowcytometric analysis of epidermal cells 
derived from skin explants. Positive control in the analysis was HLA-A2 typing 
of the T2A2 cells. 
A flow-diagram of study protocol is shown in the Figure 2-13.  
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Figure 2-13. Experimental protocol for the assessment of the efficacy of peptide loading of skin dendritic cells 
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I used the Phusion® Human Specimen direct PCR kit to identify the HLA DR1 
status of the skin donors. The PCR was performed directly from the 0.5mm 
skin biopsy punch or control single cell suspension (HLA-DR1 expressing, 
EBV transformed B cells) without prior DNA purification.  
Primers used in the reaction were originally obtained in 100µM (Table 
2-6).[138] They were brought to 25µM concentration by adding sterile DI water. 
Gene Name Sequence (5’3’) Size (bp) Alleles 
DR1 5'01 P1 TTG TGG CAG CTT AAG TTT GAA T 
255 
  
DRB1*0101-0103 
  
  
 
3'047 P2 CTG CAC TGT GAA GCT CTC AC 
  3'048 P3 CTG CAC TGT GAA GCT CTC CA 
Control 1 5'C TGC CAA GTG GAG CAC CCA A 
796 
THIRD INTRON - 
DRB1 GENES Control 2 3'C GCA TCT TGC TCT GTG CAG AT 
Table 2-6. HLA DR1 and control primers characteristics.  
 
Using the Harris Uni-CoreTM skin-sampling tool, 0.5mm punches were taken 
from the skin sample and placed directly into the 0.2ml Eppendorf tube with 
pre-prepared PCR mixture (Table 2-7). In control tubes, 2µl of single cell 
suspension (Table 2-7) or master mixture was added instead of the skin punch.  
The components of the PCR mixture with HLA-DR1 primers and control 
primers were separately prepared as per Table 2-7. The quantities of the 
mixture components were multiplied accordingly, to pre-prepare master 
mixture for three individual 20µl reactions, including:  
1) human donor skin sample;  
2) control (HLA-DR1 expressing, EBV transformed B cells);  
! "$!
3) master mix only tubes.  
 HLA-DR1 primer 
reaction 
Control primer  
reaction 
 
Components Volume Volume Final concentration 
H20 6.4µl 6.8µl  
2XPhusion® Human Specimen 
PCR Buffer 
10µl 10µl 1x 
Primer 1 0.4µl x 0.5µM 
Primer 2 0.4µl x 0.5µM 
Primer 3 0.4µl x 0.5µM 
Ctrl primer 1 x 0.4µl  
Ctrl primer 2 x 0.4µl  
Phusion® Human Specimen 
DNA Polymerase 
0.4µl 0.4µl  
Sample 2µl 2µl  
Table 2-7. Components and quantities of PCR mixture: HLA-DR1 primer reaction and 
control primer reaction. 
 
The reactions were performed on PTC-200 thermal cycler under conditions 
listed in the Table 2-8. 
 Time  Temperature N of cycles 
Lysis 5min 98°C 1 
Denaturation 10s 98°C  
35 Annealing 16s 65°C 
Extension 18s 72°C 
Final extension 1min 72°C 1 
Table 2-8. Conditions of the PCR reaction 
 
When cooled, 3µl of Orange G loading buffer was added in each 20µl tube. 
2% w/v agarose gel in 1xTAE buffer was mixed and microwaved until it 
became clear. After 2-3 min of cooling, 2µl 1% w/v ethidium bromide solution 
was added to 50µl of warm gel, mixed and placed in the casting tray with the 
comb to cool.  
The gel was loaded with 10µl of sample per well, with the first well filled with 
100bp DNA ladder and run for 55 min at 80V.  
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Wilcoxon Signed Rank test or paired samples t test was performed to test the 
differences between paired measurements, whilst Mann Whitney U test was 
used for unpaired samples. For comparison of three or more samples One-
way ANOVA was used and for the consecutive measurements, Repeated 
Measures ANOVA. For testing correlation, I used Spearman or Pearson 
correlation, depending on the distribution of the tested samples. Analysis was 
performed by using Prism GraphPad 4.0a for Macintosh. P values of less than 
0.05 were considered significant. Results were expressed as mean±SD. 
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2.2 In-vivo methods for the optimal monitoring of the immune 
response after antigen skin delivery 
 
This study was a single centre, before-after study of the optimisation of the 
detection of the immune response to intradermally delivered Tuberculin PPD 
in healthy volunteers. There were no untreated controls.  
The study was approved by South East Wales REC (reference number 
12/WA/0249) and involved healthy volunteers recruited from Cardiff University 
and Cardiff and Vale HB, who signed informed consent prior to the enrollment 
in the study. 
Participants had pre-treatment blood sample and axillary lymph node fine 
needle aspiration biopsy (LN FNA), followed by injection of single dose of 2TU 
tuberculin PPD by hollow microneedle. The injection was administered 
intradermally in the forearm, contralateral to the initial LN FNA. Participants 
with a positive reaction (induration at the site of tuberculin PPD injection of 
greater than 5mm in diameter, 48-72h after injection)3 had a post-treatment 
blood sample and axillary LN FNA, ipsilateral to the injection site, 3-5 days 
after injection. 
I used ELISPOT for the detection of IFN! producing CD4 cells (blood and LN 
derived) in response to Tuberculin PPD as a read out (Section 2.2.2). The 
cells (LN derived and PBMCs) were also analysed for the change in the 
number, type and the expression of surface markers on flowcytometry.  
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Using aseptic technique, local anaesthesia and ultrasound guidance, a 21G 
needle was inserted into the axillary lymph node and up to 10µl of fluid 
aspirated.[139] The procedure was performed by consultant radiologist, Dr 
Philippa Young. The fluid was immediately transferred to 3ml of complete 
RPMI 1640 and transported to the laboratory at ambient temperature.  
The number of white cells in the LN sample was counted in a 
haemocytometer after staining with trypan blue (1:3 dilution in PBS) and 4% 
(v/v) acetic acid to eliminate red blood cell contamination. 
Simultaneously taken blood samples were processed for PBMCs extraction 
as described in Section 2.1.1. 
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PVDF plates previously treated with 35% (v/v) ethanol and washed with PBS 
(5x), were coated with IFN! capture antibody (1:200 dilution in PBS) and 
incubated at 4°C for 18 h. [45, 140] 
The next day, wells were blocked with 1% (w/v) BSA for 1h at 37°C, followed 
by addition of cell suspension at a density of 105/100µl AIM-V medium per 
well for LNCs, and 106/100µ AIM-V for PBMCs, in 2-3 replicate wells 
depending on cell availability.  
Prior to placement in the ELISPOT plates, cells (LNCs or PBMCs) were 
incubated overnight with the study (Tuberculin PPD) and control antigens 
(PHA and tetanus toxoid) at various concentrations in complete RPMI 1640 in 
polypropylene round bottom tubes (Table 2-9), at 37°C and 5% (v/v) CO2/95% 
! "E!
(v/v) air. PHA and the mixture of viral peptides used as another control 
antigen, were added directly to the plates with the responder cells, without 
pre-incubation period. Mixture of viral peptides included containing flu matrix 
protein (MP)58-66 (GILGFVFTL), cytomegalovirus (CMV) pp65495-503 
(NLVPMVATV) and Epstein-Barr virus (EBV) BMLF1280-288 (GLCTLVAML). 
Experimental 
condition 
In vitro added antigen Final 
concentration 
Note 
1 No added antigens  background 
2 Tuberculin PPD 0.05µg/ml Only with frozen PBMCs, if repeat exp. needed 
due to strong response 
3 Tuberculin PPD 0.5µg/ml  
4 Tuberculin PPD 0.05µg/ml  
5 Tetanus toxoid  0.5U/ml Negative control 
6 flu matrix protein (MP)58-66 
(GILGFVFTL) 
20nM Negative control 
7 cytomegalovirus (CMV) 
pp65495-503 (NLVPMVATV) 
20nM Negative control 
8 Epstein-Barr virus (EBV) 
BMLF1280-288 
(GLCTLVAML) 
20nM Negative control 
9 PHA 1µg/ml Positive control 
Table 2-9. Conditions for incubation of cells prior to placement in the ELISPOT plates. 
 
Plates were incubated overnight for 20h at 37°C. 
The next day, cells were discarded and plates washed with the wash buffer 
and PBS. The incubation steps that followed included: 
• Biotinylated IFN! detection antibody (1:100 dilution in 10%FCS), 
90µl/well – 1h at 37°C 
• ExtrAvidin® -Alkaline Phosphatase (1:5000 dilution in 0.5% FCS), 
100µl/well – 1h at ambient temperature 
• 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium 
BCIP/NBT as a substrate for the alkaline phosphatase activity (1 tablet 
in 10ml of DI water), 100 µl/well – 10-12 min in the dark at ambient 
temperature 
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Each incubation step, with the exception of the last one, was completed by 
the thorough wash of the wells with 200µl/well of wash buffer (5x) and PBS 
(2x).  
Reactions were stopped by adding DI water to the wells. Plates were left to 
dry overnight in the dark at ambient temperature and read on BioReader® at 
the later date. 
First, the spots were counted as total number of spots per condition, summing 
all available wells and using customized settings in the BioReader (only spots 
with diameter "40µm were taken into account). Second, the number of 
background spots (spots from wells containing cells not-exposed to antigen) 
was subtracted from each condition. Third, the results are expressed as 
number of IFN! producing cells per 2x105 cells. 
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Single cell suspensions of lymph node cells obtained through lymph node fine 
needle aspiration biopsy (LNCs) and PBMCs were stained for flow-cytometry 
as described previously in Section 2.1.5, with the exception that staining was 
performed in 100µl of volume with up to 1x106 cells/test. The panels of flow-
cytometry antibodies for phenotyping the cells at baseline are shown in the 
Table 2-10, whilst the panels for the assessment of changes before and after 
Mantoux test are shown in the Table 2-11.  
The following test tubes were used: 
• Test tube containing cells stained with viability stain only 
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• Test tube containing cells stained with antibodies listed in the Panel A 
(Table 2-10, Table 2-11) 
• Test tube containing cells stained with antibodies listed in the Panel B 
(Table 2-10, Table 2-11) 
• Test tube containing unstained compensation beads 
• Test tubes containing compensation beads stained with each dye 
separately 
• Separate test tube for the compensation of the viability dye: suspension of 
PBMCs containing 5x105 fresh cells and 5x105 cells, previously immersed 
in 80°C water bath for 20min. 
Table 2-10. Monoclonal antibodies for flow-cytometry (baseline analysis) – panels for 
LNCs and PBMCs. !!!!!!
Panel A Panel B 
Marker Dilution Manufacturer Marker Dilution Manufacturer 
V450 anti-human 
CD3 1:30 
Invitrogen, 
Paisley, UK 
V450 anti-human 
CD3 1:30 
Invitrogen, 
Paisley, UK 
eFluor®506 
viability dye 
See text E-bioscience, 
Hatfield, UK 
eFluor®506  
viability dye 
See text E-bioscience, 
Hatfield, UK 
FITC 
anti-human CLA 1:30 
Biolegend,  
London, UK 
FITC 
anti-human CLA 1:30 
Biolegend,  
London, UK 
PE 
anti-human CCR7 1:30 
Biolegend,  
London, UK 
Biotin 
anti-human CCR8 
 
 
 
 
Streptavidin PE 
7.8µg/ml 
 
 
 
 
 
1µl per 
106 cells 
Gift from Dr 
McCully (CU, UK), 
origin ICOS 
Corporation 
(Seattle, USA) 
 
Biolegend, 
London, UK 
APC 
anti-human CD8 1:100 
Biolegend,  
London, UK 
APC 
anti-human CCR10 1:40 
Biolegend,  
London, UK 
PerCPCy5.5 
anti-human CD69 1:100 
Biolegend,  
London, UK 
PerCPCy5.5  
anti-human CD8 1:30 
Biolegend,  
London, UK 
APC Cy7 
anti-human CD4 1:30 
Biolegend,  
London, UK 
APC Cy7 
anti-human CD4 1:30 
Biolegend,  
London, UK 
PE Cy7 
anti-human CD45RA 1:30 
Biolegend,  
London, UK 
PE Cy7 
anti-human CCR4 1:30 
Biolegend,  
London, UK 
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Panel A Panel B 
Marker Dilution Manufacturer Marker Dilution Manufacturer 
Pacific Blue 
anti-human CD19 1:100 
Biolegend,  
London, UK 
V450 anti-human 
CD3 1:30 
Invitrogen, 
Paisley, UK 
eFluor®506 
viability dye 
See text E-bioscience, 
Hatfield, UK 
eFluor®506  
viability dye 
See text E-bioscience, 
Hatfield, UK 
FITC 
anti-human CD4 1:100 
Biolegend,  
London, UK 
FITC 
anti-human CD4 1:100 
Biolegend,  
London, UK 
   PE anti-human CD207 1:30 
Biolegend,  
London, UK 
APC 
anti-human CD8 1:100 
Biolegend,  
London, UK 
APC 
anti-human CD8 1:100 
Biolegend,  
London, UK 
PerCPCy5.5 
anti-human HLA DR 1:100 
BD Pharmigen, 
Oxford, UK 
PerCPCy5.5 anti-
human CD69 1:100. 
Biolegend,  
London, UK 
   APC Cy7 anti-human CD154 1:30 
Biolegend,  
London, UK 
   PE Cy7 anti-human CD1a 1:30 
Biolegend,  
London, UK 
Table 2-11. Monoclonal antibodies for flow-cytometry (before and after Mantoux test) – 
panels for LNCs and PBMCs. 
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Wilcoxon Signed Rank test was performed to test the differences between 
paired measurements. Analysis was performed by using Prism GraphPad 
4.0a for Macintosh. P values of less than 0.05 were considered significant. 
Results were expressed as mean±SD. 
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2.3 In-vivo methods for the efficient and non-invasive assessment 
and monitoring of the residual !-cell function in type 1 
diabetes  
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This pilot prospective observational study, approved by Berkshire Research 
Ethics Committee (reference number 10/H0505/87), was designed to assess 
stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma 
C-peptide response in the same individual with Type 1 diabetes. 
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Seventeen non-obese, adult patients with type 1 diabetes (duration of #5 
years) were recruited in the Bristol area (UK), through the South West Newly 
Diagnosed Diabetes Collection database, after signing informed consent. 
Inclusion criteria: age 18-45 years, normal renal function, HbA1c<10% 
(86mmol/mol), daily insulin requirement of <0.8 units/kg/day and detectable $-
-cell function measured at a post-meal UCPCR. 
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Ensure Plus® (Abbott Nutrition, 6ml/kg (max 360ml)) was used as a Mixed 
Meal (MM) stimulant of $-cell insulin production, in both standard MMTT and 
standard mixed meal stimulated urinary C-peptide (uCP) measurements in 
hospital and at home. 
For the home meal stimulus, the largest meal of the day was used. Patients 
were not asked to calculate or take a note of carbohydrate or protein content 
in their meal. [131] 
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Patients underwent a standard MMTT in the hospital after overnight fast.  
They were asked to withhold taking long acting insulin on the morning of the 
hospital MMTT. They could take very short acting insulin up to 2 hours before 
the test and regular insulin up to 6 hours before the test. Test was conducted 
only if fasting value by capillary blood glucose was between 3.9-11.1mmol/l. 
Serum samples for C-peptide (sCP) and glucose were collected at -10, 0, 15, 
30, 60, 90 and 120 min6 after Ensure Plus.  
Urine samples were collected from the 2nd morning void before MM and 120 
min after MM – hospital MM-UCPCR. 
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Following the hospital MMTT, patients were asked to collect urine once 
monthly on 6 occasions at home (Figure 2-14):  
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Urine was collected at home 120 min. after Ensure Plus (taken after overnight 
fast and insulin dosing adjustments as with Standard MMTT) following pre-
meal void, providing that the capillary blood glucose before the test was 
between 3.9 and 11.1 mmol/l. 
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Urine was collected at home 120 min after an evening meal of their choice 
following pre-meal void once a month. There was no requirement to withhold 
any insulin injections during the collection of urine after home meal stimulation. 
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Samples were collected irrespective of the level of the pre-meal capillary 
blood glucose.  
Figure 2-14. Time-line of urine sample collection for UCPCR after different stimuli. !
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Urine samples were collected in boric acid containers and transported to the 
laboratory at ambient temperature within 72h, for analysis by Diabetes 
Research Network Wales Laboratory, Swansea University.  
Blood samples for glucose and C-peptide were collected in serum separator 
tubes (SST), allowed to clot, and centrifuged within 30 min. Serum was 
transferred into cryovials, kept at -20°C and sent frozen on dry ice for analysis 
by Diabetes Research Network Wales Laboratory, Swansea University.  
Urine C-peptide, expressed as UCPCR in nmol mmol-1, and serum C-peptide, 
expressed in pmol l-1, were measured by ELISA. 
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Hospital Hospital Home Home Home Home Home Home 
  
  
    
 
Test Screen 
Hosp. 
MMTT 
serum + 
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UCPCR 
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UCPCR 
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UCPCR 
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Home  
MM- 
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Additional samples from 22 patients from MonoPepT1De were included in the 
analysis. This placebo controlled, double-blinded, randomized Phase Ib study, 
approved by NRES Committee South West – Exeter was designed to assess 
the safety of pro-insulin derived peptide C19-A3 in newly diagnosed patients 
with T1D within 100 days from first insulin injection.  
These samples were used to assess correlation between change in residual 
$-cell function assessed by the production of serum C-peptide during 
standard MMTT and urinary C-peptide stimulated by standard Mixed Meal 
(see below) at baseline, after 3 and 6 months. Patients aged 18-45 years, 
possessed *0401 allele at the HLADRB1 gene locus, had starting peak serum 
C-peptide above 0.2 nmol/l on standard MMTT and positive at least one islet-
cell autoantibody. The samples were analysed before unblinding. 
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The study was powered on the ability to confirm a correlation between the 
peak sCP MMTT value and the 120minute UCPCR of >0.6. Correlations 
below this level were not considered to be valuable. 25 paired sets of data 
were calculated to provide 90% power to detect as statistically significant 
correlations of 0.6 or more at the p<0.05 level. I planned to recruit 30 
participants to achieve a minimum of 20 complete sets of data. Due to slow 
recruitment of recently diagnosed patients satisfying the entry criteria, an 
interim analysis of results was conducted after 16 complete paired data sets 
had been obtained for the baseline correlation (17 subjects recruited). This 
showed a stronger correlation that the predicted minimum and, having 
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reached its primary end point, the study was concluded at this stage.  
Non-parametric Spearman correlation was performed for correlating peak 
sCP during standard MMTT and stimulated UCPCR and for correlating area 
under the curve (AUC) sCP to peak sCP during standard MMTT.  
The AUC was calculated for the 120 min. period of the standard MMTT using 
the sCP value at each time point.  
The Wilcoxon signed rank test was performed to compare stimulated UCPCR 
between different time points over the follow up period.  
All data are expressed as mean±SD. The difference was considered 
statistically significant if p value was < 0.05. 
GraphPad Prism version 4.0a for Macintosh was used to for the analysis. 
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3.1 Introduction 
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In pursuing the goal of restoring tolerance to self-antigens responsible for 
autoimmunity in Type 1 diabetes, the choice of the delivery route is of 
paramount importance. Apart from epidermal and dermal skin delivery, other 
possible routes for PIT include the intranasal (i.n.), the sublingual (s.l.), the 
subcutaneous (s.c.) and the intravenous (i.v.). Skin has a number of 
advantages, including reliable dosing and absorbance of drugs (versus i.n and 
s.l.). In addition, completed Phase Ia trial of i.d. delivery of proinsulin C19-A3 
peptide in Type 1 diabetes indicates safety of this route [116], which is in line 
with studies on PIT in clinical allergy [80]. Delivery into the skin has an 
advantaged over the s.c. route of a lower risk of hypersensitivity [141]. 
Furthermore, the skin is an easily accessible large organ with a well 
developed system of immune surveillance. Thus, the skin is an attractive 
candidate for the optimal delivery route of PIT.  
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Skin has three layers, from top to bottom: epidermis, dermis and hypodermis 
(Figure 3-1).  
 
Figure 3-1. Histology of the human skin  !
<=>+/?.>) 
The epidermis varies in thickness from 50µm on the eyelids to 1mm on the 
palms and soles. The most abundant cells in this layer are keratinocytes (90-
95% of all cell types) that are arranged in several layers, from top to bottom: 
stratum corneum, stratum granulosum, stratum spinosum and stratum basale. 
Epidermal cells originate from mitotic divisions of stem cells of the basal layer 
and advance to the top over 30 days, undergoing morphological and 
biochemical differentiation (keratinisation). The other cells in this layer are: 
dendritic cells (DCs), are also known as Langerhans cells (LCs), representing 
3-5% of the epidermal cells, which have a function of antigen presenting cells 
(APCs); melanocytes, which are melanin pigment containing cells that are 
scattered in the basal layer in the ratio of 1 melanocyte to every 4-10 basal 
keratinocytes; Merkel cells, which function as mechanoreceptors and exhibit 
neuroendocrine and epithelial features; and lymphocytes, which are 
epidermis 
papillary dermis 
reticular dermis  
subcutaneous 
tissue 
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positioned mainly in the basal layer and represent less than 1.3% of 
epidermal cells [143]. 
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The superficial papillary dermis is arranged as upward projections that 
alternate with epidermal down-facing projections, which increases the surface 
of contact between the two layers. Deeper, reticular dermis is formed of 
coarser collagen bundles and a thicker elastic network. The dermis contains 
fibroblasts, dermal dendritic cells, mast cells and lymphocytes, as well as 
vessels and nerve endings, scattered around the network of collagen and 
elastic fibers. 
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This is a fatty tissue that provides thermoregulation, insulation, mechanical 
protection and a nutritional store of energy. 
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Figure 3-2 gives an insight into the origin and function of different dendritic cells 
(DCs) that function as professional antigen presenting cells (APCs) 
throughout the body.  
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Figure 3-2. Types of the dendritic cells.[144]
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Skin is the tissue rich in dendritic cells. They interact not only to provide 
efficient antimicrobial resistance, but also to maintain tolerance to self-
antigens. One of the most studied type of skin APCs are the Langerhans cells 
(LC), which connect with each other through long dendritic projections 
creating an important immunological barrier in the suprabasal epidermis, 
where they mostly reside, representing 3-5% of all nucleated cells in this skin 
layer.[145] They are easily identified in the epidermis by the haematopoetic 
marker CD45 and MHC class II molecules.[146] They express lectin receptors, 
such as Langerin (CD207) [147] and CD205 [148], that have a role in the 
uptake of foreign pathogens. Adhesion molecules such as CD11c; E-cadherin 
[149] and EpCAM [150] connect LCs to neighboring keratinocytes. Another, 
surface marker, found only in humans is CD1a, a member of the CD1 protein 
family, presents microbial lipid antigens to T cells.[151] Although they don’t 
share the same origin as conventional DCs, they exhibit similar behavior as 
migratory DCs. [144] 
On the other hand, dermal dendritic cells express MHC class II and are mostly 
langerin negative, and do not express adhesion molecules such as EpCAM 
and E-cadherin.[152] Some dermal DCs also express lectin type receptor, 
such as DC-SIGN.[153] They are a much more diverse group, but two 
subpopulations of human dermal DCs can be characterised by their 
phenotype: one is CD1ahigh/CD4+/DC-SIGN-/CD14-; the other is 
CD1alow/CD4+/DC-SIGN+/CD14+. CD14+ dermal DCs have a number of 
functional differences to epidermal LCs, with the latter being more potent in 
the induction of CD8+ T-cell responses through IL-15, and the first playing a 
role in promoting antibody responses, either by directly acting on activated B 
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cells or by priming T follicular helper-like CD4+ cells.[154] They show similar 
characteristic of weak allogeneic stimulation as macrophages, suggesting 
common origin.[145] CD1ahigh dermal DCs exhibit properties of both LCs and 
CD14+ dermal DCs.[154] Some studies suggest the existence of dermal 
langerin(+) DCs that can be distinguished from epidermal LCs by the CD103 
expression in mouse.[155] 
Apart from their role in antimicrobial defense, skin APCs have a role in 
maintaining self-tolerance. Little is known about the signals and factors that 
determine the perception of an antigen by an APC, originating from both sides 
of this interaction; that is, foreign to be fought versus self to be tolerated. In 
addition, elegant studies have attempted to define which subsets perform the 
role of maintenance of peripheral tolerance in vivo [156, 157], but the results 
are likely to be related to the particular transgenic model studied, and the 
relationship to human skin dendritic cell subsets remains uncertain.[158, 159] 
There are some suggestions from studies on human skin explants that LCs 
have a greater potential to elicit tolerogenic responses in responding T-cells 
[160], although data from humanised mouse model suggest existence of 
CD141+ subset of dermal DCs with tolerogenic properties as well.[161] 
When delivering self-antigen into the skin to restore tolerance, it is important 
to target the area with the most abundant tolerogenic DCs. This goal can only 
be achieved with the right delivery device.  
$"#"! I.,/A4=%5@=/T@3-%5@T/;@%C>3%,B@%.@.,/5@%/AA?0>,B@34.-%
Most of our knowledge of immune responses following skin delivery comes 
from vaccine studies. Current convention is that most vaccines are delivered 
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to the muscle through the needle, where there is no abundance of immune 
cells and from where, due to the rich circulation, antigen is rapidly removed 
into the systemic circulation to trigger immune responses elsewhere. The 
most studied alternative is skin delivery to the dermis via a conventional 
needle. Skin delivery provides significant antigen dose reduction, as local 
uptake by numerous APCs is more efficient in comparison to conventional 
muscle administration.[162] Although superior to muscle, standard intradermal 
delivery places the antigen into the lower dermal layers with the sparser 
distribution of APCs that are less accessible to antigen in comparison to the 
rich network of LCs in the epidermis[145] that potentially can present antigen 
more efficiently and in more tolerogenic manner.  
Due to its potential to deliver superficially to target APCs with less local 
irritation, microneedle technology could be valuable for the efficient delivery 
for peptide immunotherapy. Microneedles are needles of less 1000µm length 
that constituted with appropriate drug formulations, deliver into the skin more 
superficially than standard intradermal needles. A number of different 
microneedles categories are available, and can be divided into four major 
groups (Table 3-1).  
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Microneedle type Mechanism of delivery 
Solid microneedles Pre-treatment of the skin to form pores through which 
subsequently topically applied drug will penetrate to reach 
deeper skin layers. 
 
Coated microneedles Needles carry the drug on their surface, such that it diffuses 
into the skin following insertion. 
 
Dissolving microneedles Needles are made of a polymer mixed with the drug of 
choice. The microneedle dissolves upon insertion into the 
skin. 
 
Hollow microneedles Needle is attached to a standard syringe, liquid drug is 
delivered through one or more projections.  
or 
Needles are attached to a reservoir filled with the liquid drug 
released once the microneedle is in situ at the desired 
place. 
Table 3-1. Microneedle types and mechanisms of drug delivery 
 
Peptides used in immunotherapy are large molecules that are not suitable for 
transdermal delivery, and are conventionally administered via hypodermic 
needle. Hollow microneedles were studied as an alternative.[163, 164] Also, 
the low doses of peptides required for immunotherapy allow delivery through 
coated and dissolving microneedles. 
Some useful conclusions on pharmacokinetics can be drawn from animal 
studies on the use of solid [165], dissolving [166] and hollow microneedles 
[163] for insulin delivery that showed efficiency in lowering blood glucose. 
Consistent with the animal experiments, this type of needle in humans 
induced faster insulin absorption.[167, 168] Faster absorption of drugs via 
hollow microneedles most likely happens via dermal lymphatics.[169] Studies 
using parathyroid hormone (PTH) delivery via coated microneedles for the 
treatment of osteoporosis have progressed to Phase I and Phase II trials. A 
microneedle patch led to faster time to peak concentration and shorter half-life 
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of PTH than subcutaneous injection method with comparable improvement in 
bone mineral density.[170]  
As with pharmacokinetics, studies on both animals and humans in the field of 
vaccine delivery can shed some light on immune responses after microneedle 
delivery. Hollow microneedles deliver antigen in a volume of liquid from the 
standard syringe; they are designed to target dermis and their reliability and 
dose-sparing effect in comparison to intramuscular delivery was tested using 
influenza vaccine administration.[164] Although potentially better in superficial 
delivery, due to their length (400-600µm vs approximate 200µm of human 
epidermal thickness), they largely miss the APC enriched area in the 
suprabasal epidermis. Microneedle arrays with short microprojections of 
approximately 100µm of length, dry coated with vaccine antigen, packed to an 
ultra high density (21.025/cm2), provide more reliable epidermal delivery.[171] 
A similar technology, using longer and less densely packed microprojections, 
failed to show comparable efficiency [172], suggesting that, in addition to 
length, it is important that an array is used that targets critical number of 
epidermal DCs that have approximate density of 500 cells per mm2 in mice 
[173], with similar density in humans.  
Another parameter to consider when choosing a delivery device is the level of 
injury to the skin caused by the injection or needle insertion. The larger extent 
of the injury during peptide delivery, the more probable is the pro-
inflammatory response in the up-taking APCs that can send a wrong message 
to the responding T cell, steering away from the tolerance. This is of particular 
concern when dissolving microneedles are used because of the possibility 
that dissolved or degraded matrices have pro-inflammatory effects or other 
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side effects if devices are used frequently.[174] In comparison to hypodermic 
injection, influenza vaccine delivered by hollow microneedles induced more 
irritation in human subjects [175], although this can simply be due to more 
superficial and therefore more visible effects. Solid microneedles cause very 
mild skin irritation measured by erythema and blood flow. This effect is less 
prominent with shorter microneedles of 200µm length vs 400µm.[176] A study 
using nanopatch technology for influenza vaccine delivery suggested that that 
slow insertion of the array into the skin (less than 1m/s) causes significantly 
less cell death in comparison to other technologies.[177] In addition, invasive 
delivery may expedite traffic of LCs from the skin to the lymph node, which 
may have implications on shortening the beneficial local contact with the 
delivered antigen in the skin.[178]  
For immunotherapy, it is clearly important that the presentation of antigen 
does not trigger or exacerbate existing autoimmune responses by inducing 
pro-inflammatory rather than tolerogenic signals. Preclinical studies suggest 
that peptide immunotherapy is most effective when the peptides are delivered 
to immature APCs that have not been activated by inflammatory stimuli.[179, 
180] These cells regularly migrate to the draining lymph nodes and present 
self-antigens as part of the normal process of maintaining tolerance to self-
antigens.[181, 182] The rich network of LCs in the suprabasal epidermis, with 
possibly greater potential for tolerance than other skin DC subsets, seem to 
be a logical target for peptide immunotherapy. The presence of adjuvant and 
the type of the antigen should also be taken into account. For example, large 
viral antigens induce immunity, rather than tolerance, despite efficient delivery 
to superficial LCs.[171] 
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3.2 Hypothesis 
I hypothesise that microneedle technology has the potential to increase the 
efficacy of peptide delivery to epidermal DCs without causing significant local 
inflammation, in comparison to  standard intradermal delivery.  
3.3 Aims 
1. To study the targeting of epidermal DCs by peptide delivered by 
hollow microneedles. 
2. To study the targeting of epidermal DCs by peptide delivered by dry 
coated microneedles. 
 
 
 
  
! CBB!
3.4 Results 
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Single epidermal cell suspensions obtained from skin explants described in 
Chapter 2, were analysed by using flow cytometry. The gating strategy of the 
analysis is shown in Figure 3-3. Relevant events were gated on an SSC-
A/FSC-A graph (Figure 3-3 a), followed by gating on single cells only (FSC-
A/FSC-H graph, Figure 3-3 b) and live cells, distinguished by the live/dead 
marker (Figure 3-3 c). The dendritic cells (DC) population was defined as 
CD1a+, HLA DR+ cells (Figure 3-3 d).  
Once characterised in this way, further analysis of the DCs included staining 
for Langerin and CD11c. Staining with one antibody type (clone 923B7, rat) 
showed Langerin expression in only part of this population (Figure 3.3 e), but 
the use of another antibody (clone10E2, mouse) later in the project, indicated 
that almost entire the DC population deriving from epidermal sheets express 
Langerin (Figure 3-4). However, CD11c was not expressed on these DCs, 
irrespective if the fixative was used during flow cytometric staining and despite 
staining by different antibodies derived from different clones.  
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Figure 3-4. Flowcytometric analysis of the dendritic cells in the epidermal cell 
suspension. a) CD1a+ (Pacific Blue channel), HLA DR+ (PerCP-Cy5.5 channel) cells from 
the live epidermal population were defined as dendritic cells; b) Langerin staining with 
alternative antibody (PE channel) of CD1a+ cells, HLA DR+ cells; c) CD1a+ (Pacific Blue 
channel), Langerin+ cells from the live epidermal population. 
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Figure 3-3. Flowcytometric analysis of the single epidermal cells suspension 
containing dendritic cells, gating strategy. a) Entire epidermal cell population; b) Gating 
on single cell events only; c) Epidermal cells negative for live/dead marker (APC-Cy7 
channel) were characterised as live cells; d) CD1a+ (Pacific Blue channel), HLA DR+ (PerCP-
Cy5.5 channel) cells from the live epidermal population were characterised as dendritic cells; 
d) Langerin staining (FITC channel) of CD1a+, HLA DR+ cells. FSC-H/A - forward scatter-
height/area, SSC-A - side scatter-area, L/D marker – live/dead marker. 
a) b) c) 
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Mean viability of epidermal cells was 33.7±20.5% (Figure 3-5 a). The population 
of live epidermal cells contained on average 1.15±0.25% of DCs defined as 
CD1a+, HLA DR+ cells (Figure 3-5 b).  
 
 
Figure 3-5. Flowcytometric analysis of the epidermal single cell suspension. a) percent 
of live cells in the epidermal cell suspension; b) percent of dendritic cells (CD1a+, HLA DR+) 
in the live epidermal cell suspension. N=9, results expressed as mean with SD, standard 
deviation.  
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To assess the functional capacity of DCs obtained, I co-cultured epidermal 
cells suspensions with allogeneic donor PBMCs in MECLR, as described in 
Chapter 2. The experiment, shown in Figure 3-6 a, suggested that 5x104 of 
ECs/well (estimated to contain around 500DCs) is sufficient to drive 
proliferation of 2x105 of allogeneic donor PBMCs. This was confirmed in a 
subsequent experiment (Figure 3-6 b) showing significant MECLR proliferation 
in comparison to background proliferation of PBMCs in 9 replicates.  
 
 
 
 
 
 
Figure 3-6. Mixed Epidermal Cells Reaction proliferation (MECLR) driven by epidermal 
DCs. a) titration of the optimal count of epidermal cells (ECs)/well in MECLR; statistical test 
used: One-way ANOVA (p<0.005) with Bonferroni’s Multiple Comparison post test. b) 
proliferation in MECLR with 50,000 ECs/well in comparison to PBMCs alone. PBMCs - 
peripheral blood mononuclear cells; statistical test used: Wilcoxon signed rank test. 
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To assess ability of APCs to uptake injected antigen, ten µg of HLA-DR1 
restricted hemagglutinin (306-318) Influenza A virus peptide 
PKYVKQNTLKLAT (FP1) was injected in the skin explant via hollow 
microneedles or standard 26Gneedles. Explants were subsequently incubated 
in the organ skin bath culture for 4h, followed by generation of the single cell 
suspension of the epidermal cells (Chapter 2), which were co-cultured with 
HLA DR1 restricted, FP1 specific cloned T cells for 12h. It is worth mentioning 
that the process of generating single epidermal cell suspension described in 
the Chapter 2, involved several washing steps, making the possibility of the 
existence of the free peptide in the cultures, negligible. The measure of the 
response was the production of IFN! in the supernatants of these reactions, 
harvested after the incubation period and quantified by ELISA. 
I used PCR analysis of skin to test for the expression of HLA DR1 in skin 
donors. I analysed samples from 20 different donors and detected 3 HLA-DR1 
positive donors (217, 219 and 228). In addition, the first three consecutive 
donors that tested negative for HLA-DR1 (213, 214 and 221) were included in 
the experiment as negative controls – Figure 3-7. The rest of the negative 
donors were not included in further assays, i.e. co-cultures with the cloned T-
cells., due to the limited availability of the cloned T cells.  
! CB$!
 
Figure 3-7. HLA DR1*0101-0103 typing. Positive donors: donors 217,219 and 228; negative 
donors: donors 213, 214 and 221; positive control: HLA DR1 expression EBV transformed B-
cell line; mix: PCR master mix; control and HLA DR1 primer: see Chapter 2.  
 
To assess baseline sensitivity of cloned T cells specific to FP1, I incubated 
the cells overnight at 37°C in 10% v/v FCS in RPMI containing increasing 
concentrations of FP1 and APCs (HLA DR1 expressing, EBV transformed B 
cells) in ratio 1:2 i.e. 6x104 APCs and 3x104 cloned T cells per well – Figure 
3-8.  
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Figure 3-8 Sensitivity of HLA-DR1 restricted cloned T cells to FP1 peptide. Cloned T 
cells were incubated overnight with HLA DR1 expressing, EBV transformed B cells in ratio 1:2. 
IFN! produced in these reactions was used as a measure of the clone stimulation. The mean 
and SD of the three separate experiments is shown in the graph. !
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When ECs from HLA DR1 negative individuals, loaded with FP1 peptide, were 
co-cultured with HLA DR1 restricted, FP1 specific cloned T cells, no additional 
stimulation of the cloned T-cells was observed in comparison to stimulation 
driven by untreated DCs, irrespective of the delivery device used, i.e. hollow 
microneedle or standard 26G needle. Stimulation was assessed by production 
of IFN! by the cloned T-cells and expressed as ratio of IFN! produced in 
cultures driven by FP1 loaded DCs and untreated DCs – Figure 3-9.  
 
 !!!
 
 
 
 
Figure 3-9. IFN" production by FP1 specific cloned T cells stimulated by HLA DR1 
negative donors. Stimulation expressed as IFN! ratio derived from cloned T cells stimulated 
by FP1 loaded DCs/untreated DCs. MN delivery: FP1 injected into the skin explant by hollow 
microneedle; ID: FP1 injected into the skin by standard 26G needle. 
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Table 3-2. IFN" production by FP1 specific cloned T cells co-cultured with epidermal 
cells (containing DCs) from HLA DR1 negative donors. APCs: HLA DR1 positive EBV 
transformed B cell line; Cloned T cells: FP1 specific, HLA DR1 restricted cloned T cells; EC 
UT: epidermal cells derived from untreated skin; EC MN: epidermal cells derived from skin 
injected with FP1 by hollow microneedle; EC ID: epidermal cells derived from skin injected 
with FP1 by standard 26G needle; FP1 in vitro: FP1 added to the co-culture in vitro. IFN! 
expressed in pg/ml; all experiments done in 2 replicate wells. 
 
  
 
Donor 213 
IFN" pg/ml 
Donor 214 
IFN" pg/ml 
Donor 221 
IFN" pg/ml 
APCs 0 0 14 
Cloned Tcells 
ls 
327 400 1129 
EC UT 0 0 14 
APCs+cloned Tcells 773 933 865 
APCs+cloned Tcells+FP1 (in vitro) 19431 22352 17833 
Cloned Tcells+FP1 (in vitro) no data no data 15010 
EC UT + cloned Tcells 428 525 1246 
EC MN + cloned Tcells 369 513 1334 
EC ID + cloned Tcells 334 595 1283 
N of replicates per donor 2 2 2 
! CBD!
In contrast, when ECs from HLA DR1 positive individuals, loaded with FP1 
peptide, were co-cultured with HLA DR1 restricted, FP1 specific cloned T cells, 
I observed an increase in the stimulation of the cloned T-cells, in comparison 
to stimulation driven by untreated DCs. The same trend was seen with each 
of the delivery devices used i.e. hollow microneedle or standard 26G needle - 
Figure 3-10, Table 3-3. 
!!!!!!
 
Figure 3-10. IFN" production by FP1 specific cloned T cells stimulated by HLA DR1 
positive donors. Stimulation expressed as IFN! ratio deriving from cloned T cells stimulated 
by FP1 loaded DCs/untreated DCs. MN delivery: FP1 injected into the skin explant by hollow 
microneedle; ID delivery: FP1 injected into the skin by standard 26G needle. !!!!!!!!!!!!
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Table 3-3. IFN" production by FP1 specific cloned T cells co-cultured with epidermal 
cells (containing DCs) from HLA DR1 positive donors. APCs: HLA DR1 positive EBV 
transformed B cell line; Cloned T cells: FP1 specific, HLA DR1 restricted cloned T cells; EC 
UT: epidermal cells deriving from untreated skin; EC MN: epidermal cells deriving from skin 
injected with FP1 by hollow microneedle; EC ID: epidermal cells deriving from skin injected 
with FP1 by standard 26G needle; FP1 in vitro: FP1 added to the co-culture in vitro. IFN! 
expressed in pg/ml; all experiments done in 2 replicate wells. 
!!!!!!!
  
 
Donor 217 
IFN" pg/ml 
Donor 219 
IFN" pg/ml 
Donor 228 
IFN" pg/ml 
APCs 7 69 0 
Cloned Tcells 
ls 
23 11 7 
EC UT 8 16 0 
APCs+cloned Tcells 39 169 7.3 
APCs+cloned Tcells+FP1 (in vitro) 156 3444 9738 
Cloned Tcells+FP1 (in vitro) no data no data 4818 
EC UT + cloned Tcells 9 132 22 
EC MN + cloned Tcells 65 228 125 
EC ID + cloned Tcells 183 695 115.3 
N of in vitro replicates per donor 2 2 2 
! CCB!
I compared IFN! ratios obtained from HLA-DR1 negative donors to the ones 
measured in the reactions driven by HLA-DR1 positive donors, and found 
trend towards higher stimulation in positive donors with both delivery devices 
(IDneg:0.99±0.15, IDpos:11.08±9.92, p=0.1; MNneg:0.99±0.11, MNpos:5.18±3.09, 
p=0.1; Mann-Whitney test) – Figure 3-11. 
!!! ! ! !!
Figure 3-11. IFN" production by FP1 specific cloned T cells stimulated by HLA-DR1 
positive donors. Stimulation expressed as IFN! ratio deriving from cloned T cells stimulated 
by FP1 loaded DCs/untreated DCs. a) MNpos/neg: FP1 inserted into the skin explant by dry 
coated microneedle in HLA-DR1 positive or negative donors, respectively. b) IDpos/neg: FP1 
injected into the skin explant by standard 26G microneedle in HLA-DR1 positive or negative 
donors, respectively. Statistical test used: Mann-Whitney test. !!!!!!!!! !
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I used similar system to assess ability of APCs to uptake antigen inserted into 
the skin ex vivo, via dry microneedles. However, this time I used HLA-A2 
restricted clone, due to the much higher prevalence in the general population, 
hence higher probability to obtain skin samples originating from the donors, 
HLA matching the available cloned T cells.  
Dry microneedles coated with 11.8µg lytic protein BMLF-1 (280-288) Epstein-
Barr virus peptide GLCTLVAML (EBVP1) were inserted in the skin and kept in 
place for 15 min. As a control, 2µg or 11.8µg of the same peptide was injected 
into the skin via standard 26G needles. Explants were subsequently 
incubated overnight and processed to obtain single cell suspension as 
described in chapter 2. Single EC suspensions were co-cultured with HLA-
A*0201 (HLA-A2) restricted cloned T cells, specific for EBVP1, for 12h. 
To estimate the quantity of peptide retained in the skin, I used 
spectrophotometric analysis of the 5-TAMRA labeled EBVP1 peptide 
harvested from the needle before and after insertion (Chapter 2). It showed 
that only 17.0±1.4% of the coated peptide remained in the skin after 15 min of 
insertion of the dry coated microneedle – Figure 3-12, Table 3-4.  
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Figure 3-12. Efficacy of EBVP1 delivery via dry coated microneedle. The amount of 
peptide on the needle was quantified by the spectrophotometric analysis of 5-TAMRA labeled 
EBVP1 washed from the needle coated with 11.8µg of labeled peptide. Before: amount of 
peptide washed from the needle without insertion into the skin. After: amount of peptide 
washed from the needle after 15 min. long insertion into the skin. 
 
 
 
Table 3-4. Efficacy of EBVP1 delivery via dry coated microneedle. The amount of peptide 
on the needle was quantified by the spectrophotometric analysis of 5-TAMRA labeled EBVP1 
washed from the needle coated with 11.8µg of labeled peptide. Before: amount of peptide 
washed from the needle without insertion into the skin. After: amount of peptide washed from 
the needle after 15 min. long insertion into the skin. !
I used flowcytometric analysis of the skin to test for the expression of HLA-A2 
in skin donors. I analysed samples from 11 different donors and detected 
seven HLA-A2 positive donors. Four donors that tested negative for HLA-A2 
were included in the experiment as negative controls. Figure 1-3 shows 
examples of flowcytometric analysis of HLA–A2 negative (a) and positive 
donors (b).!!
!
!
 
Peptide Before After 
Quantity (µg) 11.85±1.77 9.8±1.27 
Percentage on the needle 
ls 
100±0 83.0±1.4 
N of replicates  3 3 
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Figure 3-13. Representative example of the expression of HLA A2 (FITC channel): on 
the epidermal cells deriving from skin explants stained for HLA-A2 (black lines); on unstained 
epidermal cells deriving from the same skin explant - negative control (solid gray); on HLA A2 
expressing human T2A2 cell line - positive control (dark gray lines). a) HLA A2 negative 
donor; b) HLA A2 positive donor. !
To assess baseline sensitivity of cloned T cells specific to EBVP1, I incubated 
the cells overnight at 37°C in 10% (v/v) FCS in RPMI containing increasing 
concentration of EBVP1 and APCs (HLA-A2 expressing, antigen processing 
(TAP)-deficient human T-B lymphoblastoid hybrid cell line – T2A2 cells) in 
ratio 1:2 i.e. 6x104 APCs and 3x104 cloned T cells per well – Figure 3-14. 
 
 
 
 
 
Figure 3-14. Sensitivity of HLA-A2 restricted cloned T cells to EBVP1 peptide. Cloned T 
cells were incubated overnight with HLA-A2 expressing, T2A2 cells in ratio 1:2. MIP1-$ 
produced in these reactions was used as a measure of the clone stimulation. n=3 
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Figure 3-15. MIP1-! production by EBVP1 specific cloned T cells stimulated by HLA-A2 
negative donors. Stimulation expressed as MIP1-$ ratio deriving from cloned T cells 
stimulated by EBVP1 loaded DCs/untreated DCs. MN delivery: EBVP1 injected into the skin 
explant by dry coated microneedle; ID delivery: EBVP1 injected into the skin by standard 26G 
needle. 
 
When ECs from HLA-A2 negative individuals, loaded with EBVP1 peptide, 
were co-cultured with HLA-A2 restricted, EBVP1 specific cloned T cells, no 
additional stimulation of the cloned T-cells was observed in comparison to 
stimulation driven by untreated DCs, irrespective of the delivery device used 
i.e. dry microneedle or standard 26G needle. Stimulation was assessed by 
production of MIP1-$ by the cloned T-cells and expressed as ratio of MIP1-$ 
produced in cultures driven by EBVP1 loaded DCs and untreated DCs – Figure 
3-15, Table 3-5. 
!
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Table 3-5. MIP1-! production by EBVP1 specific cloned T cells co-cultured with 
epidermal cells (containing DCs) from HLA-A2 negative donors. APCs: HLA-A2 
expressing, T2A2 cells ; Cloned T cells: EBVP1 specific, HLA-A2 restricted cloned T cells; EC 
UT: epidermal cells deriving from untreated skin; EC MNc: epidermal cells deriving from skin 
into which microneedle coated with coating solution only was inserted;  MNpep: epidermal 
cells deriving from skin into which microneedle coated with EBVP1 was inserted EC ID: 
epidermal cells deriving from skin injected with EBVP1 by standard 26G needle; EBVP1 in 
vitro: EBVP1 added to the co-culture in vitro. MIP1-$ expressed in pg/ml; all experiments 
done in 2 replicate wells; some donors shared negative controls for cloned T cells and APCs 
as samples were processed on the same day. 
 
 
 
 
 
 
 
 
 
 
Donor 334 
MIP1-! 
pg/ml 
Donor 335 
MIP1-! 
pg/ml 
Donor 336 
MIP1-!  
pg/ml 
Donor 339 
MIP1-!  
pg/ml 
APCs 0 0 0 0 
APC+ Cloned Tcells 
ls 
40 40 43.5 46 
EC UT 0 0 0 0 
APCs+cloned Tcells+EBVP1 (in vitro) 764 650 641 375 
EC UT + cloned Tcells 40 36.5 40 43 
EC MNc + cloned Tcells 33 33 36.5 40 
EC MNpep + cloned Tcells 33 33 40 40 
EC stID + cloned Tcells 36.5 40 43.5 46 
N of replicates per donor 2 2 2 2 
! CC%!
I compared MIP1-$ ratios obtained from HLA-A2 negative donors to the ones 
measured in the reactions driven by HLA-A2 positive donors, and found 
significantly higher stimulation with positive donors when microneedle delivery 
was used (MNneg:0.89±0.08, n=7; MNpos:2.50±1.03, n=4; p=0.006, Mann 
Whitney test) and a trend towards an increase when peptide was injected via 
standard 26G needle (IDneg:1.04±0.09, IDpos:1.86±0.49; p=0.05, Mann 
Whitney test). This suggests exclusive stimulation when peptide is presented 
by the HLA matched donor –Figure 3-16, Table 3-6. 
In this comparison, I only used intradermal injections of 2µg of peptide, as all 
HLA-A2 negative controls received this amount of peptide through i.d. delivery. 
 
 
 
 
 
Figure 3-16. MIP1-! production by EBVP1 specific cloned T cells stimulated by HLA-A2 
positive donors. Stimulation expressed as MIP1-$ ratio deriving from cloned T cells 
stimulated by EBVP1 loaded DCs/untreated DCs. a) MNpos/neg: EBVP1 inserted into the skin 
explant by dry coated microneedle in HLA-A2 positive or negative donors, respectively. b) 
IDpos/neg: EBVP1 injected into the skin explant by standard 26G microneedle in HLA-A2 
positive or negative donors, respectively. Statistical test used: Mann-Whitney test 
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Table 3-6. MIP1-! production by EBVP1 specific cloned T cells co-cultured with 
epidermal cells (containing DCs) from HLA-A2 positive donors. APCs: HLA-A2 
expressing, T2A2 cells; Cloned T cells: EBVP1 specific, HLA-A2 restricted cloned T cells; EC 
UT: epidermal cells deriving from untreated skin; EC MNc: epidermal cells deriving from skin 
into which microneedle coated with coating solution only was inserted; MNpep: epidermal 
cells deriving from skin into which microneedle coated with EBVP1 was inserted EC ID: 
epidermal cells deriving from skin injected with 2µg or 11.8µg EBVP1 by standard 26G 
needle; EBVP1 in vitro: EBVP1 added to the co-culture in vitro. MIP1-$ expressed in pg/ml; 
all experiments done in 2 replicate wells; some donors shared negative controls for cloned T 
cells and APCs as samples were processed on the same day. !
The greater efficacy of microneedle delivery in comparison to the delivery of 
2µg peptide via standard 26G needle delivery was not confirmed when results 
of paired samples (MN and ID injection into the explant derived from the same 
donor) were analysed - Figure 3-17a, Table 3-6. However DCs showed 
suggestion toward more potent stimulation of the cloned T cells when higher 
dose of peptide was intradermally injected into the skin (10µg) in comparison 
to MN delivery – Figure 3-17b, Table 3-6. 
 
 
 
Donor295 
MIP1-! 
pg/ml 
Donor297 
MIP1-! 
pg/ml 
Donor305 
MIP1-! 
pg/ml 
Donor306 
MIP1-! 
pg/ml 
Donor337 
MIP1-! 
pg/ml 
Donor338 
MIP1-! 
pg/ml 
Donor340 
MIP1-! 
pg/ml 
APCs 0 0 0 0 0 0 0 
Cloned Tcells 
 
798 631 171 171 50 50 46 
EC UT 42 40 0 0 0 0 0 
APCs+cloned 
Tcells+EBVP1 (in vitro) 
3361 3320 1317 1317 489 489 375 
Cloned Tcells+EBVP1 (in 
vitro) 
no data 3450 no data no data no data no data no data 
EC UT + cloned Tcells 333 552 229 410 43.5 40 43 
EC MNc + cloned Tcells 429 599 236 425 40 40 40 
EC MNpep + cloned Tcells 1326 2073 635 817 67 80.5 63.5 
EC ID (2µg) + cloned 
Tcells 
no data no data   74 97 63.5 
EC ID (11.8µg) + cloned 
Tcells 
  1128 1164    
N of in vitro replicates per 
donor 
2 2 2 2 2 2 2 
! CCD!
 
 
 
 
 
Figure 3-17. MIP1-! production by EBVP1 specific cloned T cells: microneedle vs 
intradermal delivery in HLA-A2 positive donors. Stimulation expressed as MIP1-$ ratio 
deriving from cloned T cells stimulated by EBVP1 loaded DCs/untreated DCs. MN delivered: 
EBVP1 inserted into the skin explant by dry microneedle coated with 11.8µg of EBVP1. ID 
delivered: EBVP1 injected into the skin via standard 26G needle: a) 2µg injected 
intradermally; b) 11.8µg injected intradermally. Statistical test used: Wilcoxon signed rank test. 
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3.5 Summary of findings 
1. Single epidermal cell suspension can be obtained from organ bath 
cultures, by using enzymatic digestion. This novel approach combines 
known steps to obtain epidermal cells, including sufficient DCs for 
phenotypic and functional characterization at the desired time-point, 
without the need for prolonged “walk-out’ methods. This is important 
because we can use this as a surrogate for skin delivery in vivo and 
assess the effect in the precise moment in time. 
 
2. The phenotype of cells obtained is similar to those previous described 
in the epidermis – with the exception of CD11c, suggesting some 
damage of the DCs in the process. 
 
3. The DCs are functional as shown by their ability to stimulate 
allogeneic donor PBMCs in the MECLR with just 500 DCs driving the 
reaction. The functional capacity of enzymatically obtained epidermal 
DCs was previously only used in murine skin models, but not in 
models with human skin.   
 
4. The organ bath culture is viable for long enough to study uptake of 
antigen delivered into the skin and presentation to the T cells by 
epidermal DCs. This is a novel step in the translation studies, which 
has an alternative the murine studies that are limited by thinness of 
the murine skin, making it very difficult to assess delivery devices 
designed for humans.  
 
5. This set of experiments showed that both hollow and dry coated 
microneedles are comparable to standard indradermal 26G needles 
in targeting epidermal DCs, with some suggestion of superiority in the 
case of dry microneedles. 
 !
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Dendritic cells obtained from the epidermal layer of skin explants are most 
likely Langerhans cells as evidenced by co-expression of unique classifier 
markers for skin DCs, such as HLA DR, CD1a and langerin. However, after 
staining with one flowcytometry antibody, expression of langerin is not evident 
in all DCs. This is maybe caused by membrane deformations in the process of 
langerin internalization [183], resulting in the unavailability of this particular 
epitope. Another possibility is the contamination of the sample with langerin(-) 
! C@B!
dermal DCs during the epidermal separation process. This is less likely, given 
that the staining with another antibody indicates langerin expression by most 
CD1a+, HLA DR+ cells extracted form epidermal sheets.  
Another problem encountered with the flowcytometric analysis of this 
population is the lack of the CD11c surface marker expression expected to be 
found in this population. It is possible that enzymatic epidermal separation 
followed by trypsinisation to obtain single cells suspension leads to cleavage 
of some surface markers, such as CD11c.  
It is worth mentioning that the blood samples from the skin donors were not 
available, hence I did not have opportunity to compare MECLR reactions 
driven by epidermal APCs to the MLR reaction driven by blood derived APCs 
from the same individuals. Irrespective, impression was that the proliferation 
in the MECLR was weaker than what we would normally expect from the 
standard MLR. Lack of CD11c possibly affecting the function, together with 
the old age of the skin donors, the possibility of hypoxic injury to the DCs in 
the ex-vivo organ bath culture and previous cryopreservation of the responder 
PBMCs, can be explanation for the relatively low proliferation in these cultures. 
However, it has to be kept in mind that epidermal DCs obtained in such a way 
may also be in immature state and therefore less potent in driving MECLR 
reactions. Supportive of this explanation is the finding by Steinman et al. that 
epidermal DCs were able to drive proliferation comparable to splenic DCs 
only after maturation in culture.[184] Nevertheless, skin organ bath culture 
provides live and functional DCs suitable for the assessment of the #24h long 
effect of different agents. It is thus a feasible ex-vivo prelude to in-vivo studies 
that are limited due to ethical considerations.  
! C@C!
$"Z"! J431@,/01%,B@%3/1B,%:W/0%*7:%
It is important to deliver the peptide for PIT in the optimal, minimally invasive 
way, to the correct antigen presenting cells that should be in the immature 
state and with the potential to transmit tolerogenic signal. The available data 
suggest that the best candidates for this role are skin Langerhans cells that 
are densely distributed in the suprabasal epidermis. In addition, their 
superficial position makes them available for topical immune-modulatory 
agents aiming to enhance PIT by increasing the tolerogenic potential of DCs 
without causing systemic effects of both peptide and tolerance enhancer. 
I developed the system for the assessment of the delivery to the epidermal 
DCs, majority of which are LCs. This is expected based on the epidermal 
separation methodology and evidenced by the phenotype of the cells obtained 
in such a way.  
I assessed hollow microneedles and dry coated microneedle compared to 
standard hypodermic needle intradermal injection as devices for this purpose. 
Dissolving microneedles were not considered in this project because of the 
concern that degraded matrices may exacerbate a pro-inflammatory effect. 
Delivery of antigens by pre-treatment of the skin to form pores by solid 
microneedles was also not considered due to difficulties in regards to 
quantification of antigen dose delivered. Antigen delivery in the liquid state 
through hollow microneedles allows precise quantification of dose delivered to 
the skin, whilst the estimated quantity of antigen delivered from the dry 
microneedle is less than 20% of the coated material. This depends on the 
solubility of the peptide and the degree of polishing of the needles (Xhao 
personal communication). 
! C@@!
Targeting epidermal DCs was assessed by their ability to present delivered 
peptide to antigen- specific cloned T cells in the context of the right HLA type. 
The fact that both types of cloned T-cells were able to present their respective 
peptides to itself, means that they have ability to react to any free peptide 
present in the cultures, even in the absence of the HLA matched APCs. Lack 
of the stimulation of the cloned T-cell by the APCs originated from the HLA 
mismatched donors, indicated that there was no free or bound peptide in the 
cultures, as these cells were not able to capture and retain peptide after 
insertion into the skin, and any free peptide would have been eliminated 
during the washing procedures for the generation of single cell suspension. 
On the other hand, APCs of the right HLA type, captured ex vivo delivered 
peptide, retained it despite number of washing procedures, effectively 
presented it and stimulated cloned T cells.  
The problem with experiments involving cloned T cells was variability of their 
sensitivity to respective peptides as evidenced by wide range of production of 
signature cytokines (IFN! or MIP1-$). Clones had to be kept in an activated 
state to be ready for the unpredictable availability of skin samples (all skin 
samples were processed and used the same day without cryopreservation). 
That required maintaining the clones in the culture for many weeks, which 
may have led to loss of sensitivity. Also, cloned T cells were presented with 
peptide loaded DCs in various stages of activation of the T cells in their cycle 
ranging from 7 to 17 days from initial stimulation. The use of stimulation index 
i.e. normalization to untreated samples helped to overcome this problem to a 
certain extent and reduced large discrepancy between donors. 
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Data comparing FP1 peptide delivery by hollow microneedles to the standard 
intradermal delivery by 26G needles did not show any convincing difference 
between those two devices. Although the length of the microneedles should 
allow delivery in close proximity to the epidermis, the “jet” effect from the 
volume insertion is more likely to displace peptide solution deeper in the 
dermis. However, some presentation by epidermal DCs was detected with 
both devices. It is likely that FP1 peptide solution reached the epidermis 
through “flush back”, which was facilitated by the hydrophilic nature of this 
peptide (23% of hydrophilic residues, 38% of hydrophobic residues, 38% 
other residues; Peptide property calculator, GenScript, USA). The degree of 
“flushback” may be dependent on peptide solubility. 
The use of FP1 specific cloned T-cells was limited by the rarity of the HLA 
DR1 type (1 in 9 people in general population) [185] to which this clone is 
restricted. This demanded screening of a large number of already limited skin 
donors. For this reason, I decided to use different cloned T-cells, specific for 
EBVP1 peptide, but restricted to class I HLA-A2 with 50% of individuals being 
carriers of this type.  
Data comparing EBVP1 peptide delivery by dry coated microneedles to the 
standard intradermal delivery by 26G needles showed exclusive presentation 
when peptide was delivered in the right HLA context.  
The data suggested that dry coated microneedles with the 500µm long 
projections are capable of targeting epidermal DCs. Although there was no 
difference to standard 26G needle delivery when comparable peptide dose 
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was injected in the skin explant of the same donor, comparison to HLA-A2 
negative donors is suggestive of more efficient delivery via microneedles.  
When higher dose was delivered via 26G needles, there was a trend of higher 
stimulation of cloned T cells, although numbers were small to draw any 
meaningful conclusions. However, with less than 20% of peptide delivered 
during skin insertion, efficacy of the delivery of this particular peptide from dry 
coated microneedle is low and represents a disadvantage, due to the possible 
influence of the individual properties of the skin, including the age of the 
recipient, which was not tested in this system. The explanation may be that 
EBVP1 is very hydrophobic peptide with 67% hydrophobic uncharged 
residues, 0% hydrophilic and 33% other residues (Peptide property calculator, 
GenScript, USA), which makes diffusion of the peptide to the tissue more 
difficult. This may not be an issue with other more hydrophilic peptides, such 
as proinusulin derived C19-A3 peptide, which is currently in clinical trial 
delivered via standard 26G needle. Another way to increase the quantity of 
peptide delivery from the microneedle is the use of arrays with larger number 
of needles that will allow a higher starting amount of peptide.  
Overall conclusion from this set of experiments is that both hollow and dry 
coated microneedles are comparable to standard indradermal 26G needles in 
targeting epidermal DCs, with some suggestion of superiority in the case of 
dry microneedles. An additional advantage for the use of dry microneedles 
comes from the findings that they are less invasive and less painful delivery 
devices [186, 187] that offer the possibility of self-administration by patients 
[188], which is important advantage where there is a need for a chronic 
administration. Effect on pain is related to the reduction of depth of the 
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insertion and absence of the injected volume with the solid microneedles. In 
addition, solid microneedles potentially deliver more to the epidermal DCs 
than to the dermal. To further assess this speculation, the model should be 
developed to isolate dermal DCs from the skin bath culture and compare it to 
their epidermal counterparts. Taken!together, these findings suggest that dry 
coated microneedles are potentially optimal delivery device for peptide 
immunotherapy. Future work will focus on increasing efficacy of delivery and 
the actual application in the administration of peptide immunotherapy in Type 
1 diabetes6 
This is a model that enables the ex vivo study of the antigen delivery and 
consequent uptake and presentation by skin DCs that offer excellent 
surrogate for the in vivo conditions, with obvious limitations discussed above, 
but without drug-related ethical considerations. That allows rapid 
assessments of the effect of various antigens delivered via different devices, 
which can be used as a robust step in translating novel therapies to clinic. 
  
! C@%!
 
 
 
 
 
 
7B4.,@3%8 HF&(F7HLHFJ%IE%JI'H+INHFD7%HFPD+IFLHFJ%
DF%6+H6(+(JDIF%EI+%6H6JD*H%DLL<FIJ&H+(6Q%
 
 
 
 
 
 
 
 
 
 
! C@"!
4.1 Introduction 
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Dendritic cells (DCs) are professional antigen presenting cells, seen as a 
bridge between innate and adaptive immunity. They have a crucial role in the 
defense against ‘foreign’, but at the same time they patrol around the body, 
take-up and present peptides from dying cells and other self-antigens, 
maintaining tolerance to ‘self’.[180] In the attempts to understand the 
intriguing mechanisms allowing this balance, two different opinions 
predominate.[189] One favours tolerogenic DC lineages such as CD8+ 
conventional DCs [190, 191] and plasmocytoid DCs.[191] Another 
emphasizes maturation of DCs as an important control point that propels DCs 
on the road of inflammation as opposed to tolerance. Possibility to modulate 
maturation of the DCs and affect self-antigen presentation and the 
autoimmune process, has been an important research focus. 
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Upon encounter with the microbial agent, DCs mature through activation of 
Toll-like receptors [192] and TNF% receptors and CD40 ligand [193]. As a 
result, DCs increase expression of class II MHC [194], co-stimulatory 
molecules, such as CD80 and CD86 [195, 196], and increase production of 
growth factor IL-2 [197], chemokines [198] and cytokines, such as IL-12.[199] 
These phenotypic and functional changes render DCs capable of triggering 
pro-inflammatory immune response and efficient defense.  
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On the other side, there is ample evidence to suggest capacity of DCs to 
induce T cell tolerance through generation of Tregs (Chapter 1). IL-10, TGF-$ 
or IL-35 secreted by DCs are strongly implemented in this process.[200] In 
vitro data suggest that immature, monocyte-derived DCs are weak initiators of 
immunity, but when co-cultured with allogenic T-cells, they make them 
refractory to antigenic stimulation. This effect is partially blocked by anti-IL-10 
antibodies, suggesting generation of Tr1 cells.[201] One of the proposed 
mechanisms through which immature DCs achieve suppression is low 
expression of MHC molecules and co-stimulatory factors.[202] Also, it has 
been suggested that suboptimal antigen presentation, together with increased 
indolamine 2,3-dioxygenase expression (IDO) by DCs leads to inhibition of T 
cell proliferation.[55] Another molecule, immunoglobilin-like transcript 3 (ILT3) 
works as an immune inhibitory receptor. It is selectively expressed on 
dendritic cells, and some other cells such as monocytes and macrophages. 
The extracellular domain of ILT3 binds to the T cells, sending inhibitory 
signals.[203] On the other hand, T cells, in particular Tregs can affect 
dendritic cells. LAG-3, transmembrane CD4-related protein that is expressed 
by Tregs upon activation, binds MHC class II on the APCs, modulating its 
function towards suppression.[204]   
Considering the key role of DCs in the induction and activation of both effector 
T cells and Tregs, it is no surprise that discrepancies in DCs number, 
phenotype and function have been linked to pathogenesis of autoimmune 
diseases.[205, 206] It is encouraging that immuno-modulating therapies in 
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multiple sclerosis, for example, have been shown to restore DCs phenotype 
and function in non-specific manner.[206]  
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A number of authors have reported pharmacological modulation of DCs to 
enhance their tolerogenic potential.[207] Agents used include rapamycin, 
vitamin A, growth factors such as G-CSF, VEGF, VIP, cytokines such as IL-10 
and hormones such as vitamin D and glucocorticoid (GC) 
dexamethasone.[208] In vitro IL-10 primed DCs showed tolerogenic profile 
and low T-cell activation properties, as well as generation of Tregs that 
strongly suppressed T cell reactivity [209] [32] 
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Amongst listed, most commonly in vitro and in vivo studied agents are vitamin 
D3 and dexamethasone.  
Vitamin D3 is known for its immunomodulating capacities that are mainly 
attributed to its action on DCs.[210, 211] Vitamin D3 primed DCs (vitD3-DCs) 
have stable immature phenotype featuring low expression of CD80, CD86 and 
CD40, as well as CD1a, CD83 and MHC class II.[212, 213] They produce IL-
10 instead of IL-12 in the cultures. VitD3-DCs are able to prevent priming of 
naïve CD4 or CD8 T cells, induce apoptosis of effector T cells and induce 
antigen-specific Tregs from naïve T cells.[214, 215] There are several 
proposed mechanisms to explain these immunosuppressive effects. VitD3-
DCs express high level of PDL1, which leads to low expression of co-
stimulatory molecules and higher production of IL-10. This may be crucial in 
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inducing Tregs from naïve CD4+ cells.[215] There is evidence from another 
study that vitD3-DCs induce Tregs through increase in DCs IDO 
expression.[216]  
Dexamethasone modulated DCs (dex-DCs) share the similar phenotype and 
functional status favoring induction of IL-10 producing cells over IFN! 
producing cells.[215, 217-220] However Tregs generated with 
dexamethasone show features of IL-10 producing Tr1 and suppress in non-
specific, bystander fashion, whilst effects of vitamin D3 are antigen-
specific.[215]  
When used combined, dexamethasone and vitamin D3 showed similar results 
as either agent alone [221], but retained antigen-specific suppression, which 
is the feature of vitD3-DCs. Other study suggested that Tregs induced by 
vitD3-DCs alone [222] and vitD3/dex-DCs [223] are more likely to generate 
Tr1 type Tregs. Direct killing of effector T cells is another possible mechanism 
of action of vitD3-DCs[212] and vitD3/dex-DCs.[224] 
Variety seen between different studies can be attributed to difference in many 
factors, such as type and dose of the modulating agent and experimental 
conditions, but it seems that DCs have array of action modalities and their 
disposal that can be used depending on the environment.  
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Systemically administered and inhaled glucocorticoids (GC) in patients with 
asthma are shown to increase circulating Tregs.[225] The similar results were 
repeated in several small studies on different autoimmune diseases [226-229], 
with one indicating that addition of vitamin D3 to GC improved outcome in 
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steroid resistant asthma.[229] However, large study involving over 50 patients, 
on effect of GC with and without vitamin D3 on asthma failed to show 
beneficial effect of adjuvants to specific-immunotherapy [230], as did the 
study looking at effect of systemic steroids in healthy individuals. [231] 
Discrepancy in the results can be explained by heterogeneity of studied 
populations and difficulties in defining and monitoring target antigen 
presenting cell population and Treg population in blood. 
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As discussed in Chapter 1, skin is preferable route for administering antigen-
specific immunotherapy (ASI) due to the abundance of DCs that are easily 
accessible both by antigens and modulating agents. Mode of antigen delivery 
as a way of promoting DC tolerance was discussed in Chapter 3. Here I 
discuss possibilities of pharmacological modulation of skin DCs through local 
administration of agents. 
There is evidence from murine models that antigen-specific therapy 
administered subcutaneously (s.c.) was more effective when given in 
combination with s.c. dexamethasone.[232] However, subcutaneous way of 
delivery is more likely to achieve systemic effects due to proximity of skin 
vasculature. Authors went on to show that s.c. dexamethasone, as a 
tolerogenic adjuvant to immunotherapy, enriches CD11c low CD40 low 
macrophages in blood, which was suggestive of a systemic effect. [233]  
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The success of topical vitamin D3 in the treatment of T-cell mediated skin 
disease, psoriasis, is supportive of the concept of targeting local immune cells. 
It seems that when vitamin D3 is applied locally into the mouse skin, as an 
adjuvant to vaccine formulations, it targets skin DCs.[234] The 
Immunomodulatory effect of vitamin D3 in the skin is dependent on a subset 
of DCs. Whilst Langerhans cells (LCs) pretreated with vitamin D3 induce 
Foxp3+ Tregs in TGF$ dependent fashion, dermal DCs (DDCs) promoted 
Foxp3- IL10+ Tregs, effect dependent on IL-10, despite comparable 
expression of vitamin D receptor between two subsets. [235] 
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When administered to the skin explants, another modulating agent, IL-10, 
favoured migration of immature dermal DCs with functional qualities 
conducive to T cell tolerance.[236] This is consistent with recognised role of 
IL-10 in DCs biology, and encouraging for the approach of the local skin 
administration of IL-10. The potential limitation to this approach is difficulty in 
targeting skin DCs and creating IL-10 rich microenvironment in and around 
skin DCs as opposed to other skin resident cells. 
Use of developing gold nanoparticles (NP) technology can overcome this 
problem. Gold nanoparticles are inert, non-toxic, and can be readily 
endocytosed by DCs and other phagocytic mononuclear cells.[237, 238] Even 
non-phagocytic T cells can load up to 104 of these particles per cell.[239] This 
can significantly enhance uptake of antigens and bioactive molecules 
attached to them, such as peptides and IL-10 and enable administration of 
smaller “local immuno-modulating” IL-10 dose without systemic effects 
recognised when higher doses are used. [240, 241] 
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4.2 Hypothesis  
I hypothesise that preconditioning of the skin DCs with agents such as topical 
steroid or intradermally injected IL-10 can enhance their tolerogenic 
responses.  
4.3 Aims 
1. To study effect of topical steroid pretreatment on tolerogenic 
potential of skin DCs 
2. To study effect of pretreatment of intradermally injected IL-10, 
alone or attached to gold nanoparticles, on tolerogenic potential of skin 
DCs. 
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4.4 Results  
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There was no significant difference in the proportion of live epidermal cells 
deriving from skin treated with PBS (untreated in further text) and live 
epidermal cells deriving from skin treated with topical 0.05% (w/w) 
betamethasone cream for 24h in the organ bath culture at 37°C in an 
atmosphere of 5% (v/v) CO2/95% (v/v) (Figure 4-1, Table 4-1). Viability of cells 
was measured by live/dead marker on flow cytometry (Figure 4-2) and 
expressed as percentage of live cells out of the total number of cells in the 
single cell suspension obtained after incubation and as described in Chapter 2.  
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 Untreated 
(%) 
Steroid 
(%) 
Exp 1 13.6 16.9 
Exp 2 12.1 16.8 
Exp 3 66.3 13.3 
Exp 4 26.6 36.7 
Exp 5 28.3 40.5 
Exp 6 39.7 27.6 
Exp 7 14.9 13.2 
Exp 8 37.6 26.2 
Exp 9 64.6 66.7 
N 9 9 
Mean 33.7 28.7 
SD 20.5 17.4 
 
Table 4-1. Flowcytometric 
analysis of the viability of 
epidermal cells with and without 
topical steroid treatment. 
Untreated: cells deriving from 
untreated skin; Steroid: cells deriving 
from skin treated with 0.05% (w/w) 
betamethasone; %: percent of live 
dendritic cells out of the total number 
of live epidermal cells. N: number of 
replicates; SD: standard deviation. 
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Figure 4-1. Flowcytometric analysis of 
the viability of epidermal cells with and 
without topical steroid treatment.  
Untreated: % of live epidermal cells deriving 
from untreated skin. Steroid treated: % of 
live epidermal cells deriving from skin 
treated with 0.05% (w/w) betamethasone. 
Statistical test used: Wilcoxon signed rank 
test. 
 !
! C&$!
 
 
 
 
 
 
 
Figure 4-2. Viability of epidermal cells following exposure to the topical steroid 
treatment, flowcytometric analysis of the representative sample. Epidermal cells 
negative for live/dead marker (APC-Cy7 channel) were characterised as live cells; LD marker 
– live/dead marker; FSC-A – forward scatter - area; a) epidermal cells deriving from untreated 
skin; b) epidermal cells deriving from skin treated with 0.05% (w/w) betamethasone. 
 
 
 
 
 
 
 
 Untreated 
(%) 
Steroid 
(%) 
Exp 1 1.05 1.31 
Exp 2 0.80 1.49 
Exp 3 1.64 1.29 
Exp 4 1.30 0.50 
Exp 5 1.17 0.64 
Exp 6 1.21 1.35 
Exp 7 1.05 1.49 
Exp 8 0.84 0.49 
Exp 9 1.26 1.54 
N 9 9 
Mean 1.15 1.12 
SD 0.25 0.44 
 
Table 4-2. Flowcytometric 
analysis of the epidermal cells 
solution with and without topical 
steroid. 
Untreated: cells deriving from 
untreated skin; Steroid: cells deriving 
from skin treated with 0.05% (w/w) 
betamethasone; %: percent of the 
total number of live epidermal cells. 
N: number of replicates; SD: 
standard deviation. 
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Figure 4-3. Analysis of the proportion of 
DCs in the epidermal cells solution with 
and without topical steroid treatment.  
Untreated: % of live epidermal cells deriving 
from untreated skin. Steroid treated: % of 
live epidermal cells deriving from skin 
treated with 0.05% (w/w) betamethasone. 
Statistical test used: Wilcoxon signed rank 
test. 
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There was no significant difference in the proportion of dendritic cells deriving 
from untreated skin and dendritic cells deriving from skin treated with topical 
0.05% (w/w) betamethasone cream for 24h in the organ bath culture at 37°C 
in an atmosphere of 5% (v/v) CO2/95% (v/v) (Figure 4-3, Table 4-2). Dendritic 
cells were characterized as CD1a+, HLA DR+ cells in the epidermal single 
cells suspension (Figure 4-4).  
Viability was measured by live/dead marker on flow cytometry and expressed 
as percentage of live CD1a+, HLA DR+ cells out of the total number of live 
cells in the single cell suspension obtained after incubation and as described 
in Chapter 2. Gating strategy is described in Chapter 2. 
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Figure 4-4. Viability of dendritic cells following the exposure to the topical steroid 
treatment, flowcytometric analysis of the representative sample.  
CD1a+, HLA DR+ cells from the live epidermal population were characterised as dendritic 
cells; a) dendritic cells deriving from untreated skin; b) dendritic cells deriving from skin 
treated with 0.05% (w/w) betamethasone. 
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Surface markers used for phenotyping of the epidermal dendritic cells are 
shown in the Table 4-3.  
Marker Role 
CD11c Adhesion molecule, binds fibrinogen 
CD1a MHC class I like molecule, has specialised role in presentation of lipid antigens 
CD207 Langerin C-type lectin, uptake of foreign antigens 
CD40 Binds CD40L (CD154), co-stimulatory molecule required for the activation of APCs 
CD80 Co-stimulator, ligand for CD28 and CTLA-4 
CD83 Marker of DCs maturation 
CD86 Co-stimulator, ligand for CD28 and CTLA-4 
Epcam Adhesion molecule, connects LCs to the neighboring keratinocytes 
HLA-DR MHC class II molecule 
Table 4-3. Surface markers used for the phenotyping of the epidermal DCs !
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DCs deriving from the skin pre-treated with topical steroid showed significantly 
lower expression of HLA-DR, expressed as Mean Fluorescent Intensity (MFI), 
in comparison to DCs from untreated skin (43419±28858, 23833±15273, n=9, 
p=0.0039) - Figure 4-5, Figure 4-6, Table 4-4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Untreated 
(MFI W/m2) 
Steroid 
(MFI W/m2) Exp 1 CD%EB6 ""$B6 
Exp 2 CBDEB6 "@&B6 
Exp 3 CB#BBB6 #$@&&6 
Exp 4 C&@$B6 $C&C6 
Exp 5 #@&C"6 @&EDE6 
Exp 6 #DE&B6 CDD&D6 
Exp 7 $"#@B6 #@EDD6 
Exp 8 &EBBB6 &&D#C6 
Exp 9 $%@"@6 @E#E%6 
N E E 
Mean #&#CE @&D&& 
SD @DD$D C$@"& 
Table 4-4. HLA DR expression on 
skin dendritic cells with and 
without topical steroid treatment  
Untreated: dendritic cells deriving 
from untreated; Steroid: dendritic 
cells deriving from skin treated with 
0.05% (w/w); MFI: Mean Fluorescent 
Intensity, expressed in W/m2; N: 
number of replicates; SD: standard 
deviation. 
Figure 4-5. HLA DR expression on skin 
dendritic cells with and without topical 
steroid treatment. Untreated: dendritic 
cells deriving from untreated skin; Steroid 
treated: dendritic cells deriving from skin 
treated with 0.05% (w/w) betamethasone. 
MFI: Mean Fluorescent Intensity. 
Statistical test used: Wilcoxon signed rank 
test. 
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Figure 4-6. HLA DR expression on skin dendritic cells 
with and without topical steroid treatment, 
flowcytometric analysis of the representative sample. 
Expression of HLA DR (PerCP-Cy 5.5 channel) on the 
dendritic cells deriving from untreated skin (black lines) and 
skin treated with 0.05% (w/w) betamethasone (dark gray 
lines). Unstained sample used as control (solid gray). 
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Tocal steroid treatment induced significant reduction in the expression CD80 
co-stimulatory marker (Figure 4-7, Figure 4-8, Table 4-5), whilst there was no 
significant reduction in the expression of other tested co-stimulatory markers 
CD86 (Figure 4-9, Table 4-6), CD83 (Figure 4-10, Table 4-7) and CD40 (Figure 4-11, 
Table 4-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 Untreated 
(MFI W/m2) 
Steroid 
(MFI W/m2) Exp 1 $EB$6 &E@#6 
Exp 2 $&%%6 ##@"6 
Exp 3 CB&#6 D#C6 
Exp 4 @@$%6 CE$B6 
Exp 5 #DBD#6 ##BB"6 
Exp 6 %B$$#6 &EBE$6 
N % % 
Mean &%#B @"D% 
SD @&%D C%DB 
 
Table 4-5. CD80 expression on 
skin dendritic cells with and 
without topical steroid treatment.  
Untreated: dendritic cells deriving 
from untreated skin; Steroid: 
dendritic cells deriving from skin 
treated with 0.05% (w/w); MFI: Mean 
Fluorescent Intensity, expressed in 
W/m2; N: number of replicates; SD: 
standard deviation. !
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Figure 4-8. CD80 expression on skin dendritic cells with 
and without topical steroid treatment, flowcytometric 
analysis of the representative sample. 
Expression of CD80 (PerCP-Cy 5.5 channel) on the dendritic 
cells deriving from untreated skin; (black lines) and skin 
treated with 0.05% (w/w) betamethasone (dark gray lines). 
Unstained sample used as control (solid gray). 
Figure 4-7. CD80 expression on skin 
dendritic cells with and without topical 
steroid treatment. 
Untreated: dendritic cells deriving from 
untreated skin; Steroid treated: dendritic 
cells deriving from skin treated with 0.05% 
(w/w) betamethasone. MFI: Mean 
Fluorescent Intensity; Statistical test used: 
Wilcoxon signed rank test. 
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 Untreated 
(MFI W/m2) 
Steroid 
(MFI W/m2) Exp 1 C#$@6 C@&D6 
Exp 2 C&@@6 C@B%6 
Exp 3 C#"%6 #EC6 
Exp 4 &$&$6 C%EC6 
Exp 5 #$%B6 #&$%6 
Exp 6 C@E"6 C%CC6 
Exp 7 @CCD6! C@$%6!
N " " 
Mean @@$C C%E& 
SD C@E@ C@&" 
Table 4-6. CD86 expression on 
skin dendritic cells with and 
without topical steroid treatment. 
Untreated: dendritic cells deriving 
from untreated skin; Steroid: 
dendritic cells deriving from skin 
treated with 0.05% (w/w); MFI: Mean 
Fluorescent Intensity, expressed in 
W/m2; N: number of replicates; SD: 
standard deviation. 
 Untreated 
(MFI W/m2) 
Steroid 
(MFIW/m2) Exp 1 &B@$6 &&$%6 
Exp 2 &&#D6 &ECC6 
Exp 3 CDB6 E@6 
Exp 4 &B"6 @ED6 
Exp 5 E%$6 @E#6 
Exp 6 $#D6 @E%6 
N % % 
Mean C&E% C&"$ 
SD C#C" C"%B 
 
Table 4-7. CD83 expression on 
skin dendritic cells with and 
without topical steroid treatment. 
Untreated: dendritic cells deriving 
from untreated skin; Steroid: dendritic 
cells deriving from skin treated with 
0.05% (w/w); MFI: Mean Fluorescent 
Intensity, expressed in W/m2; N: 
number of replicates; SD: standard 
deviation. 
 
Figure 4-9. CD86 expression on skin 
dendritic cells with and without topical 
steroid treatment. 
Untreated: dendritic cells deriving from 
untreated skin; Steroid treated: dendritic 
cells deriving from skin treated with 0.05% 
(w/w) betamethasone. MFI: Mean 
Fluorescent Intensity. Statistical test used: 
Wilcoxon signed rank test.  
Untreated Steroid treated
0
1000
2000
3000
4000
5000
n=6
p=0.11
Figure 4-10. CD83 expression on skin 
dendritic cells with and without topical 
steroid treatment. 
Untreated: dendritic cells deriving from 
untreated skin; Steroid treated: dendritic 
cells deriving from skin treated with 0.05% 
(w/w) betamethasone. MFI: Mean 
Fluorescent Intensity. Statistical test used: 
Wilcoxon signed rank test. 
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 Untreated 
(MFI W/m2) 
Steroid 
(MFI W/m2) Exp 1 ED"6B EB# 
Exp 2 DD%6B CBC@ 
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Exp 6 @B% C## 
N % % 
Mean %@$6& #"$6$ 
SD &DD6% &EC6& 
 
Table 4-8. CD40 expression on 
skin dendritic cells with and 
without topical steroid treatment. 
Untreated: dendritic cells deriving 
from untreated skin; Steroid: 
dendritic cells deriving from skin 
treated with 0.05% (w/w); MFI: Mean 
Fluorescent Intensity, expressed in 
W/m2; N: number of replicates; SD: 
standard deviation. !
Figure 4-11. CD40 expression on skin 
dendritic cells with and without topical 
steroid treatment. Untreated: dendritic 
cells deriving from untreated skin; Steroid 
treated: dendritic cells deriving from skin 
treated with 0.05% (w/w) betamethasone. 
MFI: Mean Fluorescent Intensity; Statistic 
test used: Wilcoxon signed rank test. 
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Proliferation was expressed as proliferation index (PI), i.e. ratio of proliferation 
in the MECLR and unstimulated responder PBMCs, in order to correct for 
background originated from the some degree of the spontaneous PBMCs, 
often encountered with previously cryopreserved cells. I observed significantly 
lower proliferation rate measured by 3H thymidine incorporation (cpm) in 5-
day long MECLR driven by DCs from steroid treated skin, expressed as PI 
(8.29±6.35) comparing to the untreated (2.73±1.39) - Figure 4-12, Table 4-9. The 
average baseline proliferation in the MECLR before steroid treatment was 
1636±861cmp, with the responder PBMCs proliferation of 459.11±463.4cpm.  
There was no proliferation from epidermal cells (untreated: 29.4±10.5, steroid 
treated: 49.9±60.7). 
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Table 4-9. Proliferation in MECLR 
driven by DCs with and without 
exposure to the topical treatment. 
MECLR proliferation index (PI): 
Mixed Epidermal Cells Reaction 
proliferation/PBMC proliferation 
ratio; Untreated: MECLR PI driven 
by dendritic cells deriving from 
untreated skin; Steroid: MECLR PI 
driven by dendritic cells deriving 
from skin treated with 0.05% (w/w); 
N: number of replicates; SD: 
standard deviation. !
Figure 4-12. Proliferation in MECLR 
driven by DCs with and without 
exposure to the topical treatment. 
MECLR proliferation index (PI): Mixed 
Epidermal Cells Reaction 
proliferation/PBMC proliferation ratio; 
Untreated: MECLR PI driven by dendritic 
cells deriving from untreated skin; Steroid 
treated: MECLR PI driven by dendritic 
cells deriving from skin treated with 
0.05% (w/w) betamethasone; Statistical 
test used: Wilcoxon signed rank test. 
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Production of Interleukin 10 (IL-10) measured in the supernatants of MECLR 
reactions showed trend for lower levels in the reactions driven by steroid 
treated in comparison to untreated DCs, although it was not significantly 
different (Figure 4-13, Table 4-10). At the same time, the level of Interferon ! 
(IFN!) was significantly lower (Figure 4-14, Table 4-11) and IL10/IFN! ratio 
significantly higher (Figure 4-15, Table 4-12) in the supernatants of the reactions 
driven by steroid exposed DCs.   
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Table 4-10. IL-10 produced in the 
MECLRs driven by DCs with and 
without exposure to the topical 
treatment. IL-10 – Interleukin 10 
produced in the supernatants of 
MECLRs; Untreated: IL-10 from 
MECLRs driven by dendritic cells 
deriving from untreated skin; Steroid: 
IL-10 from MECLRs driven by 
dendritic cells deriving from skin 
treated with 0.05% (w/w) 
betamethasone; N: number of 
replicates; SD: standard deviation. !
Figure 4-13. IL-10 produced in the 
MECLRs driven by DCs with and 
without exposure to the topical 
treatment. IL-10 – Interleukin 10 
produced in the supernatants of MECLRs; 
Untreated: IL-10 from MECLRs driven by 
dendritic cells deriving from untreated 
skin; Steroid treated: IL-10 from MECLRs 
driven by dendritic cells deriving from skin 
treated with 0.05% (w/w) betamethasone; 
Statistical test used: Wilcoxon signed rank 
test. 
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Table 4-11. IFN" produced in the 
MECLRs driven by DCs with and 
without exposure to the topical 
treatment. IFN! – Interferon ! produced 
in the supernatants of MECLRs; 
Untreated: IFN! from MECLRs driven by 
dendritic cells deriving from untreated 
skin;  Steroid: IFN! from MECLRs driven 
by dendritic cells deriving from skin 
treated with 0.05% (w/w) 
betamethasone; N: number of replicates; 
SD: standard deviation. !
Figure 4-14. IFN" produced in the 
MECLRs driven by DCs with and 
without exposure to the topical 
treatment. IFN! – Interferon ! produced 
in the supernatants of MECLRs; 
Untreated: IFN! from MECLRs driven by 
dendritic cells deriving from untreated 
skin; Steroid treated: IFN! from MECLRs 
driven by dendritic cells deriving from skin 
treated with 0.05% (w/w) betamethasone; 
Statistical test used: Wilcoxon signed rank 
test. 
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Untreated  
(IL10/IFN" 
pg/ml) 
Steroid 
(IL10/IFN" 
pg/ml) 
Exp 1 @6"B CB6&% 
Exp 2 B6E@ @6"% 
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N E E 
Mean B6"% C6E@ 
SD B6"% &6CC 
Table 4-12. IL-10/IFN" ratio produced in 
the MECLRs driven by DCs with and 
without exposure to the topical 
treatment. IL-10/IFN! ratio – Interleukin 
10/Interferon ! ratio produced in the 
supernatants of MECLRs; Untreated: IL-
10/IFN! ratio from MECLRs driven by 
dendritic cells deriving from untreated skin; 
Steroid: IL-10/IFN! ratio from MECLRs 
driven by dendritic cells deriving from skin 
treated with 0.05% (w/w) betamethasone; 
N: number of replicates; SD: standard 
deviation. 
Figure 4-15. IL-10/IFN" ratio produced 
in the MECLRs driven by DCs with and 
without exposure to the topical 
treatment. IL-10/IFN! ratio – Interleukin 
10/Interferon ! ratio produced in the 
supernatants of MECLRs; Untreated: IL-
10/IFN! ratio from MECLRs driven by 
dendritic cells deriving from untreated 
skin; Steroid treated: IL-10/IFN! ratio from 
MECLRs driven by dendritic cells deriving 
from skin treated with 0.05% (w/w) 
betamethasone; Statistical test used: 
Wilcoxon signed rank test. 
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To explore this further, I wanted to clarify the mechanism by which steroid 
pretreatment affects DCs by flow-cytometric and functional assessment of T 
cell proliferation in response to DC stimulation, in particular focusing on 
evidence for Treg induction. Epidermal single cell suspension deriving from 
steroid treated skin from the donor A (untreated skin used as a control) was 
co-cultured for 14 days with allogeneic donor CD4+ naïve T cells (responder 
B), isolated from PBMCs through positive MACS column separation. The aim 
was to assess phenotype and the suppression capacity of T cells cultivated in 
such a way, on proliferation in the fresh co-culture of epidermal cells and 
PBMCs (the same pair of donors as the original culture). However, three 
replicates of this protocol resulted in low number of harvested cells insufficient 
to drive MECLR or to be analysed by flow cytometry. The conclusion was that 
DCs obtained from human skin explants are not potent enough to drive the 
reactions necessary for this experiment. 
Instead, I used single epidermal cell suspension obtained from epidermal 
sheets generated through suction blister method (courtesy of Dr Alhadjali), 
following four day long in vivo topical steroid treatment of one arm, whilst the 
other arm was left untreated. Epidermal sheet was enzymatically digested as 
described with the ex vivo skin explants and the same suppression protocol 
was followed as described above and in the Chapter 2.!
Representative example of the flowcytometric analysis of the cells obtained 
after 14 days of the incubation period is presented in the Figure 4-16. 
!!
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Figure 4-16. Representative example of the flowcytometric analysis of the cells 
harvested after 14 days long incubation of the epidermal cells suspension (with and 
without in vivo steroid pre-treatment) and the allogeneic responder CD4+ naïve T cells. 
Cells were gated on the live CD3+, CD4+ population. CD127 and CD25 staining is shown. a) 
harvest after stimulation by untreated epidermal cells; b) harvest after stimulation by steroid 
treated epidermal cells (in vivo exposure); c) CD127lowCD25pos T cells extracted from the 
responder PBMCs through MACS separation; d) summary of the findings from 3 different 
cultures, expressed as the percentage of the CD4+ cells. Statistical test used: One-way 
ANOVA with multiple comparison post-test.  !!!!
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I assessed proliferation of the responder naïve T cells (responder B) 
stimulated in the MLR type cultures driven by blood derived APCs (irradiated 
PBMCs) from the original skin donor, donor A and compared it to the 
proliferation in the same donor-responder culture, but with added T cells 
harvested from the 14 days long incubation period with epidermal cells with 
(Ts) and without (Tc) in vivo steroid exposure. I observed higher proliferation 
in the cultures with added T cells (Tc and Ts) in comparison to the baseline 
MLR, with the trend towards higher proliferation in the culture with the Tc than 
Ts - Figure 4-17a.  
IFN! and IL-10 measured in the supernatants of these reactions showed 
similar pattern of higher levels in the cultures supplemented with Tc in 
comparison to Ts - Figure 4-17 c and d.  
As a control, I used suppression capacity of the responder Tregs (defined as 
CD4+CD25posCD127low T cells). In the two replicates, I only observed trend 
towards suppression when higher number of 50x103 Tregs was used per well 
- Figure 4-17 b. 
!!!!
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!
!
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Figure 4-17. Effect of Tcells pre-stimulated by steroid exposed and untreated epidermal 
DCs, on proliferation and cytokine production. a) effect on proliferation; b) effect of Tregs 
used as a control; c) effect on IFN! production; d) effect on IL-10 production. MLR – Mixed 
lymphocyte reactionTc – T cells originated from the culture stimulated by untreated epidermal 
cells; Ts – T cells originated from the culture stimulated by steroid treated epidermal cells; 
Tregs – CD4+ CD25+CD127 – T cell from responder B. Statistical test used: One-way 
ANOVA with multiple comparison post-test, no significant differences were observed 
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Pure IL-10 (IL-10p) and IL-10 non-covalently attached to the gold 
nanoparticles (NP IL-10) was added to MLR cultures to compare their 
capacity to reduce proliferation. [242] 
Addition of both IL-10p (Figure 4-18 a, Table 4-13) and NP IL-10 (Figure 4-18 b, 
Table 4-13) caused trend towards reduction of proliferation, proportional to the 
increasing IL-10 concentration.  
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Figure 4-18. In-vitro effect of IL-10 on proliferation in MLR. MLR-proliferation without 
added IL-10; IL-10 1-100 ng/ml – proliferation with 1-100 ng/ml of IL-10 added in the 
culture; Statistical test used: Repeated measures ANOVA. a) effect of IL-10p b) effect of 
NPIL-10. Each line represents data from the same donor-responder combination.!
a) b) 
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When IFN! concentration from the supernatants of these reactions was 
measured, only IL-10p induced significant reduction of IFN!, whilst only trend 
towards reduction was observed with NP IL-10 (Figure 4-19, Table 4-14). 
! 
 IL-10p 3H thymidine 
incorporation (cpm) 
mean±SD 
Reduction 
(%) 
NPIL-10 3H thymidine 
incorporation (cpm) 
mean±SD 
Reduction 
(%) 
rPBMC $%D6BF@EC6D  $"C6&F&"$6@  
dPBMC CBB6CF%&6E  $"6%F&"6C  
MLR "D@CF"""E  CC#@CFD$BE  
IL-10 1 ng/ml %EB@F%$"% CC6"$ CB#$DF"CE&! D6#!
IL-10 10 ng/ml $#%%F$BBB &B6CC E""%F%"&&! C#6#!
IL-10 1 ng/ml %EB@F%$"% CC6"$ CB#$DF"CE&! D6#!
 
Table 4-13. In-vitro effect of IL-10 on proliferation in MLR. MLR-proliferation without 
added IL-10; IL-10 1-100 ng/ml – proliferation with 1-100 ng/ml of IL-10 added in the 
culture; reduction – reduction of proliferation with increasing concentration of IL-10 in 
comparison to MLR without added IL-10, expressed in %.  !
Figure 4-19. In-vitro effect of IL-10 on IFN  production in MLR. MLR-proliferation without 
added IL-10; IL-10 1-100 ng/ml – proliferation with 1-100 ng/ml of IL-10 added in the culture; 
Statistical test used: Repeated measures ANOVA. a) effect of IL-10p b) effect of NPIL-10. 
Each line represents data from the same donor-responder combination. 
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 IL-10p IFN" (pg/ml) 
mean±SD 
Reduction 
(%) 
NPIL-10 IFN" (pg/ml) 
mean±SD 
Reduction 
(%) 
rPBMC BFB  BFB  
dPBMC "6$FC%6"  C@6#F@C6$  
MLR CBC"$F""#E  $B#%F##BB  
IL-10 1 ng/ml CCEDF$BB6$! DD6@ $CB&F#EC$! GC6C!
IL-10 10 ng/ml $$@6@F&%%6% E#6% @#CBF@DDD! $@6@!
IL-10 100 ng/ml &$C6EF@&#6#! E%6$! C"@#F@$&D! %$6D!
 
Table 4-14. In-vitro effect of IL-10 on IFN" production in MLR. MLR-proliferation 
without added IL-10; IL-10 1-100 ng/ml – proliferation with 1-100 ng/ml of IL-10 added 
in the culture; reduction – reduction of proliferation with increasing concentration of IL-
10 in comparison to MLR without added IL-10, expressed in %.  !
! C$#!
When anti-IL-10 was added in the cultures containing NP-IL-10, effect on 
proliferation and to some extent, IFN! concentration was reversed, in 
comparison to the cultures without anti-IL-10 previously presented the Figure 
4-18 a , Figure 4-19 (Figure 4-20, Table 4-15).  
 
 
 
 
 
 
 
 
 
Figure 4-20. In-vitro effect of combined NP IL-10 and anti-IL-10 on proliferation and IFN" 
production in MLR. MLR-proliferation and IFN! production without added IL-10; IL-10 1-100 
ng/ml – proliferation and IFN! production with 100-1ng/ml of IL-10 added in the culture; anti- 
addition of anti-IL10 into the cultures; a) effect of proliferation in MLR b) effect on IFN! 
production in MLR. 
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 3H thymidine 
incorporation (cpm) 
mean±SD 
Reduction 
(%) 
IFN" (pg/ml) 
mean±SD 
Reduction 
(%) 
rPBMC %D%6$F##E6$  BFB  
dPBMC &%6C"FB6@%  CD6%F@%6#  
MLR C%C%$F&C@$  @$$C6BFCC$C6B  
IL-10 1 ng/ml C%&&"F$%%! C6B% &DD"F$$#! G$@6&"!
IL-10 10 ng/ml C%#$$F@E$" GC6"E &"$#FCB@#! G#"6C%!
IL-10 100 ng/ml C$D$@F@$&&! C6E#! C$EEFC##! &"6&@!
 
Table 4-15. In-vitro effect of combined anti-IL10 and NP IL-10 on proliferation and 
IFN" production in MLR. MLR-proliferation and IFN! production without added IL-10; 
IL-10 1-100 ng/ml – proliferation and IFN! with 1-100ng/ml of IL-10 added in the 
culture; reduction – reduction of proliferation and IFN! production with increasing 
concentration of IL-10 in comparison to MLR without added IL-10, expressed in %.  
 !
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On the basis of this proof of principle experiment, I proceeded to examine the 
effect of locally injected high dose IL-10 in the skin organ bath culture.  
50µl of high concentration of 10µg/ml of IL-10 in both IL-10p and NP IL-10 
form and plain NP without IL-10, but with correspondent concentration of gold, 
was injected into the skin in the organ bath culture. After four hour long 
incubation, single cell suspension was performed as previously described. 
The suspension was co-cultured with mismatched PBMCs donors in the 
MECLR type of the reaction. Proliferation and IFN! production was expressed 
as a ratio: modulated MECLR driven by DCs exposed to NP, NP IL-10 or IL-
10p / MECLR driven by untreated DCs. The average baseline proliferation and 
IFN! production in the MECLR driven by DCs deriving from the untreated skin 
was 4659±5140 cpm and 7369±10468 pg/ml, respectively. Proliferation of 
responder PBMCs was 531.6±297.1 cpm, whilst production of IFN! from 
these cells alone was below threshold of detection. Consistently with previous 
experiments, there was no proliferation or IFN! production from epidermal 
cells alone. 
Statistically non-significant trend towards reduction of proliferation was 
observed with IL-10p only in two out of three donor-responder combinations in 
the MECLR, whilst reduction of IFN! was suggestive in both IL-10p and NP IL-
10 modulated reactions in all MECLR (Figure 4-21, Table 4-16). 
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Table 4-16. Ex-vivo effect of combined NP IL-10 and 
anti-IL-10 on proliferation and IFN" production in 
MECLR. NP MECLR/MECLR - proliferation ratio and 
IFN! production ratio in MECLRs driven by DCs exposed 
to plain NP; NP IL-10 10µg/ml MECLR/MECLR - 
proliferation ratio and IFN! production ratio in MECLRs 
driven by DCs exposed to NP IL-10; IL-10 10µg/ml 
MECLR/MECLR - proliferation ratio and IFN! production 
ratio in MECLRs driven by DCs exposed to plain IL-10p.  
 !
Figure 4-21. Ex-vivo effect of combined NP IL-10 and anti-IL-10 on proliferation and IFN" 
production in MECLR. MECLR-proliferation ratio and IFN! production ratio without added IL-10; NP 
MECLR - proliferation ratio and IFN! production ratio in MECLRs driven by DCs exposed to plain NP; 
NP IL-10 10µg/ml MECLR - proliferation ratio and IFN! production ratio in MECLRs driven by DCs 
exposed to NP IL-10; IL-10 10µg/ml MECLR - proliferation ratio and IFN! production ratio in MECLRs 
driven by DCs exposed to pure IL-10p. Statistical test used: repeated measures ANOVA. a) effect on 
proliferation ratio in MECLR b) effect on IFN! production ratio in MECLR. Statistical test used: 
Repeated measures ANOVA. 
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4.5 Summary of findings 
1. Organ skin bath culture is a valuable ex-vivo system for studying effect 
of pharmacological modulation of skin DCs as evidenced by their 
viability and functional capacity to drive proliferation in MECLR after ex 
vivo application of treatments. 
 
2. Topical steroid treatment induces changes in the skin DCs responsible 
for their weaker capacity to activate responder T cells in the MLR type 
reactions. Although suggestive by the ex vivo model, in vivo data are 
less supportive of protolerogenic effects. Instead, generally weaker 
activation signal is more likely explanation for this phenomenon. This is 
in agreement by reduced expression of HLA-DR and some of the co-
stimulatory molecules on skin DCs following ex-vivo steroid exposure.  
 
3. IL-10, both in pure and nanoparticle bound form, has a capacity to 
suppress activity in the MLR type reactions, particularly when assessed 
by IFN! production. In vitro data are more robust, than the effect of the 
locally injected IL-10 in the skin organ bath culture, which may be 
subjects to the optimisation of the dose and duration of the treatment.  
 !
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Betamethasone cream (0.05% w/w) was chosen as a modulating topical 
steroid because of its equal potency to dexamethasone, whose ability to 
induce pro-tolerogenic changes in DCs was reviewed. In addition, our 
unpublished data suggest that when applied in vivo, this formulation has 
superior pro-tolerogenic effect on skin DCs in comparison to other agents 
including topical vitamin D3.  
Topical steroid pretreatment for 24 hrs modulates skin DCs to express 
significantly less markers of functional maturity such as class II MHC and co-
stimulatory molecule CD80, with a non-significant trend to reduction in CD86, 
and no change in the expression of CD40 and CD83. The possible 
explanation for the latter finding would be very subtle differences in individual 
markers, which does not exclude significant synergistic effect in vivo. Another 
! C$E!
reason for non-significant reduction observed with some of the markers, is low 
background expression in otherwise non-inflamed skin. 
DCs exposed to steroid pretreatment showed significantly weaker capacity to 
drive proliferation in MECLR. To support this finding, cytokines produced in 
these reactions showed a more tolerogenic profile (lower IFN! production and 
higher IL10/IFN! ratio) in MECLR driven by steroid exposed DCs comparing 
to control DCs. Important finding is that steroid affected mainly pro-
inflammatory cytokine IFN!, with no significant change of IL-10, though there 
was a trend in this direction. 
To explore this further, I wanted to clarify the mechanism by which steroid 
pretreatment affects DCs, by studying phenotype and the suppression 
capacity of T cells cultivated after stimulus from steroid treated and untreated 
epidermal DCs, in particular focusing on evidence for Treg induction. However, 
three replicates of this protocol resulted in low number of harvested cells 
insufficient to drive MECLR or to be analysed by flow cytometry. The 
conclusion was that DCs obtained from human skin explants are not potent 
enough to drive the reactions necessary for this experiment. The potential 
reasons for this are: old age of skin donors, hypoxic injury to the DCs in the 
ex-vivo organ bath culture and injury to the DCs through enzymatic 
preparation of a single cell suspension.  
To further develop this protocol, I used epidermal cells originated from the 
epidermal sheets generated through suction blister after four-day long in vivo 
application of the topical steroid. Idea was that DCs obtained in such a way 
are more viable and hence, more suitable to drive the reactions. I did not 
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observe suppression effect of T cells cultivated in such a way on baseline 
MLR, assessed by proliferation measured by 3H thymidine incorporation and 
production of IFN! and IL-10 in the supernatants. The proliferation in the all 
baseline MLRs was low, most likely because of the low number of the 
responder naïve T cells (25x103 per well) in comparison to the usual number 
of 200x103 PBMCs in the standard MLR. Although, low starting point 
represented difficulty for observing further suppression, addition of the 
sufficient number of Tregs, used as a control, showed trend towards 
suppression.  
In addition, flow cytometric analysis of the cultured T cells population, showed 
that only 20-30% of cells had Treg phenotype (CD25high, CD127low), which 
further reduced their probability to exhibit suppression. It is worth mentioning 
the possibility that some of these cells are simply activated T cells, not Tregs 
as such.  
Probably the most important finding from this set of the experiments is the 
difference between proliferation in the cultures with added T cells stimulated 
by steroid exposed and untreated APCs. Given the proliferation rate in the 
baseline MLR, it is clear that this proliferation and cytokine production came 
from the harvested T cells upon second encounter with stimulator APCs (first 
time epidermal derived, second time blood derived). Generally lower 
proliferation in the steroid cultures together with lower IFN! and IL-10 
production, raises the possibility that steroid exposed DCs had lower ability to 
prime responder naïve T cells, which resulted in the weaker proliferation and 
cytokine production upon second stimulation with the same donor APCs.  
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Although ex-vivo model showed that topical steroid treatment induced 
phenotypic and functional changes in skin DCs supportive of their modulation 
into pro-tolerogenic profile, functional assays using DCs conditioned by in vivo 
topical steroid are suggestive of weaker activation signal coming from steroid 
exposed DCs, rather than induction of tolerance. 
It is open to speculation that steroid administered in such a way and in such a 
dose and duration, may not be optimal for the tolerance induction. It is also 
worth mentioning that comparing the effect of the duration of treatment 
between ex vivo (24h) and in vivo (4 days) is not reliable due to the lack of 
circulation in the organ bath model. Future experiments with weaker steroid 
and titration of the optimal dose and the duration of the treatment are 
necessary to answer these questions.  
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Interleukin-10, both pure and non-covalently attached to NP shows 
suppression of proliferation in MLR and production of IFN! measured in the 
supernatants of these reactions. The effect was NP independent, as it could 
be counteracted by addition of anti IL-10 antibody. Although, IL-10 attached to 
NP retained it’s biological effect, IL-10 concentrations needed to achieve 
comparable suppression were ten fold higher with NP IL-10 than with IL-10p. It 
is possible that biological activity of IL-10 is, to some extent altered by the 
chemical process of particle generation. Another explanation is that 
nanoparticles became promptly phagocytosed, which shortened the time for 
IL-10 activity through its extracellular receptors, although this is less likely 
given non-covalently bound IL-10. In addition, the link of IL-10 to NP might 
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have been unstable leading to the inaccuracy of the calculation of the free to 
bound cytokine ratio, making comparison to the free IL-10 even more difficult.  
These in vitro reactions provided sufficient guidance to proceed with ex-vivo 
experiments on skin explants.  
The injected dose of IL-10 was much higher than the injection of 10ng used in 
similar ex vivo models on tolerogenic effect on skin DCs [236], but still 
significantly lower than the dose that is expected to have systemic effect, for 
example 8µg/kg IL-10 used for the treatment of Crohn’s disease. [241] DCs 
conditioned by locally injected IL-10p and NP-IL10 for 4hrs, showed a 
suggestion of weaker capacity to drive proliferation in MECLR. When IFN! 
production in these reactions was measured, the same trend was observed, 
although in some reactions plain NPs reduced the level of IFN! as well.  
The absence of strong suppression in the ex vivo model, previously observed 
in vitro, is most likely to be due to the large individual variation in the response 
to locally injected IL-10 on the background of a weaker MLR type reaction 
(MECLR). Other possible explanation is short duration of incubation to allow 
for the IL-10 effect, given that previous study incubated skin explants for 48h. 
An insufficient dose of locally injected IL-10 is less likely, as the same study 
showed effect with much smaller dose. In addition, the problem of the effect of 
plain NPs could have been solved by simultaneous injection of anti-IL10 
antibody.[236] Optimisation of the protocol required a large number of 
replicates, which was not feasible at this stage due to limitation of the skin 
sample availability. 
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However, the ex-vivo trends on the background of the significant in vitro data, 
were suggestive that small dose of locally injected IL-10 has the potential to 
modulate skin DCs into pro-tolerogenic profile. Although anticipated dose-
sparing benefit of NP IL-10 was not shown, in vivo tolerogenic potential of IL-
10 can not be excluded, particularly if used as enhancer to peptide 
immunotherapy. 
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5.1 Introduction 
Alongside the importance of the optimal delivery of peptide immunotherapy, it 
is crucial to efficiently monitor its effect. Detection of a significant immune 
response in the blood following antigen specific immunotherapy (ASI) has 
been a challenge for many trials, and to this day no ideal marker for 
monitoring immune and therapeutic efficiency has been established.[132] 
Detection of cellular immune responses to self-antigen in the blood may be 
very difficult, as the frequency of cells responding to any given antigen is very 
low (less than 1 in 10,000 cells).[45] Irrespective, accessibility of the blood 
makes it the most commonly used source of immune cells in human studies. 
On the contrary, in murine models, lymphoid organs, such as spleen and 
lymph nodes, are usually used to harvest cells and monitor immune 
interventions. Here, I explore the concept of translating this approach into 
humans by using minimally invasive ultrasound guided fine needle aspiration 
(FNA) of the regional lymph node (LN), a technique commonly used in clinical 
practice for cancer diagnostics.[139]. To our knowledge, only one study to this 
date used lymph node biopsy to monitor response to transdermally applied 
myelin peptides for the treatment of multiple sclerosis, and showed increase 
in number of dendritic cells following antigen stimulation in the regional 
axillary lymph node.[243]  
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Lymph nodes are secondary lymphoid organs, strategically positioned at the 
convergence of the lymphatic vessels that collect extracellular fluid (lymph) 
from peripheral tissues, where it is produced from filtration of the blood. 
Relevant to this project are axillary lymph nodes regional to the arm because 
antigens are injected into the skin of the upper limb. They are divided into five 
groups depending on their draining area and their position relative to the other 
structures in the axilla (Figure 5-1)[244]: 
1. The lateral group lies behind the axillary vein and drains the upper limb. 
2. The pectoral group that drains most of the breast is situated at the inferior 
border of the pectoralis minor muscle.  
3. The posterior, or subscapular, nodes are located in the posterior axillary 
fold and drain the posterior shoulder. 
4. The central group, near the base of the axilla, receives the lymph from the 
previous three groups.  
5. The apical nodes lie medial to the axillary vein and superior to the 
pectoralis minor muscle. The apical nodes receive the lymph from all the other 
groups and sometimes directly from the breast. They drain to subclavian 
truncs, which enter jugular-subclavian venous confluence or join common 
thoracis duct.  
For the purpose of this project, we performed aspiration of the lateral group.  
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The histology of the lymph node is presented in the Figure 5-2. The lymph node 
is formed from two juxtapositioned zones, cortex and medulla.[24] The outer 
cortex primarily consists of B cells organised in follicles that become 
secondary follicles during the immune response with areas of rapid 
proliferation called germinal centers. They become dormant with the resolving 
immune process. Next to the outer cortex is a deeper cortex or paracortex, 
where T cells and dendritic cells (DCs) reside.  
Arriving via afferent lymphatics from the peripheral tissue, lymph carrying 
soluble and cell bound antigens, passes through the lymph sinuses, before 
entering cellular paracortical areas. Naïve T cells arrive to the paracortex from 
the blood through speciailised blood vessels known as high entothelial 
venules (HEV), attracted by the same chemokines, such as CCR7 that guided 
antigen presenting cells (APCs) from the peripheral tissue. This directed traffic 
enables the presence of all the relevant cells in the same place to enhance 
interaction of the T cells with the antigen in question. In the same way, B cells 
!
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Figure 5-1. Anatomy of the axillary lymph nodes. Adapted from O’Rahilly R, 
Muller F, Carpenter S, Swenson R, eds. Basic Human Anatomy. Hanover, USA: 
Dartmouth Medical School, 2008. http://www.dartmouth.edu/~humananatomy/. 
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deriving from the blood first pass through paracortex where they encounter 
antigens and helper T cells necessary for their activation. They then proceed 
to the outer cortex where they proliferate in the germinal centres. Lymph 
leaves the node via efferent lymphatic vessels in the medulla that also 
contains strings of macrophages and antibody secreting plasma cells, known 
as medullary cords.  
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It is very important to understand the dynamic communication between 
peripheral tissue and its regional lymph node during the immune response, 
particularly one that develops after antigen skin injection. In this following 
section, I will consider the role of several cell groups involved in the process.  
Figure 5-2. Histology of the lymph node. Adapted from Murphy K, Travers P, Walport 
M, eds. Janeway’s Immunobiology. 7th Edition. New York: Garland Science, 
Taylor&Francis Group, LCC, 2008.  
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Soluble antigens are the first to arrive to the lymph node. They are followed by 
antigen bearing DCs, guided by chemotactic chemokines.[245] CCR7, a 
chemokine receptor known to mediate the mobilisation of skin DCs under 
inflammatory conditions, also controls homing from non-inflammed skin. In 
parallel to the expression of CCR7, migrating Langerhans cells (LCs) 
downregulate E-cadherin, molecule responsible for their adhesion to 
keratinocytes.[246] Timing of the arrival depends on the type of DCs, with 
more loosely connected dermal DCs arriving sooner than LCs, who require 
matrix metalloproteases (MMP), such as MMP-2 and MMP-9 to allow 
translocation through epidermal basal membrane.[247] Data from transgenic 
mice expressing photoconvertible dye indicate that approximately 5% of all 
DCs found in the skin-draining LNs arrive from the skin each day.[248] This is 
reflected in studies in humans, showing that DCs found in the skin draining 
LNs partially originate from the skin. Flowcytometric analysis of cancer-free 
human LNs excised during surgery for melanoma, showed two subsets of 
CD1a expressing cells: CD1ahighCD11cint, with high intracellular expression of 
Langerin, most likely to be migratory skin LCs; and CD1aintCD11chigh, 
migratory dermal DCs. Interestingly, CD1a+ cells despite their mature 
phenotype (high expression of CD80, CD83 and CD40), showed low potency 
in stimulating proliferation of allogeneic donor T cells. The other two subsets 
(CD11c+CD1a-) are most likely to be blood derived. They are distinguished by 
their variable expression of CD14 into CD14+ and CD14-.[249] 
Immunocytochemistry study on human lymph nodes, showed that CD1a+ cells 
(either Langerin positive or negative) are mainly localised in the paracortex of 
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the axillary lymph node, whilst CD14+ cells reside in the medullary areas and 
B cell zones. [250]  
?"$"!"! <+2&88.+
Another important player in this continuous conversation between skin and its 
LN are T cells. Naïve T cells arrive to LNs exclusively via HEV in the process 
involving CD62L, which allows CCR7 on T cells to engage with their ligand, 
secondary lymphoid tissue chemokine (SLC), expressed on endothelial 
cells.[251] This interaction facilitate homing of the naïve CD45RA+ T cells into 
the paracortex where they will meet antigen presented on the APC.  
In parallel, memory cells are engaged in the process. There are two subsets 
of memory CD45RA- T cells, distinguished on the basis of their expression of 
CCR7.[252]  
CD45RA-CCR7- cells, or effector memory cells, are less likely to home into 
the LN due to the lack of CCR7. They aim for the peripheral tissues where 
they arrive thanks to their high expression $1 and $2 integrins [253] and 
receptors for inflammatory chemokines such as CCR1, CCR3 and CRR5 [254, 
255], necessary for homing into the inflamed tissues. There they target their 
antigen, being ready to quickly produce inflammatory cytokines such as IFN!, 
IL-4 or IL-5.[252] On the other hand, CD45RA-CCR7+ cells or, central memory 
cells, are found in secondary lymphoid organs. Additionally equipped with 
CD62L to home in the LN, they probably share the same migratory routes via 
HEV into the LN as naïve T cells. They need a longer time to be activated and 
probably can function as a potent activator of the dendritic cells, through the 
rapid expression of a costimulatory molecule. They produce IL-2, but not IFN! 
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upon stimulation. A small fraction of these blood cell express CD69 and 
CD25.[252]. On the contrary, a significant proportion of T cells in the lymph 
node, both naïve and memory, express CD69[256], which in this tissue is 
more likely to represent a retention rather than a activation marker. 
The distinction between central and effector memory is not as clear in the skin. 
T cells specialised for entry into cutaneous sites are characterised by 
expressing high levels of CLA, a ligand for E-Selectin, CCR4 and CCR6.[257] 
The majority are CD45RA-CCR7- effector memory cells, with predominant Th1 
phenotype, but there is a proportion of CLA+ CCR7+ cells, which are known as 
“central memory skin homing cells” that can enter the skin, but most likely 
have access to the lymph nodes as well.[258] A significant proportion of skin 
memory cells express CD69. [259]  
The skin is also a site of a vast number of T regulatory cells. 
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As discussed in the Chapter 1, T regulatory cells are responsible for the 
maintenance of self-tolerance, being tailored to recognise mainly self-antigens. 
It is believed that secondary lymphoid organs, i.e. lymph nodes are the place 
where T regs interact with their cognate antigens. Analysis of human inguinal 
LN showed that they comprise approximately 5-7% of CD4+ population. The 
majority of Tregs in human lymphoid tissues, defined as CD4+CD127-
CD25++Foxp3+ cells, are CD69+ CD45RA- cells with Ki67+ phenotype and 
wide TCR repertoire. This implies that in healthy secondary lymphoid organs, 
Tregs are under constant polyclonal activation and expansion. Although 
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suppressive, they are not anergic as they produce IL-2, IL-10 and IFN!.[256] 
One can speculate that LN Tregs are in the state of the continuous alert, 
surveying prolific T cell responses taking place in the lymph node, ready to 
suppress inappropriate self-reactive ones.  
It is interesting to explore how do skin Tregs compare to their LN counterparts. 
They express high levels of CD25, L-selectin, Foxp3, GITR, intracellular 
CTLA-4, low CD69 levels and high levels of skin homing addressins such as 
CLA, CCR4 and CCR6. The suppression of the proliferation of CD25lo T cells 
that skin Tregs mediate is dependent on cell-cell contact and unaffected by 
inactivation antibodies for IL-10 and TGF-$.[260] 
Other studies also suggested the presence of memory regulatory T cells in 
the human skin. Approximately 20% of adult T cells in the skin express Foxp3, 
in contrast to only 5% in the blood and LN. The majority of adult skin Tregs 
are CD45RO+ effector memory type, whilst foetal skin has markedly reduced 
number of CD4+Foxp3+ cells, with significantly lower percentage of CD45RO 
expressing population. This indicates that these cells have seen their antigens 
outside the thymus and populated skin at some stage in life.[261] Supportive 
of the blood origin of skin Tregs is the finding of high expression of skin 
homing receptors CLA, CCR4 and CCR6 on peripheral blood Foxp3+.[262] 
Interestingly, the majority of skin Tregs are CCR7-. They have no migratory 
capacity to traffic to regional lymph node as evidenced by experiments with 
transplanted human skin on immunodeficient NSG mice. [261]  
It was shown that skin T regs, defined as CD4+Foxp3+CD25high, accumulate in 
parallel with CD4+ effector cells upon in vivo Tuberculin PPD challenge (see 
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below). Authors debate about the origin of these cells. The previously 
mentioned finding that blood Foxp3+ cells express skin homing receptors 
argues towards their blood origin, but proliferation of skin resident Tregs 
cannot be excluded. Another possibility is that they evolve from the 
responsive memory CD4+ cells.[133]  
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A potentially useful tool for understanding the interplay between the skin and 
its draining LN after antigen challenge, which has been used in the clinical 
practice for decades to test for the immunity against tuberculosis, is a 
Mantoux test. This is a classic CD4+ mediated delayed type hypersensitivity 
(DTH) response to the intradermal injection of Tuberculin purified protein 
derivative (PPD), prepared from human strains of M. tuberculosis.[263]. With 
some exceptions, skin induration larger than 6mm in the transversal diameter, 
48-72h from intradermal injection of Tuberculin PPD is considered to be 
positive reaction suggesting clinically significant immunity against TB.4 
Histologically, the reaction starts just few hours after injection. It has two 
peaks: initial non-specific infiltration, present even in non-sensitised 
individuals, followed by specific one, found only in sensitised subjects.[263, 
264] After 4-6h from injection, the majority of infiltrating cells are neutrophils 
[264], followed by T cells that begin to appear after 12h. [265] At 24h the 
majority of infiltrating cells are macrophages, whilst at 48h they are largely 
replaced by T cells, predominantly CD4+.[264, 265]  
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It is not clear where this activation of PPD specific T cells takes place. There 
is some evidence that it actually happens in situ in the skin. A study looking at 
the expression of cellular marker of proliferation, Ki67 and shortening in the 
telomere length, indicative of cell’s replicative history, in the skin cells after 
Mantoux test, detected proliferation only in the skin, but not in the blood. That 
was consistent with the increase in the PPD specific T cells in the skin only, 3 
days after Tuberculin in vivo challenge.[266] 
The possibility that PPD specific T cells from blood and skin are different 
entities also is suggested from a study looking at blood responses in healthy 
Mantoux negative individuals. T cells from some M. tuberculosis exposed or 
BCG vaccinated individuals with negative Mantoux can undergo blast cell 
transformation when incubated with Tuberculin PPD in vitro.[267] A study in 
people diagnosed with tuberculosis who have negative Mantoux test suggests 
the lack of the expression of skin homing antigen CLA as a possible cause. 
Blood derived PPD specific cells in these individuals are CLA-, in contrast to 
the Mantoux positive TB sufferers whose PPD specific cells are CLA+. These 
CLA- also have lower capacity to produce IFN! incubated with PPD.[268] 
 
In summary, skin, a very efficient barrier to the outer world, is the home of 
twice as many T cells than in the peripheral circulation. These T cells have 
remarkable diversity in their TCR repertoire that is only slightly less than that 
of their peripheral blood counterparts [258]. Taken together with the skin’s 
richness in dendritic cells, potent antigen presenters, we start to understand 
the importance of this active immune surveillance that can develop to either, 
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protective immunity or immune tolerance depending on the nature of the 
stimulus. Part of this interplay spills over into the regional lymph node. 
Capturing the immune response in the draining lymph node following antigen 
skin delivery is logical, but up until now, not developed as an approach in 
understanding and monitoring the immune process after therapeutic 
intervention. If proven effective, this approach has the potential to 
substantially accelerate the development of effective antigen specific therapy 
in humans. 
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5.2 Hypothesis 
I hypothesise that an ultrasound guided fine needle lymph node aspiration can 
develop into an effective, but minimally invasive monitoring technique of the 
effect of the antigen skin specific immunotherapy in humans.  
5.3 Aim 
1. To assess feasibility and optimise methods for monitoring immune 
response in the draining lymph nodes after intradermal antigen skin 
delivery in comparison to PBMCs isolated from the blood of the same 
subject, drawn at the same time as lymph node aspiration. 
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5.4 Results 
I recruited 25 healthy volunteers (21 female, 4 male) with the mean age of 
28.9±7.1 years. Detailed methods are given in Chapter 2. Lymph node 
aspirate from the first subject was used to obtain an initial estimate of number 
of cells available for analysis, their profile (number of CD4+, CD8+ and CD19+ 
cells) and viability, whilst the rest of the subjects (n=24) were included in the 
main part of the study. They were subjected to Mantoux test, with 15 of them 
being clinically positive i.e. induration larger than 6mm, 48h after Tuberculin 
PPD injection.  
Samples from 12 Mantoux positive subjects were used in an ELISPOT assay 
designed to detect IFN-! producing cells amongst lymph node cells (LNCs) 
and PBMCs before and after in vivo injection of 2 TU of Tuberculin PPD. Two 
time points were assessed: two and five days after injection, including 7 and 5 
subjects, respectively.  
Samples from the rest of the three Mantoux positive subjects were used for 
flow cytometric analysis of lymph node aspirate and PBMCs before and two 
days after in vivo injection of 2TU of Tuberculin PPD. I used pre-treatment 
samples from these subjects and additionally two Mantoux negative subjects 
for the general flow-cytometric analysis of the lymph node aspirate in 
comparison to PBMCs. Additional four subjects had more extensive flow 
cytometric analysis as described in the Chapter 2. Progress of the study is 
shown in the Figure 5-3. 
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Figure 5-3. Study progression flow chart. Mantoux negative individuals were excluded 
from the second analysis after Tuberculin PPD injection. 2 days ELISPOT: ELISPOT before 
and 2 days after Tuberculin PPD; 2 days FC analysis: flow cytometry analysis before and 2 
days after Tuberculin PPD; 5 days ELISPOT: ELISPOT before and 5 days after Tuberculin 
PPD. 
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I obtained on average of 3.3±2.1x106 white cells per aspirate, calculated from 
39 analysed samples (15 Mantoux positive individuals had baseline sample 
and the sample after Tuberculin PPD, whilst seven Mantoux negative 
participants had only baseline sample, as did the subjects who had baseline 
flow cytometric analysis only) - Figure 5-4a. There was no significant correlation 
between the cortex diameter and the aspirate count – Figure 5-4b. 
 
 
 
 
Figure 5-4. Lymph node aspirate. a) average number of white cells per LN aspirate. The 
cells were counted after staining with trypan blue with addition of 4% acetic acid to eliminate 
red blood cell contamination. N=39. b) correlation between aspirate white cell count at the 
diameter of the aspirated lymph node cortex. Statistical test used: Pearson’s correlation. 
 
First, the cells were analysed on flow cytometry. As shown in Figure 5-5, the 
majority of blood and lymph node derived lymphocytes were live. The LN 
aspirate contained a significant percentage of red cell contamination, although 
it was possible to identify the position of the lymphocyte gate, with clear CD3+ 
population. In order to preserve as many cells of interest as possible, I did not 
use any red cell elimination method. 
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Figure 5-5. Representative example of gating strategy. a) lymphocyte gate in the LN aspirate; b) singlets gate in 
the LN derived lymphocytes; c) live cell gate amongst the LN derived lymphocytes; d) CD3+lymph node derived 
lymphocytes; e) lymphocyte gate amongst PBMCs; f) singlets gate in the blood derived lymphocytes; g) live cell gate 
amongst blood derived lymphocytes. h) CD3+ blood derived lymphocytes.
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The ratio of CD3+ vs. CD19+ appeared more in favour of CD3+ cells, in the 
blood (13.1±3.7) than in the lymph node (4.4±2.8), but the difference was not 
statistically significant – Figure 5-6.  
 
 
 
 
Figure 5-6. Summary of the ratio of CD3+/CD19+ cells in lymph node and blood. 
Statistical test used: Wilcoxon signed ranked test. 
 
Although the predominance of CD4+ cells was obvious in both blood derived 
(CD4:61.9±8.1%; CD8:26.5±5.3%) and lymph node derived CD3+ cells 
(CD4:79.6±9.9%; CD8:15.3±6.7%), this was significantly more marked in the 
lymph node aspirate (n=12, p=0.02) – Figure 5-7. 
 
 
 
 
 
Figure 5-7. Summary of the ratio of CD4+/CD8+ cells in lymph node and blood derived 
CD3+ population. Statistical test used: Fisher’s exact test. 
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Figure 5-8 shows an example of the distribution of CD4+ and CD8+ cells 
amongst CD3+ population of both LNCs (a) and PBMCs (b).  
 
Figure 5-8. Representative flow cytometric analysis of the CD4:CD8 ratio in the CD3+ 
population: a) lymph node derived; b) blood derived.  
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Next, I analysed four matching LN and blood samples for the expression of 
CD45RA and CCR7 to establish the distribution of naïve and memory T cells. 
The CD45RA+CCR7+ cells were characterised as naïve, CD45RA+CCR7- as 
(effector memory CD45RA+) TEMRA cells, CD45RA-CCR7+ as central memory 
cells and CD45RA-CCR7- cells as effector memory cells. There were 
significantly less CD8+ TEMRA cells in the LN samples, even when CD8+ 
population only, was taken into account. Another difference was trend towards 
more marked predominance of central to effector memory in the LN, again 
more consistent in the CD8+ population - Figure 5-9. 
Analysis of CD69 expression revealed significant higher proportion of CD69+ 
cells in the LN, in both, CD4+ and CD8+ population. When combined 
presentation of CD69 and CD45RA was looked at, I was able to distinguish 
four different populations of T cells: population I – CD69- naïve cells 
(CD45RA+CD69-), population II – CD69+ naïve cells (CD45RA+CD69+), 
population III – CD69+ memory (CD45RA-CD69+) and population IV – CD69- 
memory (CD45RA-CD69-). Percentage of CD69- cells, both naïve and 
memory, was significantly higher in blood, whilst CD69+ naïve and memory 
were significantly more represented in the lymph node. This similar pattern 
was observed in CD3+, CD4+ and CD8+ populations – Figure 5-10, Table 5-1. 
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Figure 5-9. Flow cytometric analysis of CD45RA and CCR7 expression in the LN and in 
the blood. a) Representative example of flow cytometric analysis; b) summary graph of 
central memory/effector memory ratio in CD3+, CD4+ and CD8+ populations from 4 different 
healthy individuals at baseline; C) summary graph of the % of TEMRA cells in CD3+, CD4+ and 
CD8+ populations from 4 different healthy individuals at baseline. Naïve = CD45RA+CCR7+, 
Central memory: CD45RA-CCR7+, Effector memory: CD45RA-CCR7-, 
TEMRA=CD45RA+CCR7. Statistical test used: Paired samples t test.  
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Figure 5-10. Flow cytometric analysis of CD45RA and CD69 expression in the LN and in 
the blood. a) Representative example of the flow cytometric analysis; b) summary graph of 
four populations of T cells: population I – CD69- naïve cells (CD45RA+CD69-), population II – 
CD69+ naïve cells (CD45RA+CD69+), population III – CD69+ memory (CD45RA-CD69+) and 
population IV – CD69- memory (CD45RA-CD69-), in CD3+, CD4+ and CD8+ population in 
the LN and blood. 
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Analysis of the expression of the skin homing receptors in the blood and the 
lymph node, showed no significant differences, with the exception of 
significantly higher expression of CCR4 and CLA in the CD8+ blood cells in 
comparison to the lymph node derived cells (p=0.01 and p=0.03, respectively) 
- Figure 5-11. 
 
 
 CD3 CD4+ CD8+ 
 LNC PBMC p LNC PBMC p LNC PBMC p 
Population 1 52.6±12.5 72.0±8.6 0.01 49.7±13.8 65.6±11.6 0.01 72.2±9.3 82.8±4.6 0.04 
Population 2 10.8±4.8 2.4±1.9 0.01 10.8±4.8 1.3±1.2 0.01 10.3±6.7 3.8±2.2 0.08 
Population 3 19.5±5.1 1.1±0.7 0.005 23.4±9.4 1.0±0.9 0.01 8.9±3.0 1.0±0.5 0.009 
Population  4 17.1±6.5 21.8±5.3 0.03 16.1±4.7 32.1±10.4 0.01 8.6±4.5 12.4±5.5 0.04 
Table 5-1. Comparison between distribution of four populations of T cells based on the 
expression of CD69 and CD45RA, in the LN and blood. Statistical test used: Paired sample T 
test.  
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Figure 5-11. Flow cytometric analysis of skin homing receptors in the LN and in the blood. a) Representative example of the flow cytometric analysis; b) Summary graph of the expression of 
skin homing receptors in the skin and blood amongst CD4+ and CD8+ cells. CCR4 and CLA expression was significantly higher in the blood CD8+ cells (p=0.01 and p=0.03, respectively).
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Interestingly, majority of CLA positive cells in the blood and the lymph node 
are central memory cells – Figure 5-12. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 5-12. Comparison of naïve vs memory. Lymph node CD3+ cells (n=4, p=0.007); 
Blood derived CD3+ cells (n=4, p=0.007). Statistical test used: One-way ANOVA with the 
Tukey’s multiple comparison test. 
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I observed a significant increase in the ultrasonographically measured 
thickness of the lymph node cortex (before: 0.18±0.03cm; two days 
after:0.24±0.08cm, n=10) – Figure 5-13. 
 
 
 
 
 
 
Figure 5-13. Lymph node cortex thickness at baseline and two days after Mantoux test. 
Statistical test used: Wilcoxon signed ranked test. !
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To understand the process behind the response in the regional axillary lymph 
node after in vivo intradermal injection of 2TU Tuberculin PPD in the forearm, 
I used the ELISPOT assay designed to detect IFN-! producing cells amongst 
lymph node cells (LNCs) and PBMCs collected before and after the injection. 
It involved incubation of cells in two different concentrations of Tuberculin 
PPD (0.5µg/ml and 5µg/ml) and control stimulants, 1µg/ml PHA, 0.5u/ml 
Tetanus toxoid and viral peptide mix (VM) containing flu matrix protein (MP)58-
66 (GILGFVFTL), cytomegalovirus (CMV) pp65495-503 (NLVPMVATV) and 
Epstein-Barr virus (EBV) BMLF1280-288 (GLCTLVAML) at 20nM each (Chapter 
2).  
Lymph node cortex thickness
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Representative examples of ELISPOT plates demonstrating a response of 
LNCs and PBMCs to the two different in vitro concentrations of Tuberculin 
PPD and control stimulants, before and two days after in vivo Tuberculin PPD 
injection, are shown in Figure 5-14, Figure 5-15. With the exception of viral mix 
(VM) response, all images are from the same person. Although derived from a 
different subject from the rest of the wells, VM responses in the blood and LN 
are originated from the same subject, to illustrate the comparison between the 
lymphocytes of a different origin.  
 
Figure 5-14. Representative example of the ELISPOT plate used for counting IFN! 
producing cells in the suspension of lymph node aspirate cells (LNCs) before and two 
days after in vivo injection of Tuberculin PPD. 1x105 LNCs/well were plated.  
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Figure 5-15. Representative example of the ELISPOT plate used for counting IFN! 
producing cells in the suspension of PBMCs before and two days after in vivo injection 
of Tuberculin PPD. 2x105 PBMCs/well were plated. Wells illustrating VM response are not 
from the same person as the rest of the wells. 
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There was significant increase in IFN! producing cells amongst LNCs after 
two day of Tuberculin PPD injection (Figure 5-16a), whilst the response in 
PBMCs remained unchanged (Figure 5-16b).  
 
 
 
 
 
 
 
Figure 5-16. Summary of the ELISPOT response to in vitro Tuberculin PPD before and 
two days after in vivo injection. a) Number of IFN-! producing cells per 2x105 cells from the 
lymph node aspirate before and two days after Tuberculin PPD injection (n=7, p=0.016). b) 
Number of IFN-! producing cells per 2x105 PBMCs before and two days after Tuberculin PPD 
injection (n=7, p=0.16). The response of the each subject is shown as connected before-after 
points. Subjects’ codes with their Monteux response in brackets are shown in the legend. 
Statistical test used: Wilcoxon signed ranked test. 
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LNCs showed significantly increased response to PHA following Tuberculin 
PPD injection (Figure 5-17a). This observation is most likely to be a non-specific 
response to the adjuvant-like elements in the PPD injection, rather than to 
PPD itself, given a lack of response to the specific stimulus Tetanus toxoid 
and mix of the viral peptides, used as control (Figure 5-17 b and c).  
 
Figure 5-17. Summary of the ELISPOT response of LNCs to in vitro PHA, Tetanus 
toxoid and viral mix before and 48h after in vivo Tuberculin PPD injection. a) Response 
to PHA (n=7, p=0.03); b) Response to tetanus toxoid (n=3, p=1.00); c) Response to viral mix 
of CMV, ENV and flu peptides (n=2). The response of the each subject is shown as 
connected before-after points. Subjects’ codes are shown in the legend. Statistical test used: 
Wilcoxon signed ranked test. 
 
 
 
LNCs - PHA
Before After
0
250
500
750
1000
1250
CT02
KW03
SB04
RE06
AO07
KB20
n=7
p=0.03
CS22
LNCs - Tetanus toxoid
Before After
0
10
20
SB04
RE06
AO07
n=3
p=1.00
LNCs - Viral mix
Before After
0
10
20
KB20
CS22
n=2
a) b) 
c) 
! "$(!
At the same time, I detected a response to Tetanus toxoid and the mix of viral 
peptides in the blood of the matching individuals, suggesting validity of the 
ELISPOT assay in subjects with immunity against these antigens. It remained 
unchanged before and after Tuberculin PPD injection – Figure 5-18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-18. Summary of the ELISPOT response of PBMCs to in vitro control antigens 
before and two days after in vivo Tuberculin PPD injection. a) Tetanus toxoid (n=3, 
p=0.75).  Statistical test used: Wilcoxon signed ranked test; b) Mix of the flu, CMV and EBV 
derived peptides (n=2). The response of the each subject is shown as connected before-after 
points. Subjects’ codes are shown in the legend. 
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The response of PBMCs to PHA was very often so extensive that it was not 
possible to count (Figure 5-14, Figure 5-15), either manually or with a Bioreader, 
and therefore is not shown in the graphs.
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I used flow cytometry to assess changes in the number and profile of lymph 
node derived T cells and HLA-DR+ cells in comparison to their blood derived 
counterparts, before and two days after Tuberculin PPD injection.   
With limited number of replicates (n=3), there was no change in the 
CD4+:CD8+ ratio after Mantoux test, neither in LNCs (Figure 5-19a) nor PBMCs 
LNCs (Figure 5-19b).  
 
!! 
 
 
 
Figure 5-19. CD4+/CD8+ ratio before and two days after Tuberculin PPD. The ratio of the 
each subject is shown as connected before-after points. Subjects’ codes with their Monteux 
response in brackets are shown in the legend. a) LNCs, n=3, p=0.5; b) PBMCs, n=3, p=1.00 
Statistical test used: Wilcoxon signed ranked test. 
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There was no significant difference in the overall expression of marker CD69 
in either blood or lymph node derived CD4+ or CD8+ cells, measured as MFI – 
Table 5-2. 
 
The previously described large LN derived CD69+ population, appeared to 
show an increase in percentage two days after Tuberculin PPD injection, 
although with the small numbers tested, this did not reach statistical 
significance. No such a trend was observed in the blood – Figure 5-20, Figure 
5-21. 
 
 
 
 
 
 
 
 
CD69 MFI BEFORE AFTER n p 
CD4+ LNCs 625.7±244.0 450±81.59 3 1.00 
CD8+ LNCs 373.3±175.0 241.3±104.9 3 1.00 
CD4+ PBMCs 109.4±16.3 116.5±28.8 3 1.00 
CD8+ PBMCs 137.3±21.5 144.7±41.0 3 1.00 
Table 5-2. CD69 expression calculated as MFI on blood derived and lymph node 
derived T cells. Statistical test used: Wilcoxon signed ranked test. 
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Figure 5-20. Representative example of CD69 expression on blood and lymph node 
derived T cells before and two days after Tuberculin PPD injection. Gates: gray solid – 
unstained live cells; blue line – baseline; red line –  two days after Tuberculin PPD injection. 
a)CD4+PBMCs; b) CD8+ PBMCs; c) CD4+ LNCs; d) CD8+ LNCs. 
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Figure 5-21. Percentage of CD69+ cells on lymph node derived T cells before and two 
days after Tuberculin PPD injection. a)CD4+ cells; b) CD8+ cells. Statistical test used: 
Wilcoxon signed ranked test 
 
Expression of another activation marker, CD154, was generally low in both 
blood derived and lymph node derived T cells, with no increase after 
Tuberculin PPD injection – Table 5-3.  
CD154 MFI BEFORE AFTER n p 
CD4+ LNCs 62.2±27.6 45.3±18.3 3 0.75 
CD8+ LNCs 29.8±45.5 9.6±16.6 3 0.75 
CD4+ PBMCs 89.9±46.0 71.8±20.0 3 1.00 
CD8+ PBMCs 66.0±47.6 53.5±25.6 3 1.00 
Table 5-3. CD154 expression calculated as MFI on blood derived and lymph node 
derives T cells. Statistical test used: Wilcoxon signed ranked test. 
 
I also did not observe any significant changes in the expression of HLA-DR on 
both B-cells (CD19+ HLA DR+ cells) or other HLA-DR expressing cells (CD19- 
HLA-DR+ cells) – Table 5-4.  
HLA DR MFI BEFORE AFTER n p 
CD19+ HLA DR+ 
LNCs 35531±4578 24048±8416 3 0.25 
CD19+ HLA DR-  
LNCs 15660±5698 7672±1527 3 0.25 
CD19+ HLA DR+ 
PBMCs 24189±2931 21951±5981 3 0.59 
CD19+ HLA DR-  
PBMCs 18256±873 16992±4451 3 0.75 
Table 5-4. HLA-DR expression calculated as MFI on blood derived and lymph node 
derives T cells. Statistical test used: Wilcoxon signed ranked test. 
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There was no significant increase in the ultrasonographically measured 
thickness of the lymph node cortex (before: 0.20±0.04cm; five days 
after:0.22±0.06cm) – Figure 5-22. 
 
 
 
 
 
 
Figure 5-22. Lymph node thickness at baseline and five days after Mantoux test. 
Statistical test used: Wilcoxon signed ranked test. !
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As with the two day time point, I again used the ELISPOT assay to detect 
IFN-! producing cells amongst lymph node cells (LNCs) and PBMCs collected 
before and five days after Tuberculin PPD injection. This was performed in the 
separate group of subjects.  
Contrary to the two day time-point, after five days of Tuberculin PPD injection, 
I did not detect an increase in IFN-! producing cells in the LNCs suspension, 
in any, except one replicate – Figure 5-23 a. There was also no significant 
change in the blood - Figure 5-23 b. 
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Figure 5-23. Summary of the ELISPOT response to in vitro Tuberculin PPD before and 
five days after in vivo injection. a) Number of IFN-! producing cells per 2x105 cells from the 
lymph node aspirate before and five days after Tuberculin PPD injection (n=5, p=0.75); b) 
Number of IFN-! producing cells per 2x105 PBMCs before and five days after Tuberculin PPD 
injection (n=5, p=0.12). The response of the each subject is shown as connected before-after 
points. Subjects’ codes with their Mantoux response in brackets are shown in the legend. 
Statistical test used: Wilcoxon signed ranked test. 
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A consistent change of the non-specific response to PHA was lacking after 
five days (Figure 5-24a), which was also the case with the response to tetanus 
toxoid (Figure 5-24b). 
 
 
 
 
 
 
 
 
 
 
 
!
Figure 5-24. Summary of the ELISPOT response of LNCs to in vitro PHA and Tetanus 
toxoid before and five days after in vivo Tuberculin PPD injection. a) Response to PHA 
(n=5, p=1.00); b) Response to tetanus toxoid (n=3, p=0.25). The response of the each subject 
is shown as connected before-after points. Subjects’ codes are shown in the legend. 
Statistical test used: Wilcoxon signed ranked test. 
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Again, I detected a response to Tetanus toxoid in the blood, which remained 
unchanged before and five days after Tuberculin PPD injection –  
Figure 5-25. 
 
 
 
 
 
Figure 5-25. Summary of the ELISPOT response of PBMCs to in vitro Tetanus toxoid 
before and five days after in vivo Tuberculin PPD injection. n=3, p=0.19; The response of 
the each subject is shown as connected before-after points. Subjects’ codes are shown in the 
legend. Statistical test used: Wilcoxon signed ranked test. 
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Five subjects had a Mantoux negative test. They only had baseline 
investigations (two flowcytometry and five ELISPOT), without a post-treatment 
sample. Flowcytometric analysis performed in two individuals was included in 
the analysis of profile of LN cells presented in the beginning of this chapter. 
Other five subjects had baseline IFN! ELISPOT. 
At baseline, before in vivo challenge, I detected PPD specific IFN! producing 
cells in the blood, even in Mantoux negative individuals – Figure 5-26. 
 
 
 
 
 
 
 
 
 
Figure 5-26. Summary of the baseline ELISPOT response of PBMCs to in vitro 
Tuberculin PPD at in Mantoux negative subjects. n=5, p=0.06; The response of the each 
subject is shown as connected before-after points. Subjects’ codes are shown in the legend. 
Statistical test used: Wilcoxon signed ranked test. 
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5.5 Summary of findings 
1 Ultrasound guided lymph node fine needle aspiration is minimally 
invasive procedure that provides a sufficient number of live and 
functional T cells for phenotypic analysis and functional assays. 
 
2 Hollow microneedle is reliable device for intradermal delivery of 
Tuberculin PPD. 
 
3 Fine needle aspiration of the lymph node is superior tool to the blood 
sampling, for the monitoring of the dynamics of the antigen-specific 
immune response following antigen skin delivery.  
 !
The results presented here show that lymph node fine needle aspiration 
provides a sufficient number of live and functional T cells to detect the cellular 
immune response after antigen skin delivery.  
The hollow microneedle is an efficient intradermal delivery device as 
evidenced by clinically measurable and significant immune responses to 
Tuberculin PPD i.e. positive Mantoux test in 15 out of 22 treated subjects. The 
failure to elicit positive Mantoux test in 31% of participants is expected in the 
general British population with variable history of BCG vaccination and 
generally low exposure to M. tuberculosis.  
Monitoring the early response in the draining lymph node following in vivo 
injection of Tuberculin PPD seems to provide more sensitivity than 
conventional monitoring in the blood.  
Responses detected in blood most likely come from the PPD specific effector 
memory or even TEMRA cells capable of rapid production of IFN!. These cells 
patrol in the peripheral circulation of sensitive individuals in abundance (up to 
1 in 1000 of PBMCs). The high baseline frequency of these cells prevented 
detection of possible small early changes after in vivo challenge. I and others 
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detected baseline IFN! response even in the Mantoux negative individuals, 
which suggest a different origin and/or phenotype of cells involved in the skin 
response.[269]  
Contrary to the peripheral circulation where the frequency of Tuberculin PPD 
specific IFN! secreting cells was high, a low frequency of these cells at 
baseline in the lymph node and their accumulation following antigen challenge 
made their efficient detection possible.  
Low level of the IFN! production at baseline from the lymph node derived 
cells suggests an absence of effector memory in the lymph node. This was 
the case not only in response to Tuberculin PPD, but also to the control 
antigens, tetanus toxoid and mixed flu, EBV and CMV derived peptides. In 
both cases, this once again, contrasted with high levels of IFN! producing 
cells responding to the same antigens in the same individual’s peripheral 
blood. I can not exclude the possible need for longer cultures to prime lymph 
node T cells, as indicated in the study looking at baseline response to 
Tuberculin PPD where authors performed 7 days long incubations, rather than 
the overnight in vitro incubation, that I used in this study.[270] 
I consistently detected an increase in PPD specific IFN! producing LN cells 
two days after skin challenge in all six subjects included. An increase in the 
diameter of the lymph node cortex and the concomitant increase in the PHA 
response raised the possibility of non-specificity. One can speculate that there 
is a high level of baseline activation in the lymph node tissue, which may 
explain enhanced response to PHA after additional priming by potent adjuvant 
present in the Tuberculin PPD.  
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However, the lack of the amplification to the control antigens, tetanus toxoid 
and mix of viral peptides, argues that the final response is specific.  
Interestingly, five days after in vivo Tuberculin PPD, the increase in IFN! 
producing LN cells was no longer consistent in all individuals. – Figure 23. 
It is important to take into account the complex relationship between the skin, 
its draining lymph node and the peripheral blood to understand the type and 
phase of the response that is being captured by LN FNA.  
This raises the question of the origin of the IFN! that is being detected the 
lymph node two days after Tuberculin PPD challenge. It is unlikely to be the 
result of activated naïve cells, as this process requires a longer time. It is 
possible that one of the responses happening in the lymph node is the 
activation of central memory cells that recognise antigen on skin deriving DCs. 
Indeed, the majority of CLA expressing cells in the lymph node and blood are 
central memory cells that might have arrived in the lymph node via skin. 
However, this would be less likely to be detected by measuring IFN! because 
central memory cells produce IL-2 rather than IFN! upon activation.[252] The 
production of IFN! suggests effector memory response, but it is not clear 
where these cells are coming from. Effector cells usually do not arrive to the 
lymph node directly from the blood, as they do not express CCR7 necessary 
for homing to the LN through HEV. It is more likely that these are effector cells 
arriving from the skin that are either in situ skin memory cells or blood derived 
memory cells, which travelled to the lymph node via skin. It is possible that 
they patrol in the blood, home in the skin guided by appropriate homing 
receptors, the expression of which is reduced once there. Some of these cells 
possibly continue to the regional lymph node where I saw reduced expression 
! &%#!
of the skin homing receptors. The only significant difference that I observed to 
support this speculation was in the CD8+ population where I saw significant 
difference between expression of CLA and CCR4 amongst CD8+ cells, in 
favour of the blood.  
Absence of CLA expression in the PPD specific blood cells in TB sufferers 
with negative Mantoux suggests that cells responsible for the skin reaction 
originate from the blood. It would be interesting to monitor parallel response in 
the lymph node in these individuals, which would certainly bring some light 
into the origin of PPD specific cells appearing early after antigen challenge in 
my study.[268]  
Temporal histological changes in the skin following Mantoux test suggest that 
proliferating T cells appear at the site within 12 hrs, reaching their peak 7 days 
later.[133] Analysis of the cells generated through suction blister technique 
following Mantoux test, suggested that T cells start to reduce CLA expression 
approximately seven days after antigen challenge. At the same time, IFN! 
and IL-2 production by PPD specific cells is again detected only at day seven. 
These data suggest that significant emigration from the skin, possibly of IFN! 
and IL-2 producing cells happens at least 5-7 days after antigen 
challenge.[271] It remains unclear why this does not mirror the changes that I 
detected in the lymph node, i.e. consistent response after two days, tailing off 
end after five days. Possible explanations are that: 1) I was detecting “early 
bird” effector cells, and more would have been captured if a longer time after 
Mantoux was allowed, i.e. seven days and more; 2) antigen bearing DCs 
arrived early in the lymph node and activated local effector cells or blood 
derived ones, attracted by the presence of antigen in the LN. This latter option 
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is less likely given that absence of the CCR7 expression on the blood effector 
T cells. The possible scenarios of the skin-lymph node conversation following 
antigen skin delivery is summarised in the Figure 5-27.  
 
Figure 5-27. Interplay between skin and its regional draining lymph node following 
antigen skin delivery. 1) Arrival of blood derived T cells upon encounter with the antigen in 
the skin; 2) Arrival of skin derived T cells upon in situ activation by an antigen; 3) Antigen 
bearing skin DCs travel to LN where they activate local effector T cells. TEM- effector T cells; 
Ag- antigen; APC – Antigen presenting cells. 
 
LN FNA after Tuberculin PPD skin delivery allowed us a glimpse into the 
interplay between skin and its draining lymph node. Whether this technique 
will be equally successful in monitoring immune response after peptide 
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immunotherapy will be a subject of the future work. Contrary to the situation 
with the Tuberculin PPD, the frequency of self-antigen specific T cells in the 
peripheral circulation is low and often undetectable even with most sensitive 
methodology such as ELISPOT. Aggregation of activated antigen specific 
cells in the draining lymph node, coupled with the very low background 
response that that I observed with the PPD challenge, could make the 
efficient detection possible.  
Another difference to consider is the nature of the response following self-
antigen challenge that will no doubt involve memory cells, Tregs and skin DCs. 
The abundance of a wide repertoire of memory cells and Tregs in the skin 
together with dendritic cells accessible to modulation towards tolerogenic 
antigen delivery is the solid basis for this expectation. However, this leaves us 
with the question, which part of this process will continue or happen in parallel 
in the regional lymph node, and what can we measure to help us in optimising 
the delivery antigen-specific immunotherapy without waiting for disease 
modulation. 
 The focus will be on detection of the tolerogenic self-antigen bearing skin 
DCs; memory cells, either resident or skin derived and/or Tregs, activated by 
resident or by migratory DCs or skin derived Tregs activated by locally 
injected self-antigen.  
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6.1 Introduction 
Assuming the right type and the right delivery of the immune therapy, as well 
as the correct way of monitoring immune response following intervention, 
which has been discussed in previous chapters, the final piece in the jigsaw 
for this process, is knowing how to effectively monitor metabolic outcome.  
Progressive "-cell destruction in type 1 diabetes leads to near absolute insulin 
deficiency. We now know that years of ongoing immunological attack, 
eventually lead to the metabolic abnormalities, starting with attenuated first 
phase insulin response (FPIR) approximately 1.5 to 5 years before 
diagnosis.[3] At the time of clinical presentation, it is estimated that 50-80% of 
"-cell function has been lost.[4] Further from this point, it seems that 
metabolic and immunological processes are different in the first year since 
clinical presentation, during which there is a steeper slope of "-- cell function 
loss (measured by standard MMTT), in comparison to the slower one during 
the second year. [5]  
While less than 1% of subjects with Type 1 diabetes have levels of 
endogenous "-cell function above the fifth percentile for healthy individuals 
after 5 years, multiple cross-sectional studies and retrospective analysis of the 
Diabetes Control and Complication Trial (DCCT) cohort has repeatedly 
demonstrated the benefits of preservation of even minor levels of "-cell 
function [272], in regards to better control measured as HbA1c [273], less 
hypoglycaemia [274], less diabetic ketoacidosis [275] and reduced long-term 
complications [276, 277].  
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With a view to assessing the future potential of new treatments for Type 1 
diabetes, there is a need for a simple, non-invasive, test for estimation and 
monitoring of the residual "-cell function in these patients. We are looking for 
the test that is sensitive enough to detect changes in the "-cell function over 
the time, and at the same time patient-friendly to allow frequent and repeated 
measurements in even a paediatric population. That will enable close 
monitoring and the detection of even subtle "-cell function changes that would 
prompt the intensification, the re-start or the change of the immunological 
intervention type. The concept of the treatment modification should be very 
similar to what has been happening for decades in cancer intervention, where 
the detection of the disease relapse quickly leads to the change of the 
treatment protocol.   
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Insulin production is complex and involves several steps. The final step 
includes cleavage of a larger precursor molecule into insulin and free C-
peptide.[278] As a result, C-peptide is stored and realised in equal amounts 
with insulin. Unlike insulin, 50% of which is removed in the first pass through 
the liver, C-peptide is predominantly metabolised in the kidney, with, 
importantly, small but significantly measurable amounts passing into the urine. 
C-peptide has a half-life around six times longer than insulin, allowing it to 
circulate at around five time the concentrations of insulin. For this reason, it 
can be readily measured in both plasma and urine.   
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Tests that estimate "-cell function are currently used mainly as a research 
tool and include: 
1 Fasting plasma C-peptide 
2 Peak stimulated plasma C-peptide (glucagon or standardised mixed meal stimulation) 
3 Area under the curve plasma C-peptide (following stimulation) 
4 Urinary C-peptide 
 
Although most convenient, fasting C-peptide seems to be relatively insensitive 
to the decline in stimulated insulin reserve around the time of diagnosis of 
Type 1 diabetes.[279] 
Stimulated plasma C-peptide values seem to correlate well with number of 
functional islet cells in islet cell auto-transplantation studies.[280] C-peptide 
stimulation tests mainly include glucagon and mixed-meal stimulation, which 
correlate well. Although more time consuming, mixed meal tolerance test 
(MMTT) seem to be more reproducible and achieves higher levels of C-
peptide.[281] Area under the curve rather than peak C-peptide is the standard 
for monitoring "-cell function in clinical trials, but the longer half-life of C-
peptide compared to insulin means that C-peptide measurements may 
overestimate insulin secretion rates.[282] 
Urinary C-peptide measurements are less invasive. Twenty-four hour urinary 
C-peptide measurements are shown to accurately assess "-cell secretory 
capacity and correlate with fasting and stimulated insulin and C-peptide.[283-
286] On the other hand, they are impractical and often inaccurate in the non-
observed setting. Post-mixed meal stimulated urinary C-peptide correlates 
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with serum insulin and plasma C-peptide in both non-diabetic [287] and 
insulin-treated diabetic patients [288].  
It has been shown that second-void urinary C-peptide is a reproducible test, 
which correlates well with 24 hour urinary C-peptide, in healthy subjects. [289] 
An important question is whether this test is suitable for estimation of already 
depleted "- cell function in patients with diagnosed Type 1 diabetes and 
whether it can be used to track the change over time, which to my knowledge 
hasn’t been addressed thus far. 
Besser et al. reported that the two-hour urinary C-peptide response to a mixed 
meal correlates well with the standard MMTT, and hence can be used for 
estimation of "- cell reserve in patients with type 1 diabetes [131]. The ratio of 
urinary C-peptide to creatinine (UCPCR) was used to avoid the need for timed 
urine collections (UCPCR). In addition, the authors showed strong correlation 
between UCPCR stimulated by standard mixed meal and usual home meal 
without omitting regular insulin dose, which further simplifies the test, making 
it more acceptable for patients.  
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Tests that are described above are mainly research tools. Estimation of "-cell 
function is not routinely performed in the clinical management of Type 1 
diabetes as the standard tests are invasive, time consuming and burdensome 
for patients. However, if a simple and reliable assessment were available, it 
would potentially have the following applications:  
(1) to identify those individuals with very low levels of "-cell function in whom 
tight glycaemia control will be difficult to achieve, and who are at particular 
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risk of ketoacidosis[290] – this information may help guide choices of insulin 
treatment regimes and glycaemic targets  
(2) to identify those patients with significant residual "-cell function to target 
for future !-cell protection therapies  
(3) to sequentially monitor "- cell function to identify those patients who are 
losing "- cell function rapidly and prioritise them for immunointervention 
treatments, such as rituximab [107] and CTLA-4 IG [106]. This group is a 
particular priority, as rates of "- cell destruction vary widely and at present the 
predictors of disease progression are not robust [291]. 
(4) to monitor the response to immunointervention and perhaps detect benefit 
or the need for repeated intervention at an early stage.  
Stimulated UCPCR is a good candidate test for this purpose, but there is no 
data to suggest that it is sensitive enough to detect loss of "-cell function in 
Type 1 diabetes over time. In particular, it would be of value to identify rapid 
progressors early – within 6 months if possible - to target intervention. The 
non-invasive nature of UCPCR testing provides the potential for repeated 
testing over time, which may be particularly valuable for early assessment of 
disease progression.  
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6.2 Hypothesis  
I hypothesise that stimulated UCPCR is a reliable test for estimation and 
monitoring of the changing "- cell function over time. 
6.3 Aims 
1. To confirm in our center that standard mixed-meal stimulated 
UCPCR correlates well with gold standard MMTT. 
2. To determine whether stimulated UCPCR can be used to 
monitor changing "- cell function over time. 
3. To determine which form of stimulation is optimal for this 
purpose. 
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6.4 Results 
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Seventeen non-obese, adult patients with type 1 diabetes (duration of #5 
years) were recruited in the Bristol area (UK), through the South West Newly 
Diagnosed Diabetes Collection database, after signing informed consent. 
Inclusion criteria: age 18-45 years, normal renal function, HbA1c<10% 
(86mmol/mol), daily insulin requirement of <0.8 units/kg/day and detectable "-
--cell function measured at a post-meal UCPCR. Detailed methods are 
described in Chapter 2. Abbreviations used are shown in Table 6-1.  
Abbreviation Explanation 
MMTT  Mixed Meal Tolerance Test 
UCPCR  Urine C-peptide creatinine ratio 
MM  Mixed meal 
uCP  Urinary C-peptide 
sCP  Serum C-peptide  
 
Table 6-1. Abbreviations of the parameters used in the study. 
 
Out of 17 eligible patients that were recruited into the study (13 males and 4 
females), 16 completed the initial MMTT in hospital. Detailed progress of the 
study in terms of number of patients is shown in the flow diagram in Figure 6-1: 
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Figure 6-1. Flow-diagram of participants’ progress during the study. 
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Demographic and clinical characteristics of the patients are shown in !
Table 6-2. 
Age (years) 33.6±5.8 
BMI (kg/m2) 25.7±3.2 
Duration of diabetes (years) 2.1±1.5  
HbA1c (%(mmol/mol)) 6.7±1.0 (50.1±11.1) 
Daily insulin requirements (U/kg/day) 0.44±0.18 
Peak C-peptide during MMTT (pmol/l) 918.00±994 !
Table 6-2. Demographic and diabetes related characteristics of the patients on 
entering the study. 
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Serum C-peptide (sCP) and glucose response to Ensure is shown in Figure 6-2. 
Participants with high C-peptide response demonstrated the most well-
controlled and stable glucose levels over the 120 min of MMTT, and vice 
versa.  
 
 
 
 
 
Figure 6-2. Serum C-peptide and glucose levels during 120 min of MMTT. a) glucose 
response b) serum C-peptide response; red lines – poor responders; green lines – 
intermediate responders; blue – good responders; n=16. 
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Peak sCP during the standard MMTT correlated strongly with the AUC sCP 
(r=0.99, 95% CI:0.97-0.99, p<0.0001, n=16) and was used as a 
representative estimate for "-cell insulin production (Figure 6-3). 
 
 
 
 
 
Figure 6-3. Peak serum C-peptide and AUC serum C-peptide during MMTT; AUC – area 
under the curve. Statistical test used: Spearman correlation. 
 
Peak sCP during MMTT correlated well with the two-hour UCPCR done on 
the same occasion (r=0.81, 95% CI:0.51-0.93, n=16, p=0.0002, Figure 6-4 a), 
as well as the home MM-UCPCR month 1 measurement (r=0.89, 95% 
CI:0.69-0.96, n=15, p<0.0001, Figure 6-4 b). There was no significant 
difference between hospital MM-UCPCR and home MM-UCPCR month 1, 
undertaken 26.8±14.1 days apart (1.29±1.11nmol/mmol vs 
0.96±0.97nmol/mmol, respectively; p=0.06, n=15).  
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Figure 6-4. Correlation betweeen peak serum C-peptide and MM-UCPCR. a) hospital 
based test; b) home based test. Statistical test used: Spearman correlation. !
Peak sCP during MMTT correlated less well with the fasting UCPCR collected 
on the same occasion (r=0.74, 95% CI:0.38-0.91, n=16, p=0.001, Figure 6-5). 
 
 
 
 
Figure 6-5. Correlation between peak serum C-peptide and fasting UCPCR measured 
from second morning void sample. Statistical test used: Spearman correlation. !
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Hospital MM UCPCR significantly negatively correlated with the patients’ daily 
insulin requirements (r=-0.76, 95%CI: -0.92 to -0.42-, n=16, p=0.0006), but 
there was a non-significant (negative) trend only with HbA1c level (r=-0.45, 
95%CI: -0.78 to 0.08, n=16, ns), with no definite correlation with time since 
diagnosis (r=-0.29, 95%CI: -0.69 to 0.26, n=16, ns) – Figure 6-6.  
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Figure 6-6. Correlation of hospital MM UCPCR with diabetes related parameters: a) daily 
insulin requirements (U/kg); b) HbA1c and c) time since diagnosis. Statistical test used: 
Spearman correlation. !
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Of the 16 patients who provided paired data at baseline, 13 (81%) returned 2 
or more home UCPCR post meal samples and 13 (81%) provided both a 
month 1 and a month 6 home UCPCR sample 
The 4 patients who were lost to follow-up did not differ significantly in 
screening variables, such as age, BMI, duration of diabetes, HbA1c or daily 
insulin requirements at baseline. There was a large discrepancy in the peak 
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serum C-peptide, which was not significant due to low numbers and high 
variation (Table 6-3). 
 Patients with the completed data 
Lost to follow-up 
patients 
p 
(Mann-Whitney) 
N 13 4  
Age (years) 34.2±5.1 31.2±8.5 0.82 
BMI (kg/m2) 26.0±3.6 24.7±1.1 0.19 
Duration of diabetes (years) 2.0±1.2 2.0±2.0 0.64 
Insulin requirements (U/kg) 0.44±0.18 0.44±0.25 0.94 
HbA1c (%) 6.7±1.1 6.8±0.7 0.46 
Peak C-peptide during MMTT (pmol/l) 1056±1052 321.0±331.9 0.23 9( n=3) 
Table 6-3. Comparison of patients with complete and incomplete data sets. 
 
Patients showed significantly lower "-cell function on home MM-UCPCR 
month 6 (0.71±0.86nmol/mmol) in comparison with home MM-UCPCR month 
1 performed on average 5.5±1.0 months earlier (1.08±0.98nmol/mmol, n=13, 
p=0.02) – Figure 6-7.  
 
 
 
!
Figure 6-7. MM-UCPCR change over 6 months. Comparison was made between UCPCR 
collected after home meal stimulation (home MM-UCPCR) 1 month and 6 months after 
entering the study. Statistical test used: Wilcoxon signed rank test. !
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Home meal-UCPCR (HM UCPCR) collected 2.1±1.1 months after hospital 
MMTT significantly correlated with peak sCP (r=0.83, 95% CI:0.50-0.95, 
p=0.0005, n=13) – Figure 6-8 a. The correlation became stronger when the 
maximal home meal-UCPCR value from all the serial monthly measurements 
was taken into account (r=0.89, 95% CI:0.67-0.97, p<0.0001, n=13) – Figure 
6-8 b. Patients on average provided 2.6±1.5 samples out of the 4 planned.  
 
 
 
Figure 6-8. Correlation of peak serum C-peptide with home meal stimulated UCPCR 
(HM UCPCR). a) first collected HM-UCPCR; b) maximal HM-UCPCR value out of serial 
monthly measurement. 
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When data from the main study were pooled with the baseline data from the 
MonoPepT1De study (before intervention), correlation between peak sCP 
during MMTT and the two-hour UCPCR done on the same occasion was 
maintained (r=0.52, 95% CI:0.24-0.73, n=38, p=0.0007, Figure 6-9). 
!!!!!!
Figure 6-9. Correlation: Peak serum C-peptide and MM-UCPCR. Data from the main study 
and MonoPepT1De study were pooled. The tests in the both studies were done under the 
same conditions. Statistical test used: Spearman correlation. !
The correlation between the change in MM-UCPCR and peak sCP was not 
evident after 3 months (r=0.3, 95% CI:-0.20-0.68, n=18, p=0.2, Figure 6-10 a), 
but reached significance after 6 months (r=0.6, 95% CI:0.08-0.86, n=14, 
p=0.02, Figure 6-10 b) of follow-up of the MonoPepT1De study subjects. I was 
only able to test the correlation of the change over time in these two 
parameters, given that it was performed before unblinding, with some of the 
subjects exposed to the study drug and some to the placebo. 
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Figure 6-10 Correlation: Change in the peak serum C-peptide and the change in the 
MM-UCPCR. $ sCP – change in the peak serum C-peptide during MMTT; $ UCPCR – 
change in the MM stimulated UCPCR done at the same occasion. a) after 3 months; b) after 
6 months. Statistical test used: Spearman correlation. !!!
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6.5 Summary of findings 
1. Standard mixed meal stimulated UCPCR strongly correlated with gold 
standard MMTT for the estimation of residual "-cell function in 
patients with Type 1 diabetes within 5 years since diagnosis, in both 
hospital and home setting.  
 
2. The use of standard Mixed Meal stimulated UCPCR was proven to be 
a useful tool for the detection of a significant change in "-cell function 
over the six months long period of follow up.  
 
3. Best of the serial measurement of home meal stimulated UCPCR can 
be used as a reliable parameter for the estimation of "-cell function.  
 
The importance of the effect of residual "-cell function on glycaemic control in 
Type 1 diabetes is reflected in the observation from standard MMTT during 
which highest C-peptide responders had near normal glucose levels, and vice 
versa. Significant negative correlation between residual "-cell function, 
measured as MM stimulated UCPCR, and daily insulin requirement supports 
this finding. The correlation with HbA1c and duration of diabetes lacks 
significance, possibly because of the effect of other parameters, such as 
compliance issues in the former and rate of disease progression in the latter.  
Besser et al. demonstrated that stimulated UCPCR could be a practical 
alternative to the standard MMTT in estimating "-cell function.[131] Our study, 
conducted in patients much earlier in the disease process, all of whom had 
well controlled diabetes (HbA1c 6.7±1.0%, daily insulin requirements 
0.44±0.18 U/kg/day) and significant residual "-cell function (peak sCP during 
MMTT >200 pmol/l in 12 out of 16 patients - mean 918.00±994 pmol/l), 
confirmed this finding, irrespective of the setting where the test was performed 
(hospital: r=0.81, p=0.0002; home r=0.89, p<0.001). Correlation remained 
significant when the data were pooled with the baseline results of the MMTT 
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test (serum and urine) from the MonoPpepT1De study, performed at exactly 
the same conditions. The correlation was not as strong as in the Besser study. 
Higher rate of production and consequently wider range of C-peptide values in 
our cohort may be the explanation for this finding.  
Although fasting UCPCR significantly correlated with the standard MMTT, the 
correlation was weaker and more diverse than with the stimulated one, 
suggesting that fasting UCPCR is less a reliable marker than stimulated one.  
In addition, I was able to show a significant decline of "-cell function during 
the follow-up period using home UCPCR, suggesting that MM stimulated 
UCPCR is not only a good estimate of "-cell function at one particular time 
point, but also a useful tool for serial monitoring. It is unlikely that the patients 
who were lost to follow-up biased the results, because they did not differ 
significantly with the group with completed data in demographic and diabetes 
related parameters.  
Potential use of stimulated UCPCR in the monitoring of "-cell function was 
additionally confirmed by the fact that the change in UCPCR correlated with 
the change in the gold standard MM stimulated sCP. The significance was 
achieved only when six months correlation was taken into account. It is 
possible that the three months change was not high and hence, sensitive 
enough.  
 
Home meal stimulation of the UCPCR (as opposed to the use of proprietary 
standardised meal supplements, such as Ensure plus), although weaker, can 
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also be a comparable alternative to the standard MM stimulation. Our results 
also suggest for the first time that variation in the stimulus from home “main 
meals” could be overcome by serial measurements, followed by choosing the 
highest out of 2-3 measurements as representative of "-cell function without 
the requirement to fast, omit insulin or count carbohydrate content of the meal 
(increase in correlation coefficient from r=0.83,p=0.0005 to r=0.89,p<0.0001). 
This approach has the potential to improve on the estimation of "-cell function 
without burdening subjects with a complex testing protocol, and should 
improve compliance rates. I suggest that this modification increases the 
accuracy of home meal stimulated UCPCR and makes it a potentially useful 
tool for assessment of residual "-cell function in large prospective cohort 
studies.!!
It has to be taken into account that this was a pilot study and therefore not 
sufficiently powered to draw solid conclusions about the efficacy of stimulated 
UCPCR in the estimation and monitoring of the "-cell function, but 
nevertheless, offers reasonable grounds for a larger definitive trail. 
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Success of peptide immunotherapy starts with the efficient delivery. Once the 
right peptide is delivered to the right cell, it is equally important to monitor the 
effect of such a therapy as closely and as precisely as possible, both in the 
regards to the immune and metabolic response.  
Currently, clinical trials are designed in such a way that the effect of the study 
drug is measured at the end of the trial period, which can be months or even 
years later. Ex-vivo human models, such as skin organ bath culture, not being 
the subject of the extensive regulatory requirements, can provide rapid 
answers on the efficacy of the treatment, within its limitations. The idea is that 
the conclusions from murine models and in-vitro cultures can be tested for the 
proof of principle in the ex-vivo models, and if proven valuable, selected for 
assessment in clinical trails. Clinical trials and subsequent clinical practice 
would, on the other hand, be equipped with a monitoring techniques to detect 
early changes in immune and metabolic responses that would improve 
efficacy. 
The ability to detect early immune responses to the study drug will allow early 
identification of the “responders”, followed by close monitoring of "-cell 
function. This would allow early recognition of changes in disease activity, and 
the potential need for a different treatment intensity and/or strategy. 
Dilemmas on optimisation and potential advances in the each step of this 
process, from delivery to the metabolic response monitoring, achieved during 
this project are summarised in the Figure 7-1.  
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Figure 7-1. Dilemmas, answers and scope for the future in the optimisation of the 
efficacy of the peptide immunotherapy.  
 
In this final chapter, I will further discuss advantages and disadvantages of the 
models and techniques that I developed, and link them with the ideas for the 
future work in this field.  
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7.1 Skin organ bath culture for the assessment of optimal 
antigen skin delivery 
T"R"R 3B&+'V8*+)/@,*+5,.B+647.4/&+S)1&7++
I have shown that the skin organ bath culture is a useful ex-vivo model that 
permits the assessment of treatment agents delivered via different devices, 
through study of the phenotypic and functional characteristics of the cells 
targeted by such a treatment. This project led to the modification of the model 
to allow assessment at a particular time point of treatment, through rapid 
extraction of the dendritic cells of interest.  
One of the advantages of the skin organ bath culture lies in the possibility to 
incubate the skin as a whole, following treatment, which mimics in vivo 
processes much better than in vitro cell cultures. In this model, an uptake of 
the delivered antigen is influenced by the full range of different cell types 
present in skin. It also has a potential to study the volume of distribution in the 
structures of skin and the access to the different skin layers.  
Another advantage is the controlled duration of treatment being assessed, 
which is enabled by the rapid extraction of the epidermal cells from the skin. 
This is different from the majority of protocols that usually obtain DCs by the 
‘walk-out’ method.[292] Although this provides purified, functional DCs, the 
issues with their number, maturity (that increases in the process of migration) 
and the potential to loose their captured antigen, makes it less favourable 
model for the purposes of this project. Enzymatic separation and digestion of 
epidermis makes the epidermal cell suspension rapidly available, with DCs in 
their less mature, nascent state. 
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Most importantly, the model allows assessment of various agents and devices 
without the regulatory limitations encountered in clinical trials.  
However, the model carries certain disadvantages. These are particularly 
related to the fact that enzymatic process may cleave some of the cell 
membrane markers essential for the full potency of the cell. Indeed, failure to 
detect CD11c on the DCs obtained through this process, which was 
independent of antibody type or addition of fixative during preparation for the 
flow cytometry, is likely to have been a manifestation of this problem.  
Finally, we have to take into account conditions in organ bath, such as the 
lack of circulation leading to the absence of the clearance of the administered 
agent from the local site, as would have happened in vivo. Also, hypoxia and 
high concentrations of metabolic by-products that would normally be cleared 
from the skin, remain in situ in this model and almost certainly would affect 
functionality of the cells. 
There is certainly room for improvement that may be the subject of future 
research. One such improvement would involve purifying DC population, with 
elimination of dead cells and keratinocytes, by flow sorting or magnetic 
separation. This would eliminate potential non-specific influence of dead cells 
on reactions, and lead to more clear results, but at the expense of loosing 
significant number of cells.  
In conclusion, within its limitations, the design of the organ skin bath culture 
used in this project allows rapid answers to the questions particularly in 
regards to the optimal delivery of the antigens, without ethical boundaries 
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encountered in the clinic, which makes it an important translational filter to the 
in-vivo human studies. 
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The skin organ bath model allowed me to investigate the efficacy of targeting 
epidermal DCs during antigen skin delivery. This set of experiments showed 
that both hollow and dry coated microneedles are comparable to standard 
indradermal 26G needles in targeting epidermal DCs, with some suggestion 
of superiority in the case of dry microneedles. 
I found that the hollow microneedle is a comparable device to a standard 26G 
needle in targeting epidermis by measuring response of the cloned T-cells to 
the peptide presented by the DCs, loaded through ex-vivo delivery. However, 
even if needles of the hollow microneedle are positioned superficially in close 
proximity of epidermal/dermal junction, the ‘jet effect’ of the volume injected 
pushed the solution deeper in the dermis, away from the targeted epidermal 
cells. Both the hollow microneedle and the 26G needle are designed for 
intradermal drug administration, and the fact that antigen delivered by them 
reaches epidermal DCs is almost certainly due to flush-back of the solution, 
followed by diffusion throughout the skin layers including the epidermis. The 
advantage of the hollow microneedle perhaps lies in the fact that its short 
needles prevent accidental deeper administrations that are possible with the 
26G needle.  
I thought to overcome the problem of ‘jet effect’, by delivering the antigen 
using dry coated microneedles. In this way, arrays of 10 needles of 400µm 
duration are coated with peptide and positioned such that the majority of the 
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coated needle length would be in the epidermis. From here, the peptide will 
gradually dissolve in the interstitial fluid and diffuse into the tissue. Although, 
this mode of delivery again seemed comparable, if not better, than 26G 
needles, I encountered several problems. Firstly, to coat the peptide on the 
microneedle, I had to dissolve it in a solution that easily evaporates after 
coating, leaving the peptide only on the needle. Also, the coating solution 
should not change the peptide. Choosing the right coating solution that meets 
all of these criteria was the subject of PhD project of Ms Xin Zhao and I will 
not discuss it in detail here. Suffice to say that EBVP1 peptide, used in this 
model, is very hydrophobic, making the task of choosing the optimal coating 
solution difficult. For example, DMSO would resolve the problem of solubility, 
but I could not use it because of its poor evaporation, which would not allow 
the peptide to dry on the microneedle after coating. A solution of glacial acetic 
acid, 2-methylbuten-2-ol and 20mg/ml PVA 2000 (10:5:2 by volume) was 
found to be optimal for this purpose. 
Once the needle was in the tissue, the hydrophobicity of the peptide 
played a role in the efficacy of the delivery. The small amount of interstitial 
fluid in a dense cellular tissue such as the epidermis reduced the dissolution 
from the needle into the aqueous interstitial tissue. As a consequence, 15 
minutes of needle insertion only allowed less than 20% of delivery, which was 
comparable, if not better, than delivery via 26G needle.  
Delivery can potentially be made more efficient by using the larger quantity 
from arrays consisting of more needles or increasing delivery time. Also, more 
soluble peptide will probably be delivered more efficiently.  
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Another improvement of this system would be to compare the proportion of 
peptide delivered to the epidermis and dermis via each device. Enzymatic 
digestion of the dermis or the ‘walk out’ method would be the way of obtaining 
dermal DCs. However, we have to bear in mind that epidermal DCs were 
obtained following peptide administration in the circular area of 0.8cm 
diameter. This provided approximately 3x105 EC (approximately 3000 DCs), 
enabling experiments that required 5x104 ECs (500 DCs) per well. It is very 
unlikely that I would be able to obtain a comparable number of dermal DCs 
from piece of dermis derived from a 0.8cm punch biopsy to enable the fair 
comparison. Indeed, when I tried to obtain dermal DCs in such a way (48h 
‘walk out’), I only obtained 10,000 live cells per one 0.8cm punch biopsy. 
According to the flow data, only 7% of these cells were CD1a+HLA-DR+, 
providing approximately 700 cells per one punch biopsy, which is not nearly 
enough to set up an experiment - Figure 7-2. However, optimising the model to 
allow dermal/epidermal comparisons this could be the subject of future work.  
 
Figure 7-2. Flow cytometry profile of the dermal dendritic cells. a) CD1a/HLA-DR 
staining; b) Langerin/CD1a staining; c) Langerin/CD1a staining. 
 
This project gave a suggestion that dry microneedle can be more efficient in 
targeting epidermis than established intradermal devices. This is because 
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they are designed to anatomically and chemically (slow diffusion from the 
needle to the surrounding space) target the epidermis, as opposed to the 
intradermal devices that rely on flash back to deliver to the epidermal DCs. 
The efficacy of the delivery by dry coated microneedles could be further 
improved by the use of devices with more densely packed arrays and water 
soluble peptides. One such peptide is C19-A3 peptide, currently tested in a 
Phase Ib trial. To study the efficacy of C19-A3 peptide delivery via dry 
microneedles, the antigen would be coated on the dry microneedle array and 
delivered to the skin ex-vivo. Subsequently, skin derived dendritic cells (either 
in epidermal cell suspension or purified as previously discussed) would be co-
cultured with C19-A3 specific cloned T cells. If proven efficient in comparison 
to standard 26G, this mode of delivery can be used in later phases of clinical 
trials on C19-A3 peptide, subject to regulatory approvals and a positive safety 
outcome from ongoing Ib phase.  
T"R"< K*B,*6&S&*.+ )-+ .)7&/)@&*86+ &*=8/)*S&*.+ 8*+ (/&(,/,.8)*+ -)/+ (&(.81&+
8SS4*).B&/,(2+!
The skin organ bath culture allowed the analysis of the effect of topical steroid 
on the tolerogenic potential of epidermal DCs. When complemented with the 
in vivo blister studies, data indicate that topical steroid treatment induced 
changes in the skin DCs responsible for their weaker capacity to activate 
responder T cells in the MLR type reactions. Although suggested by the ex 
vivo model, in vivo data are less supportive of pro-tolerogenic effects. Instead, 
generally weaker activation signal is more likely explanation for this 
phenomenon. !
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One can argue that a lack of circulation and effective clearance of steroid from 
the tissue allowed the effect to be evident after only 24h, which may not be 
the case in vivo, and would certainly require separate titration of the optimal 
treatment duration. However, reduced expression of co-stimulatory markers 
on skin DCs and the reduced capacity to drive proliferation in MECLR might 
mean an enhancement of the tolerogenic nature of these cells. I have not 
been able to demonstrate a mechanism of tolerance by using cultures of 
epidermal cells exposed to steroid and allogeneic donor CD4+ naïve T cells, 
aiming to assess the phenotype and the suppression capacity of T cells 
cultivated in such a way. The reason was the small number of cell cultivated 
in this experiment, which could be due to the old age of skin donors and 
adverse ex-vivo conditions affecting DCs, as previously discussed. When a 
similar protocol was applied with the use of in vivo steroid exposed DCs 
(obtained via suction blister), no clear tolerance was shown. A generally 
weaker signal delivered by steroid exposed cells is the more likely explanation.  
Beside topical steroid, I tested the effect of locally injected IL-10, both in pure 
form and attached to nanoparticles, in the skin organ bath culture. The 
absence of strong suppression in the ex vivo model, previously observed in 
vitro, is most likely to be due to the large individual variation in the response to 
locally injected IL-10 on the background of a weaker MLR type reaction, short 
duration of incubation to allow for the IL-10 effect and insufficient dose of 
locally injected IL-10. However, the ex-vivo trends on the background of the 
significant in vitro data, were suggestive that a small dose of locally injected 
IL-10 has the potential to modulate skin DCs into a pro-tolerogenic profile, 
particularly if used as an enhancer to peptide immunotherapy. To draw any 
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solid conclusion, this protocol would need to be optimised, particularly in 
regards to IL-10 dose and duration of effect, assessment of different types of 
nanoparticles to which IL-10 is linked and purification of DCs used in the 
cultures. 
 
In summary, despite limitations, the skin organ bath culture is a useful 
system for studying treatment effects of variety of ex-vivo delivered 
agents that bridges the in vitro models and in vivo studies in humans, 
which are restricted for ethical reasons. When used to study the optimal 
delivery of peptides, it indicated a potential role of dry coated 
microneedles in targeting epidermal DCs, important because of their 
endogenous tolerogenic potential. I have also shown that, due to the 
accessibility of epidermal DCs, they can be modified by topical 
treatments and locally injected agents. Whether true tolerogenic 
potential can be achieved in such a way, is subject to further studies 
designed to optimise the type, dose and the duration of the treatment by 
the conditioning agent.  
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7.2 Monitoring immunological and metabolic outcomes 
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In most studies in humans, immune responses are assessed in blood-derived 
cells due to their ready availability. However, the immune response is a 
dynamic process that starts in the primary tissue (skin in the case of this 
study) and subsequently takes part mainly in lymphoid organs, such as lymph 
nodes and spleen. It is very important to be able to monitor immune response 
following skin antigen delivery, in order to assess its efficacy. However the 
induced antigen-specific T cells are only present at very low levels in the 
blood, as the cells only pass briefly through the blood, travelling from the 
primary source of the antigen to the lymphoid site, or between two lymphoid 
sites. Hence, studies assessing blood derived immune cells have a high risk 
of false negative results, and any beneficial effect of peptide immunotherapy 
may be missed. On the contrary, looking at the immune processes in the 
lymphoid organ is the default method in animal models. This project explored 
the concept of translating this approach into humans by using minimally 
invasive ultrasound guided fine needle aspiration (FNA) of the regional lymph 
node (LN), a technique commonly used in clinical practice for cancer 
diagnostics.  
Our results show that LN FNA is acceptable to subjects, can be repeatedly 
and reliably performed by a skilled operator and provides a sufficient number 
of live and functional T cells to detect the cellular immune response after 
antigen skin delivery. The question that immediately arose was triggered by 
the failure to detect baseline IFN! response to specific antigens, which 
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suggests reduced effector memory response in the quiet lymph node. On the 
contrary, a specific IFN! response following Mantoux test, as detected in the 
draining lymph node, points towards effector memory, but it is not clear where 
these cells are coming from. They might have been ‘early bird’ effector cells 
arriving from the skin that are either in situ skin memory cells or blood derived 
memory cells, which travelled to the lymph node via skin; or local effector cells 
activated by the antigen bearing DCs arrived early in the lymph node from the 
skin. 
Future research should aim to characterise the groups of cells, in particular T 
cells, residing and arriving in the lymph node following in vivo antigen 
stimulation, by means of flow-cytometry.  This would particularly relate to the 
groups of cells such as central (CD45RA- CCR7+) and effector memory cells 
(CD45RA- CCR7-), naïve T cells (CD45RA+) and cells equipped with the 
machinery to home in the skin (CLA+) and/or lymph node (CCR7+). 
This ‘proof of principle’ study indicated that LN FNA is a feasible method for 
detecting IFN! immune response in humans, elicited by the antigen linked to 
the strong adjuvant. Future research should follow to detect responses to 
peptide immunotherapy, which does not involve strong adjuvants, as was the 
case with Tuberculin PPD. This would require a different approach in 
choosing read-outs. Whilst Tuberculin PPD is potent stimulator, response to 
which is very likely to be recorded through detection of cells producing an 
abundance of the pro-inflammatory cytokine IFN!, responses to peptide 
immunotherapy are likely to be more subtle, and involve generation of Tregs. 
They recognise the administered autoantigen/peptide and have an immune 
regulatory phenotype, which they achieve through production of IL-10 and 
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TGF-", amongst other proposed mechanisms. Hence, detection of, for 
example, IL-10 producing cells and flowcytometric analysis of the change in 
the proportion of Tregs following PIT delivery, would be a good starting 
approach for a follow-up study.  
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This study confirmed earlier findings that stimulated UCPCR could be a 
practical alternative to the standard MMTT in estimating "-cell function. In 
addition, it extended the application of the method to patients much earlier in 
the disease process, with well controlled diabetes and significant residual "-
cell function.  
In addition, I was able to show a significant decline of "-cell function during 
the follow-up period using home UCPCR, suggesting that MM stimulated 
UCPCR is not only a good estimate of "-cell function at one particular time 
point, but also a useful tool for serial monitoring.  
Home meal stimulation of the UCPCR, although weaker, can also be a 
comparable alternative to the standard MM stimulation, particularly when 
choosing the highest out of 2-3 serial measurements as representative of "-
cell function, without the requirement to fast, omit insulin or count the 
carbohydrate content of the meal. 
This approach has the potential to improve the estimation of "-cell function 
without burdening subjects with a complex testing protocol, and should 
improve compliance rates. !
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In summary, lymph node fine needle aspiration biopsy is a feasible non-
invasive method suitable for monitoring the cellular immune responses 
after antigen skin delivery. Subject to confirmatory study, it has a 
potential to find immediate application as an efficient and reliable tool 
for monitoring immune response after antigen-specific immunotherapy 
in clinical trials. Once recognised as ‘immune responders’ in such a way, 
participants in clinical trials can be subjected to the monitoring of the 
metabolic response to the immune intervention, by measuring "-cell 
function via stimulated UCPCR as a non-invasive and more compliant-
prone alternative to the standard MMTT. 
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#35+5256<$4+(*.$%8./54$,2$62$%#45+$(6%if)$'$i%+4)6,;$6(2%-(2$0!S4LV!:35<!FV3?!9V.!a!9!F7!&%%#,!2JF@'"AB!C,!"%#+"D*,!&($,! \31!?0!T017![,7!05!3<,7!>3)4)2+$4(a)+(56%58%85/4%256<$6+(56).%'$6'4(+(2%2$..%
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$5+)T(6%4$2$#+54%>>GX%*"%3/-)6%!%3$.#$4%?%2$..,0!9V.01V07!"$$+,!
CKK@)''(AB!C,!&%%)D+,!&)),! YO7!X,7!05!3<,7!>>G]%.$<$.,%)6'%$T#4$,,(56%#)++$46%2544$.)+$%A(+3%(68$2+)*(.(+"%
*"%-)245#3);$9+45#(2%Z&c9:K%(6%<(+450!=!-]C!>0?7!"$$+,!2IF@$AB!C,!"*#"D$",!&)*,! S0504/7!=,K,7!05!3<,7!Z/-)6%,$256')4"%."-#35('%54;)6,%+"#(2).."%256+)(6%
#5."2.56).."9)2+(<)+$'%#45.(8$4)+(6;%4$;/.)+54"%!%2$..,0!G<LL?7!&%"',!
2CC@"'AB!C,!&&"'D&',!&)+,! IOCC047!H,9,!31?![,J,!_O6<24.;;07!&--/6$%,/4<$(..)62$%(6%+3$%,E(6@%
-$23)6(,-,%)6'%2.(6(2).%256,$F/$62$,0!:35![0\!RPPO1L<7!&%%(,!D@'AB!C,!&""D&&,!&)#,! J<34N7![,F,7!05!3<,7!!3$%<),+%-)g54(+"%58%>W1M%!%2$..,%)4$%4$,('$6+%(6%654-).%
,E(60!=!RPPO1L<7!&%%*,!2K4@+AB!C,!(('"D$,!&)$,! IO1N0<7!-,=,7!05!3<,7!DT#4$,,(56%58%+3$%23$-5E(6$%4$2$#+54,%>>GYK%>>G]K%)6'%
>h>GX%*"%3/-)6%+(,,/$9(68(.+4)+(6;%."-#352"+$,0!FP!=!S356L<7!&%%&,!
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#45.(8$4)+(56%58%6)+/4).%4$;/.)+54"%!%2$..,%(,5.)+$'%845-%3/-)6%,E(60!G<LL?7!&%%+,!2JH@"AB!C,!"$(D&%&,!&*",! 931V60Z![L?4.;O0Z7![,7!05!3<,7!L$-54"%4$;/.)+54"%!%2$..,%4$,('$%(6%3/-)6%
,E(60!=!J<.1!R1\0/57!&%"(,!2CD@'AB!C,!"%&+D'*,!
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>BYM>B?]3(;3=5T#XM%4$;/.)+54"%!%2$..,%*$)4%8/62+(56).%,E(6935-(6;%
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(6%3/-)6,%(6%<(<50!J<.1!-]C!RPPO1L<7!&%"',!2K6@&AB!C,!"*'D+&,!&+&,! HL417!J,7!05!3<,7!C45;65,+(2%8)2+54,%854%+3$%25/4,$%58%*$+)%2$..%8/62+(56%(6%
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+"#$%:%'()*$+$,%(6%+3$%'()*$+$,%256+45.%)6'%25-#.(2)+(56,%+4().0%1%
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#$#+('$%A(+3%,$4/-%(6,/.(6%)6'%#.),-)%>9#$#+('$0!M.32050/!J3407!"$#',!
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Appendix – sources of materials 
Reagents 
Name Content Company 
[3H] thymidine  6.2µCi/ml in 5%FCS in supplemented RPMI 1640 Perkin Elmer, Cambridge, UK 
2-methylbuten-2-ol  Sigma-Aldrich, Poole, UK 
5-TAMRA 
(carboxytetramethylthodamine) – 
GLCTLVAML – EBVP1 peptide 
%95% purity GL Biochem (Shanghai) Ltd.,PRC 
Agarose, powder  Geneflow, Lichfield, UK 
AIM-V®+AlbuMAX BSA serum free 
media  Gibco, Paisley, UK 
Bovine serum albumin (BSA)  Promega. Madison, USA 
CD4+CD25+CD127_ Regulatory T cell 
Isolation Kit II, human  
Miltenyi Biotec GmbH, Surrey, 
UK 
Collagenase I 210 U/mg Invitrogen, Paisley, UK 
Compensation particles set, anti-mouse 
Ig k/negative control FBS  BD Pharmigen, Oxford, UK 
Deoxyribonuclease I (DNA-seI) from 
bovine pancreas %400Kunitsz/mg Invitrogen, Paisley, UK 
DiproSone® cream 0.05%w/w betamethasone (as dipropionate) 
Merck Sharp&Dohme Ltd, 
Hoddesdon, UK 
Dispase II (neutral protease, grade II) 0.89U/mg Roche, Burgess Hill, UK 
DNA ladder  100bp Thermoscientific, Loughborough, UK 
DRB1*0101-0103 primers 100µM Invitrogen, Paisley, UK 
Dulbecco’s Modified Eagle Medium 
(DMEM)  Gibco, Paisley, UK 
Dulbecco’s Phosphate Buffered Saline 
(PBS)  Sigma-Aldrich, Poole, UK 
EDTA (ethylenediaminetertraacetic 
acid) 0.5M Sigma-Aldrich, Poole, UK 
ELISA substrate solution (IFNgamma 
and IL-10) 
1Xtetramethylbenzidine (TMB) 
solution 
 
E-bioscience, Hatfield, UK 
ELISA Substrate Solution MIP-1", 
BDOptEIATM 
Two part substrate solution: 
Reagent A – H2O2, reagent B – 
TMB. 
BD Biosciences, Oxford, UK 
Ensure Plus®  Abbott Nutrition, Illinois, USA 
Ethidium bromide  Stock 10mg/ml in dH2O Sigma-Aldrich, Poole, UK 
!&*(!!
ExtrAvidin® Alkaline Phospatase  Sigma-Aldrich, Poole, UK 
Ficoll-Paque PLUS 1.077±0.001 g/ml, +20°C GE Healthcare Biosciences, Uppsala, Sweden 
Foetal calf serum (FCS)  Biosera, Boussens, France 
Glacial acetic acid  Fisher Scientific, Loughborough, UK 
Glycerol  Fisher Scientific, Loughborough, UK 
Gold nanoparticles (NP) 325 µg/ml of gold Midatech, Abingdon, UK 
Hemagglutinin (306-318) Influenza A 
virus peptide PKYVKQNTLKLAT (FP1) %97% purity Mimotopes Pty Ltd, Australia 
Heparin Sodium solution 1,000 IU/ml Wockhardt UK Ltd, Wrexham, UK 
HLA-DR1 and control primers for HLA 
DR1 typing  Invitrogen, Paisley, UK 
Human AB serum  PAA, Pasching, Austria 
Human anti IL10- antibody 1mg/ml Miltenyi Biotec, Surrey, UK 
Human C-peptide ELISA  Mercodia, Milton Keynes, UK 
Human IFNgamma ELISA Ready-Set-
Go!  E-bioscience, Hatfield, UK 
Human IL-10  Cell Signaling Technology, Danvers, USA 
Human IL-10 ELISA Ready-Set-Go!  E-bioscience, Hatfield, UK 
Human IL-10 nanoparticles 62.5µg/ml IL-10, 227µg/ml gold Midatech, Abingdon, UK 
Human IL-15, research grade 2x106iu/ml Miltenyi Biotec, Bergisch Gladbach, UK 
Human IL-2, research grade 5x106iu/ml Miltenyi Biotec, Bergisch Gladbach, UK 
Human MIB-1" DuoSet® ELISA kit  R&D Systems, Abingdon, UK 
IFN! ELISPOT Biotinylated detection 
antibody   
U-CyTech biosciences, Utrecht, 
The Netherlands 
IFN! ELISPOT coating antibody   U-CyTech biosciences, Utrecht, The Netherlands 
L-glutamine 200mM Gibco, Paisley, UK 
Lytic protein BMLF-1 (280-288) Epstein-
Barr virus peptide GLCTLVAML 
(EBVP1) 
%90% purity Mimotopes Pty Ltd, Australia 
Naïve CD4+ T cell isolation kit II, human  Miltenyi Biotec GmbH, Surrey, UK 
Nitric acid  Fisher Scientific, Loughborough, UK 
!&*)!!
Orange G sodium  Sigma-Aldrich, Poole, UK 
Ortho-phosphoric acid  Fisher Scientific, Loughborough, UK 
Paraformaldehyde  Fisher Scientific, Loughborough, UK 
Penicillin-Streptomycin solution  
5,000 units/ml of penicillin 
5,000 µg/ml of streptomycin 
Gibco, Paisley, UK 
Penicillin-Streptomycin-Neomycin 
solution 
5,000 units/ml of penicillin 
5,000 µg/ml of streptomycin 
10,000 µg/ml of neomycin 
Sigma-Aldrich, Poole, UK 
Phytohemagglutinin PHA-P, lyophilized 
powder  Sigma-Aldrich, Poole, UK 
Polyvinyl alcohol (PVA 2000)  Sigma-Aldrich, Poole, UK 
RPMI 1640, without glutamine  Gibco, Paisley, UK 
SIGMA FASTTM BCIP/NBT tablets 
5-Bromo-4-chloro-3-indolyl-
phosphate/Nitro blue tetrazolium 
(BCIP/NBT) 
Sigma-Aldrich, Poole, UK 
Tetanol Pur® Tetanus toxoid 80IU/ml Novartis, Holzkirchen, Germany 
Tris (hydroxymethyl)-methylamine  Fisher Scientific, Loughborough, UK 
Trypan blue, solution 0.4% w/v Sigma-Aldrich, Poole, UK 
Trypsin-EDTA solution 0.25% w/v Sigma-Aldrich, Poole, UK 
Tuberculin PPD RT23, for in vivo use 2TU in 0.1ml Serum Statens Institute, Copenhagen, Denmark 
Tuberculin PPD, for in vitro use 1mg/ml 
Serum Statens Institute 
Copenhagen, Denmark 
Tween 20, solution  Fisher Scientific, Loughborough, UK 
Xylocaine 1% w/v, local anaesthetic  Astra Zeneca, London, UK !!!!!!!
!&**!!
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1X TAE buffer 40 mMTris, 20mM acetic acid and 1mM EDTA in DI water 
Complete RPMI1640 
10% human AB serum v/v 0.5mM L-glutamine, 50IU/ml penicillin, 
0.05mg/ml streptomycin and 0.1mg/ml neomycin 
 
DI water Deionized water 
ELISA stop solution 2M H2SO4 
ELISA wash buffer 0.05% Tween 20 in PBS 
Flow-cytometry buffer (FCB) 0.5% (v/v) FCS and 0.01% (w/v) Na-azide in PBS 
Flow-cytometry fixative (FCF) 1% (v/v) paraformaldehyde in PBS 
MACS buffer 2mM EDTA in 0.5% (w/v) BSA in 1xPBS 
Name Content 
Orange G PCR loading buffer 0.25g of OrangeG in 30%glycerol in water 
Supplemented RPMI1640 
0.5mM L-glutamine, 50IU/ml penicillin, 0.05mg/ml streptomycin and 
0.1mg/ml neomycin 
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Name Content Company 
1450 Micro Beta Tri Lux Microplate 
scintillation counter  Perkin Elmer, Cambridge, UK 
ELISPOT plate BioReader  ByoSys, Karben, Germany 
FACS Canto II flow-cytometer  BD biosciences, Oxford, UK 
Flow Jo 8.8.6 software  Leland, Stanford, UK 
Gammacell 1000 Elite Blood Irradiator  MDS Norton, US 
GE HealthCare Ultrasound Logiq E9 
Linear probe ML1  
6-15Hz 
GE Healthcare Life Sciences, UK 
GraphPad Prism, version 4a for 
Macintosh  
GraphPad Software, SanDiego, 
USA 
NanoVue Plus Spectrophotometer  GE Healthcare Life Sciences, UK 
Photometer – Opsys MRTM Microplate 
Reader  
Dynex Tecnologies, Chantilly, 
USA 
PTC-200 DNA Engine thermocycler  MJ Research, Ramsey, USA 
Suction pump machine  Eschmann, UK 
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Equipment 
Name Content Company 
Cell culture inserts, for 24-well plate  Fisher Scientific, Loughborough, UK 
Cell culture strainer 70µm for 50ml 
centrifuge tube  
Fisher Scientific, Loughborough, 
UK 
CryoTube 1ml Thermo Scientific, Cramlington, UK 
Dry stainless steel microneedle  Cardiff School of Engineering, Cardiff, UK 
ELISA plate, Coat Corning Costar 9018 
96-well plate  Lifesciences, Tewksbury, USA 
ELISPOT filter plates High-Protein Binding Immobilon-P Membrane Millipore, Billerica, USA 
Harris Uni-CoreTM skin sampling tool for 
PCR 0.5mm Ted Pella, Redding, Canada 
LD columns for magnetic separation  Miltenyi Biotec, Surrey, UK 
Micronjet 600 Needle, hollow 
microneedle  
Nanopass Technologies, Nes 
Ziona, Israel 
MidiMacs Separator For holding the columns Miltenyi Biotec, Surrey, UK 
MiniMacs Separator For holding the columns Miltenyi Biotec, Surrey, UK 
MS columns for magnetic separation  Miltenyi Biotec, Surrey, UK 
MultiStand For holding separators Miltenyi Biotec, Surrey, UK 
PCR tube 0.2ml Eppendorf UK Limited, Stevenage, UK 
Punch biopsy 0.8cm  Kai Medical, Seki, Japan 
Round-bottom polypropylene tubes 14ml; with dual-position snap cap Fisher Scientific, Loughborough, UK 
SST blood collection tube 5ml (13x100mm) BD Vacutainer, Oxford, England 
Suction blister cup  
UHBristol NHS Foundation Trust 
Medical Engineering Department, 
Bristol, UK 
Surgical blade Removal of blister roof Swann Morton Ltd, Sheffield, UK !
 
